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Background: Low-density lipoproteins (LDL) have been associated with damage to the 
cardiovascular system in patients with type 2 diabetes mellitus (T2DM). These patients are 
two (2X) to four (4X) times more likely to develop cardiovascular diseases (CVD) compared 
to non-diabetic patients due to dysfunctional lipoprotein metabolism. Normal lipid 
metabolism involves interconversion and transfer of molecules regulated by several enzymes 
such as Apolipoprotein E (ApoE) and proprotein convertase subtilisin/kexin type 9 (PCSK9). 
ApoE and PCSK9 are involved in clearance of lipoproteins and therefore, influence lipid 
profiles. Association between ApoE and T2DM in cardiovascular diseases have been widely 
reported. PCSK9 on the other hand is emerging as an important player in lipid metabolism 
but its effects in diabetes are not known. Studies on both ApoE and PCSK9 in African 
populations are in its infancy. Each year, CVD kills more people than any other cause of 
death. Many CVDs can be traced back to pathological process of atherosclerosis, in which 
fatty material collects along walls of arteries, limiting flexibility and obstructing blood flow. 
T2DM alone has been classified as a major factor for development of CVD and one of its 
complications is the development of dyslipidaemia. Unlike PCSK9, genetic polymorphisms 
in ApoE have been well characterised as important dyslipidaemia genetic markers associated 
with coronary artery disease. The association between ApoE and PCSK9 gene 
polymorphisms with dyslipidaemia in T2DM was evaluated. Diabetic dyslipidaemia presents 
as a triad of high triglycerides, high LDL and low high-density lipoprotein (HDL). 
 
Aims and Objectives: This study aimed to evaluate the role of genetic variation in genes 
coding for ApoE2 and PCSK9 on dyslipidaemia in South African diabetic patients. Main 
objectives’ included recruitment of participants, genetic characterisation of ApoE and PCSK9 
and determination of the lipid profiles for the recruited participants.  
 
Methods: Two hundred and forty-four (n=244) participants were recruited from the 
Baragwaneth diabetic clinic, using a retrospective approach. The participants comprised of 
two groups, (i) dyslipidaemic, and (ii) non-dyslipidaemic (controls). The dyslipidaemic group 
was further divided into three groups; i) those with high cholesterol only, ii) those with high 
triglycerides only and iii) those with both high cholesterol and triglycerides which is referred 
to as the mixed group. Clinical and demographic parameters were retrieved from hospital 
records with the consent of the participants. Ethical clearance was obtained from the 
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University of Cape Town and University of Witwatersrand. Genetic characterisation of ApoE 
was carried out using polymerase chain reaction (PCR) coupled to restriction fragment length 
polymorphism (RFLP) and confirmed through sequencing while characterisation for PCSK9 
was carried out through Sanger sequencing. 
 
Results: Of the 244 participants, 165 were dyslipidaemic while 79 were not dyslipidaemic. 
The 165 dyslipidaemic participants were further divided into 33.3% (n=55) those with high  
cholesterol, 29.1% (n=48) those with high triglycerides and 37.6% and (n= 62) those with 
high cholesterol and triglycerides (mixed). The cohort comprised of 128 (52%) females, 
median (IQR) age 56.0 (48.0 – 64.0) years and 116 (48%) males with median (IQR) age of 
56.5 (48.0 – 63.0) years. Most of the characteristics between the dyslipidaemic and non-
dyslipidaemic participants were significantly different as expected in a purposive sampling 
technique. ApoE3/4 genotype had the highest frequency distribution (41%) while ApoE2/3 
genotype had the lowest frequency (7%). An uncharacterised ApoE referred to in the study as 
ApoE X with a frequency distribution of 6%, was reported for the first time. The selected 
measured parameters evaluated against a set of variables showed a significant association 
between HbA1c and age (p=<0.008) is reported. TC (p=0.00092), LDL (p=0.0184) and TG 
(p=0.0175) were strongly associated with poor glycaemic. Both LDL (p=0.0174 and HDL 
(p=0.0072) were associated with age. Homozygous ApoE2/2 and heterozygous ApoE2/3 
genotypes correlated with poor glycaemic control with a median HbA1c of 10.95% (IQR 
5.88-14.98%) and 10.20% (IQR 6.20-15.80%), respectively; while homozygous ApoE4/4 
carriers displayed good glycaemic control with a median HbA1c of 6.60% (IQR 5.70 – 
2.30%). Carriers of homozygous ApoE3/3 genotype had the highest median TC of 
6.06mmol/L (IQR 5.48 -– 6.71mmol/L) while homozygous ApoE4/4 carriers had the highest 
median triglycerides of (2.94 (IQR 1.75 – 5.13 mmol/L). Carriers of homozygous PCSK9 
rs505151 A/A (E670G) genotype had the highest frequency distribution in both groups of 
participants with dyslipidaemic (55.1%) and non-dyslipidaemic (63. 5%), followed by 
carriers of heterozygous PCSK9 rs505151G/A at 40.6% and lastly carriers of PCSK9 
rs505151G/G at (9.5%). On the other hand, carriers of homozygous PCSK9 rs28362286 C/C 
genotype were predominantly distributed with a frequency of 94.2% and 
PCSK9rs28362286C/A had a very small frequency distribution of 5.8% while 
PCSK9rs28362286A/A was absent in this population. Carriers of PCSK9 rs505151A/A 
genotype had higher HbA1c with a median of 10.10% (IQR 7.48 – 12.90) compared to 
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PCSK9 rs505151 G/A genotype with a median of 9.00% (IQR 7.03 –11.35).  The results 
show that PCSK9 rs505151G/A with lower HbA1c had non-significantly higher TC, LDL, 
TG and non-HDL but lower HDL compared to PCSK9 rs505151A/A genotype. The results 
revealed no direct reciprocal relationship between glycaemic control and level or type of 
dyslipidaemia.   
  
Conclusions: The study showed the effects of ApoE and PCSK9 genetic variation on the 
dyslipidaemia seen in black South African diabetic participants. Therefore, this study through 
ApoE and PCSK9 genotypes show that the diabetic dyslipidaemia has an underlying genetic 
influence. In addition, to the well-characterised ApoE genotypes, an uncharacterised 
genotype referred to as ApoE X genotype is reported. With these findings, consideration to 
explore possible underlying genetic predisposition is recommended especially in diabetic 
patients with dyslipidaemia that responds poorly to standard therapy.   
 
PREFACE 
This thesis is being submitted in accordance with general provision 6.9 in the General Rules 
for the degree of Doctor of Philosophy (PhD) of the University of Cape Town. Chapter 1 is a 
general literature review looking at the aspects directly and indirectly related to the thesis. 
Chapters 2 to 4 are specific to the subject, which include methods, results and discussion of 
results.  
 
The thesis outline is as follows: 
Chapter 1: This is a general introduction encompassing background on the aims and 
objectives. The main aims and objectives are covered in section 1.6. 
Chapter 2: This chapter presents the methods and materials, from the study population,  
laboratory routine analytical methods for lipids, lipoproteins, HbA1c, isolation, and 
purification of DNA as well as genotyping of ApoE. 
Chapter 3: This chapter presents the demographic characteristics of the cohort, 
Apolipoprotein E and PCSK9 genotype frequency and the associated pattern of dyslipidaemia 
Chapter 4: This chapter presents discussions on all the findings from the genetic  
characterisation of ApoE and PCSK9 forms dyslipidaemia.  
Chapter 5: Conclusion, Strengths’, Weaknesses and Recommendations. 
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CHAPTER 1: INTRODUCTION  
 
1.1 Background 
Diabetic dyslipidemia is the abnormal lipoprotein profile found in patients with diabetes. 
Therefore, the presence of diabetes is a prerequisite for this definition to be valid. Patients 
found with dyslipidaemia have often been labelled as being secondary to diabetes; and not 
much work has been done to explore the possibility of underlying genetic influences.  From 
the metabolic pathway perspective dyslipidaemia would manifest because of some 
malfunction in one or more of the proteins (enzymes) in the pathway. Therefore, the sequence 
of events expected is; i) development of diabetes, ii)  reduced function of the enzymes 
involved in lipoprotein metabolism resulting in dyslipidaemic phenotype. The focus will be 
to explore the dyslipidaemia that develops in diabetes and making diabetes the first event but 
not the primary focus.   
1.2 Diabetes Mellitus 
Diabetes mellitus (DM) is a group of metabolic diseases that results in high blood glucose  
(hyperglycemia) due to defects in insulin secretion, insulin action, or both (American 
Diabetes Association., 2009). The word mellitus was incorporated to distinguish DM from 
diabetes insipidus, a condition associated with frequent urination (Himsworth, 1936). 
Diabetes mellitus (DM) refers to diabetes that has no distinction between Type 1 diabetes 
mellitus (T1DM) and Type 2 diabetes mellitus (T2DM). It is defined as a chronic metabolic 
disorder characterised by persistent hyperglycaemia. DM has become a major epidemic of 
this century (Shaw et al., 2010), following an increase in incidence by 50% over the past 10 
years (Danaei et al., 2011). However, it is surprising given that DM is one of the world's 
oldest diseases, traced as far back as in ancient Egypt, Persia, and India (Ahmed, 2002: 
Eknoyan and Nagy, 2005). Poor glycaemic control in DM results in development of several 
long-term complications such as (i) dyslipidaemia, which can further complicate the 
cardiovascular system, (ii) peripheral vascular disease, iii) diabetic nephropathy, and (iv) 
ocular damage, (Kitabchi et al., 2009).  Through an oxidative process, DM enhances the 
formation of altered LDL particles, which are atherogenic and associated with the increased 
risk of atherosclerosis compared to healthy individuals (American Diabetes Association, 
2004; Litwak et al., 1998). DM falls into two broad categories, T1DM caused by an absolute 
deficiency of insulin secretion and T2DM caused by a combination of resistance to insulin 
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action and an inadequate insulin secretion. There are several subtypes under T2DM which 
include, maturity onset diabetes of the young, gestational diabetes, mitochondrial diabetes, 
new onset diabetes after transplant and type 3 diabetes mellitus. 
 
1.2.1 Types of Diabetes mellitus 
1.2.1.1 Type 1 Diabetes mellitus (T1DM) 
T1DM results from the pancreas' failure to produce enough insulin which is caused by 
autoimmune destruction of -pancreatic cells. The pathogenesis of T1DM involves several 
factors that include -cell autoantigens, macrophages, dendritic cells, B-lymphocytes, and T-
lymphocytes, resulting in the loss of the insulin producing -cells of the islets of Langerhans 
in the pancreas and insulin deficiency (Yoon and Jun, 2005). The inheritance/familial aspect 
is attributed to multiple genes, including certain HLA genotypes, known to influence the risk 
of developing DM. In genetically predisposed individuals the onset can be triggered by one 
or more environmental factors, such as viral infection with some evidence showing some  
association between T1DM and Coxsackie B4 virus. The majority of T1DM is of the  
immune-mediated nature, in which T-cell-mediated autoimmune attack leads to the loss of  
-cells and eventual depletion (Cnop et al., 2005). T1DM causes approximately 10% of DM  
cases in North America and Europe. However, no data is available on its prevalence in South  
Africa and Africa in general. The assumption that there is deficiency and not total absence of  
insulin is that sensitivity and responsiveness to insulin are usually normal, especially in the 
early stages. T1DM can affect both children and adults, but because the majority cases were 
in children it was traditionally termed "juvenile DM”. T1DM can have dramatic and recurrent 
swings in glucose levels, making it difficult to manage; hence it was referred to as Brittle  
unstable DM or labile DM (Vantyghem and Press, 2006). Brittle DM has episodes of  
hypoglycaemia or hyperglycaemia that prevents an individual from leading a planned life 
style.  
 
The swing between the opposite glycaemic levels seem to point towards several causes that 
can rapidly deplete or block the use of glucose. Possible causes in the swing include; i) 
metabolic errors resulting in an imbalance between elevated insulin releases relative to 
available carbohydrate, ii) possible interference from other medical conditions, iii) possible 
high temperature inactivation of insulin, and iv) production of insulin auto antibodies, which 
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at high levels can cause episodic hyperglycaemia secondary to neutralising the insulin 
(Schade and Burge, 1995). This gives a picture of clinical insulin resistance, a feature that can 
be corrected by changing the type of insulin administered (Davidson et al., 1991). Another 
fascinating feature of T1DM is partial remission. During this period, clinically, newly 
diagnosed T1DM experience a transient partial remission period (“honeymoon”), shortly 
after insulin treatment is initiated. During this period the patient's need for exogenous insulin 
decreases and in other cases, the need totally disappears with metabolic control reaching 
optimal levels. The mechanism or pathogenesis of this phenomenon is still puzzling, but the 
current thinking revolves around, i) possible combination of partial β-cell recovery with 
improved insulin secretion that reflects residual β-cell function and ii) an improvement of 
peripheral insulin sensitivity. It is interestingly to note that the residual β-cell function was 
reported to be highest in the age group 10–15 years (Hramiak et al., 1993).  
 
1.2.1.2 Latent Autoimmune Diabetes of the Adult (LADA) 
This is considered as a late onset subtype of T1DM, in which patients present with a clinical  
diagnosis of T2DM. They possess islet autoantibodies, mostly autoantibodies to glutamate  
decarboxylase (GAD). Patients in this category progress more rapidly to insulin treatment. 
This is known as latent autoimmune diabetes of the adult (LADA) and occurs in individuals 
with a clinical phenotype resembling T2DM but rapidly progress to T1DM requiring insulin 
(Irvine et al., 1976). Prevalence of LADA is not known in South Africa but studies in Nigeria 
(Padeola et al., 2015) reported similar clinical and lipid profiles to patients in Ghana  
(Agyei-Frempong et al., 2008) and among Caucasian populations.  
 
1.2.1.2.1 T1DM and dyslipidaemia 
Dyslipidaemia is a major contributing risk factor for cardiovascular disease in adult T1DM  
patients (Berenson et al., 1998). The pathophysiology of dyslipidaemia in T1DM is 
frequently a function of insulin deficiency and poor glycaemic control as well as peripheral  
hyperinsulinisation caused by intensive control. The process that leads to cardiovascular  
complications begin early at a youthful age (Lawson et al., 1999). HbA1c and waist-to-height 
ratio (WHtR) also called waist-to-stature ratio (WSR) are modifiable risk factors associated 
with change in dyslipidaemia over time in youth with T1DM (Shah et al., 2017). WHtR,  
defined as waist circumference divided by height, both measured in the same units gives an  
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index of the distribution of body fat.  
1.2.1.3 Type 2 Diabetes mellitus (T2DM) 
T2DM begins with insulin resistance, a condition in which cells fail to respond properly to  
insulin and therefore, as the disease progress, a lack of insulin may also develop (Kasuga, 
2006). T2DM mellitus accounts for 80–90% of all DM cases. It is a heterogeneous disorder 
in which 5–10% of the patients may have maturity-onset DM of youth (Fajans, 1989), 5–10% 
may have latent adult-onset autoimmune DM and another 5–10% may have DM secondary to 
rare genetic disorders (Moller and Flier, 1991). The cause for the remaining 70–85% typical 
T2DM remains obscure. However geographical differences in the incidence T2DM suggest 
that it is a heterogeneous pathology with strong genetic and environmental contributions 
(Kahn, 1994). The presence of several abnormal genes or polymorphisms for the 
development of the disease is consistent with polygenic inheritance. Secretion and 
utilisation/sensitivity of insulin, which are both genetically controlled, play a crucial role in 
the pathogenesis of T2DM (Iselius et al., 1985). Most diabetic patients have central obesity, 
which is associated with insulin resistance/insensitivity (Bouchard, 1995). Such complexity 
requires distinction between i) diabetogenic genes, involved in the development of DM and 
ii) DM related genes which ii) regulate appetite, energy expenditure, and intraabdominal fat 
accumulation.   
 
Lifestyle factors associated with T2DM and obesity include lack of physical activity, poor 
diet, stress, and urbanisation (Straznicky et al., 2011). Rural to urban migration in South 
Africa and Africa in general brings with it several challenges such as jobs, accommodation, 
transportation, water and sanitation that can induce severe stress. In 2014 the MRC of South 
Africa reported that the highest rate of obesity and overweight among adults in sub-Saharan 
Africa was found in South African women at 42%, while the combined rate of both 
overweight and obesity is 69.3%. South African men showed a 39% overall prevalence rate, 
with only a 14% obesity prevalence (Keating et al., 2014).    
 
1.2.1.3.1 Maturity Onset Diabetes of the Young (MODY) 
MODY is very rare compared with T1DM and T2DM and can therefore be mistakenly  
diagnosed. The most common types of MODY are hepatocyte nuclear factor1-alpha  
(HNF1-alpha), a gene that causes about 70 per cent of cases of MODY; HNF4-alpha which is 
not as common as the other forms of MODY. Children with this type of MODY may have a 
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birth weight around 4 kg. HNF1-beta is the type of MODY associated with several 
complications that include renal cysts, uterine abnormalities and gout. Glucokinase, the 
enzyme associated with glucose level monitoring is an example of an enzyme coded for by a 
diabetogenic gene that causes alteration in the activity of glucokinase (Steele et al., 2013). 
The common mutation results in reduced insulin secretion but may not be sufficient to cause 
DM in most individuals unless there is an increased demand for insulin.  A mutation results 
in higher than normal glucose levels (Horikawa et al., 1997). MODY can be suspected and 
recognised if a T2DM–like condition occurs in two to three or more generations and the 
pattern of inheritance is consistent with autosomal-dominant inheritance (Fagans, 1990). 
Dyslipidaemia in MODY has been reported to be lower compared to T2DM with types like 
HNF1-alpha having lipid constituents similar to non-diabetics (Schober et al., 2009; 
McDonald et al., 2012).  
 
1.2.1.3.2 Gestational diabetes mellitus (GDM) 
GDM is diagnosed in the second or third trimester of pregnancy in an individual who did not 
have DM prior to gestation (American Diabetes Association, 2007).  GDM is a common  
metabolic disease during pregnancy affecting approximately 7% (range: 2–18%) of all  
pregnancies (Buckley et al., 2012). Features such as both inadequate insulin secretion and 
insulin sensitivity resemble T2DM. Some patients return to normal glucose levels after 
delivery, while   5–10% of those affected remained diabetic, mostly with T2DM (Kim et al., 
2002). GDM is fully treatable but requires careful medical supervision throughout the 
pregnancy. If untreated, GDM can be a risk to optimal development of the fetus and might 
result in DM related complications to the mother (Vambergue and Fajardy, 2011). Risks to 
the baby include macrosomia (high birth weight), congenital heart and central nervous system 
abnormalities, and skeletal muscle malformations. Increased levels of insulin in a fetus' blood 
may inhibit fetal surfactant production and cause respiratory distress syndrome (Allen and 
Palumbo, 1981). A high blood bilirubin level may result from red blood cell destruction. 
Prevention and treatment involve a healthy diet, physical exercise, not using tobacco and 
being a normal body weight. Blood pressure control and proper foot care are also important 
for people with the disease. Type 2 DM may be treated with oral medications, which may be 
augmented with insulin (Petznick, 2011). Weight loss surgery has been reported to be an 
effective measure in obese T2 DM patients (Buchwald et al., 2009). The number of people 




DM in non-pregnant women is associated dyslipidaemia, consisting of low high-density  
lipoprotein (HDL), increased triglycerides, and postprandial lipemia (Ginsberg, 1996). 
Normal pregnancy is associated with changes in lipid metabolism, increasing lipid levels as 
gestation progresses. Both TC and TG rise throughout pregnancy with TG rising 
disproportionately in comparison to other lipid fractions reaching two to four times pre-
pregnancy levels by the third trimester (Hadden and McLaughlin, 2009). Therefore, when 
coexisting as seen in GDM, dyslipidaemia would be expected to be a prominent feature.  
1.2.1.3.3 Mitochondrial diabetes (MIDD) 
Around 1% of all cases of DM are due to mutations in the mitochondrial DNA (mtDNA) 
known as mitochondrial diabetes. This is a heterogeneous syndrome which results from an A 
to G substitution at the conserved position 3243 (m.3243A>G) of the mitochondrial DNA. 
This is often associated with deafness and is collectively, known as maternally inherited 
diabetes and deafness (MIDD) syndrome (Martinez et al., 2017). Patients with MIDD are 
often misclassified as T2DM or T1DM because physicians are unaware of the syndrome. The 
presence of DM, deafness and a family history of the same clinical features in maternal 
relatives raise the suspicion of MIDD. The age and the mode of presentation of DM results in 
misdiagnosis as either T1DM or T2DM. Some cases have an insidious onset similar to 
T2DM, but approximately 20% of cases present acutely, with a small proportion presenting 
with ketoacidosis (Murphy et al., 2008). MIDD patients lack the autoimmunity, pancreatic 
auto-antibodies and high-risk HLA polymorphisms associated with T1DM (Kavvoura, 2014).  
 
Mitochondrial dysfunction has been reported to contribute towards insulin resistance in both 
classic and non-classic insulin target tissues. In addition to insulin resistance, mitochondrial  
dysfunction is also associated with metabolic and cardiovascular abnormalities resulting in  
cardiovascular disease. Furthermore, interventions that improve mitochondrial function also  
improve insulin resistance (Befroy et al., 2007). 
 
1.2.1.3.4 New-Onset Diabetes after Transplantation (NODAT) 
The stress of surgery and post-surgical use of immune-suppressive medications can result in  
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hyperglycaemia in the recipients. NODAT a complication following organ transplant has 
been reported to occur in between 2% and 53% of transplanted patients (Pham et al., 2007).  
Hyperglycaemic state may not be persistent in all cases and therefore, referred to transient  
NODAT for the state of hyperglycaemia that started and ended within the first year of  
transplantation (Cosio et al., 2005). The incidence of NODAT is reported to be 18.0% in 
renal transplant in South Africa (Alagbe et al., 2017) and 27.4% of liver transplant in Egypt 
(Zayed et al., 2017). There may be several factors that contribute to the development of 
NODAT, but the use of immunosuppressive calcineurin-inhibitors like tacrolimus and 
cyclosporine both with diabetogenic effects are associated with an incidence of NODAT 
(Panz et al., 2002). The mechanism involves enhanced glucose absorption in the jejunum by 
upregulated expression of sodium-glucose linked transporter (SGLT1) induced by tacrolimus 
as well as induced insulin resistance (Li et al., 2015). The major complication in post-
transplant is morbidity and mortality attributable to CVD and NODAT an independent 
predictor of cardiovascular events (Yates et al., 2012).  
 
1.2.1.4 Type 3 diabetes mellitus (T3DM) 
T3DM is also known as brain DM because the brain requires insulin to form new memories.  
Receptors on the brain’s synapses facilitate the communication that creates new memories 
and insulin produced by the brain prevents amyloid -derived diffusible ligands that destroy 
the receptors (Steen et al., 2005). In T3DM the brain either does not produce enough insulin 
for new memory formation or is resistant to the insulin it produces. This leads to inability to 
form new memories resulting in T3DM with symptoms, signs and difficulties that mimic 
those of Alzheimer’s and dementia.  The similarity of these diseases makes it difficult to 
diagnose T3DM unless specifically using Magnetic Resonance Imaging (MRI) scanning 
technology. T2DM and impaired fasting glucose has been noted to occur more frequently in 
patients with AD than normal population. Dyslipidaemia reflecting disordered lipid 
metabolism with a high degree of unsaturated fatty acids when compared to traditional 
Alzheimer determined by genetic predisposition has been reported in the brain of patients 
with T3DM (Ginneken et al., 2017). ApoE is a cholesterol carrier in the brain, helping in 
amyloid aggregation and the clearing of deposits from the parenchyma of the brain. When its 
function is reduced, excessive beta-amyloid deposits occur in the brain (Huang et al., 2004). 
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1.2.3 Diagnosis of DM 
The Kidney has different threshold levels for components in the blood and therefore when the 
glucose concentration in the blood reaches its threshold it will be excreted in the urine, a  
phenomenon referred to as glycosuria. As an osmotically active substance the osmotic 
pressure of the urine increases, thus inhibits reabsorption of water causing increased urine 
production commonly referred to as polyuria. Loss of extracellular fluid (water) causes blood 
volume reduction and the intracellular fluid moves to extracellular space. The loss of fluid 
from the cells results in reduction in cell sizes (dehydration). All the four major stimuli to 
thirst, hypertonicity through the osmoreceptor, hypovolaemia, through low pressure 
baroreceptors, hypotension through high pressure baroreceptors and angiotensin II trigger the 
thirst centre resulting in the need to drink water commonly referred to as polydipsia. 
Following an extensive exercise by the American Diabetes Association’s (ADA), World 
Health Organisation (WHO) published a revised classification and diagnostic criteria for DM 
shown in Table 1 below (Diabetes Care, 1997). According to this criterion, fasting glucose 
levels from 6.1 to 6.9 millimoles per litre (mmol/l) (110 to 125 milligram/deciliter (mg/dl) 
falls under impaired fasting glucose (American Diabetes Association, 2005), plasma glucose 
at or above 7.8 mmol/l (140 mg/dl), but not over 11.1 mmol/l (200 mg/dl), two hours after a 
75-g oral glucose load falls under impaired glucose tolerance. Of these two prediabetic states, 
the latter is a major risk factor for progression to DM, as well as cardiovascular disease. 
Fasting is a preparation for sample collection the following day to assess the basal metabolic 
state of the organ. However, this does not give a real-life daily scenario and glycated 
haemoglobin offers a more real time monitor of carbohydrate metabolic events over a long 
time and this, therefore, is better than fasting glucose (Goldstein et al., 2003). In South 
Africa, the diagnosis and management of DM (SEMDSA, 2012) is very closely aligned to the 
(World Health Organisation) WHO protocol in Table 1.1 below and the American 
Association of Diabetes (ADA) (Amod et al., 2012). Therefore, in this project reference is 











Table 1.1 WHO revised diagnostic criteria for DM (American Diabetes Association, 1997)   
WHO diagnostic criteria  
Condition 2-hour glucose Fasting glucose HbA1c 
Unit mmol/l(mg/dl) mmol/l(mg/dl) IFCC mmol/mol NGSP/DCCT % 
Normal <7.8 (<140) <6.1 (<110) <42 <6.0 
Impaired fasting 
glycaemia  





≥7.8 (≥140) <7.0 (<126) 42-46 6.0–6.4 
Diabetes mellitus ≥11.1 (≥200) ≥7.0 (≥126) ≥48 ≥6.5 
Note: HbA1c – Glycated haemoglobin; DCCT – Diabetes Control and Complications Trial; IFCC – 
International Federation of Clinical Chemistry; mmol/l – millimoles/litre; mg/dl –milligram/deciliter; NGSP –
National Glycohemoglobin Standardisation Program. 
 
1.2.3.1 Prediabetes 
Prediabetes also referred to as intermediate hyperglycaemia is defined based on glycaemic  
parameters above normal but below DM thresholds. This is often associated with T2DM and 
the term prediabetes has been criticised because it implies that DM is imminent but many of 
them do not develop and it also gives an impression that the absence of disease does not 
require any intervention. Impaired fasting glucose (IFG) is the stage in which the blood sugar 
level during fasting is repeatedly higher than the accepted normal levels, but the levels fall 
below DM levels (Nichols et al., 2007). There is 50% risk over 10 years of progressing to 
overt type 2 DM for IFG if there are no modifications to the lifestyle. Prediabetes was 
defined in 1997 by the American Diabetes Association to facilitate classification of such 
individuals (American Diabetes Association, 2005). Impaired Fasting Glucose (IFG) 
diagnosis is made before commencing the Oral Glucose Tolerance Test (OGTT), but 
Impaired Glucose Tolerance (IGT) diagnosis can only be made when the OGTT is done. In 
IGT, subjects have blood glucose levels that are higher than normal but not high enough to 
warrant a diagnosis of DM. Thus, oral glucose tolerance test (OGTT) is central for its 
diagnosis. Two-hour glucose levels of 7.8 to 11.0 mmol/l (140 to 199 mg/dL) on the 75-g 
oral glucose tolerance test confirm a diagnosis of IGT (American Diabetes Association, 
2005). Both IFG, IGT and other metabolic derangements occur during the transition to DM. 
 10 
 
It may take several years before the development of DM, but what is known is that up to 70% 
of subjects with such pre-diabetic states eventually develop DM (Knowler et al., 2002;  
Larson et al., 2004). A meta-analysis involving over 1.5 million prediabetes individuals 
reported an increased risk of cardiovascular related pathologies like coronary heart disease, 
stroke, as well as all-cause mortality in the subjects (Huang et al., 2016). 
1.2.4. Glycated Haemoglobin  
Glycated haemoglobin also referred to as haemoglobin A1c, HbA1c, A1C, or Hb1c was 
initially identified as an “unusual” haemoglobin in patients with DM nearly 50 years ago 
(Rahbar et al., 1969). After that discovery, numerous small studies were conducted 
correlating it to glucose levels with a conclusion that HbA1c could be used as an objective 
measure of glycaemic control, was introduced for clinical use in the 1980s, and subsequently 
became critical in clinical practice (Massi-Benedetti, 2006). HbA1c formed in a non-
enzymatic pathway when haemoglobin is exposed to high plasma levels of glucose (Koenig 
et al., 1976). The glycation products are formed both inside and outside the cells. Glucose 
attaches to the amino groups of the proteins through the non-enzymatic process to form schiff 
base and Amadori products (Schmidt et al., 1994; Singh et al., 2001). Haemoglobin is one 
such protein glycated in such a reaction. The glycated haemoglobin builds up within the red 
cell therefore reflecting the average level of glucose to which the cell has been exposed 
during its life cycle of 120 days. The HbA1c level is proportional to average blood glucose 
concentration over the previous three months (Nathan et al., 2007).  The three months’ period 
is based on the lifespan of red blood cells (RBCs) which is four months (120 days), but not 
all red blood cells will undergo lysis at the same time. Once haemoglobin molecule is 
glycated, it remains in that state and therefore a build-up of glycated haemoglobin within the 
red cell reflects the average level of glucose to which the cell has been exposed during its life 
cycle. Glycation must be distinguished from glycosylation, an enzymatic process that results 
in the linkage of sugars to certain amino acid residues such as serine and asparagine. 
Enzymatic glycosylation is important for several functions, such as differentiating proteins, 
increasing protein half-life during circulation and formation of specific receptors for  
different ligands. Therefore, glycation a non-enzymatic process must be differentiated from  
glycosylation an enzymatic process (Brownlee, 1995). 
 
The clinical significance of HbA1c test was confirmed in patients with DM (Genuth, 1995).  
The HbA1c reference range for patients with good glucose control is ≤6.5% according to the  
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International Diabetes Federation and American College of Endocrinology (IDFACE) and 
≤7.0% for the American Diabetes Association (ADA). Both the DCCT and the UKPDS  
demonstrated that the HbA1c could predict the risk of microvascular complications in 
patients with DM. These two large studies demonstrated that reduction of HbA1c was 
associated with a significantly slower progression of microvascular disease (DCCT, 1993; 
UKPDS, 1998) The DCCT study reported that 10% reduction in HbA1c levels resulted in a 
43%–45% lowering of risk of retinopathy. HbA1c values given in Diabetes Complications 
and Control Trial percentage (DCCT %) units can be correlated to the average glucose in 
plasma circulation as an estimated average glucose (eAG) using the equation: eAG (mg/dl) = 
28.7 × A1C − 46.7 or eAG (mmol/l) = 1.59 × A1C − 2.59 (Nathan et al., 2008). On average, 
HbA1c of 6% corresponds to mean plasma glucose of 7.6mmol/L (135 mg/dl). For every 
increase in HbA1C of 1%, mean plasma glucose increases by 1.9mmol/L (35 mg/dl). Non-
diabetic subjects have an HbA1C between 3.5% and 5.5%. The glycation rate is 50% during 
the first 30-60 days prior to the HbA1C measurements and another 25% and during the 60- 
120 days (Beach, 1979).  
  
The presence of several different haemoglobin-glucose adducts like A1a (HbA1a), HbA1b, 
and HbA1c compounded by the presence of different variants resulted in the development of 
several different analytical methods. These factors lead variation in reference intervals and 
results reported by different laboratories. The publication of the DCCT revealed that the lack 
of standardisation of HbA1c methods produced very wide variability among methods, with 
values ranging from 4.0% to 8.1% on the same blood sample (Little et al., 1992). Using a  
standardisation process based on the DCCT reference method, the NGSP promoted a 
dramatic improvement in comparability of HbA1c values among laboratories. This resulted in 
the adoption of NGSP-certified methods by many laboratories (Goldstein et al., 2004) 
 
However, some clinical conditions may result in either falsely high or low HbA1c levels.   
Patients with poorly controlled DM are expected to have high HbA1c, but such patients may 
have low or normal HbA1c if there is an underlying condition that shortens the life span of 
the red cell causing increased red cell turnover (Nitin, 2010). The increased red cell turnover  
shortens the exposure of the cell to glucose, resulting in lower HbA1c levels. Such conditions 
include acute and chronic blood loss, hemolytic anemia, and splenomegaly. In these 
situations, it may be preferable to use an alternative measure of glycemic control, such as 
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fructosamine or glycated albumin (Freedman et al., 2010). On the other hand, conditions that 
prolong the life span of the erythrocyte expose the cell to glucose for a longer period resulting 
in higher HbA1c levels. These conditions include vitamin B-12 and folate deficiency 
anemias, and asplenia (Kilpatrick et al., 1998). Iron deficiency anaemia has also been 
associated with higher HbA1c levels, which decrease once treatment for the anaemia has 
commenced (Brooks et al., 1980).  Racial and ethnic differences in HbA1c and blood glucose 
have also been described but the reasons for these differences are still speculative (Herman 
and Cohen, 2012). Due to these factors, some researchers are sceptical about using HbA1c on 
its own for the diagnosis of DM and therefore, encourage the inclusion of traditional glucose 
criteria when screening for and diagnosing DM.  
 
1.2.4.1 Use of Point of Care Testing (POCT) for HbA1c 
HbA1c point-of-care instruments have greatly improved availability of results for patient  
management. This has gone a long way in preventing treating “history” when patients return 
a few weeks later for management review based on results of the tests. However, a faster 
result is not necessarily equivalent to traditional, core laboratory testing. Preanalytical,  
analytical and post-analytical factors can influence the quality of POCT that could lead to  
misinterpretation. The assays employed are generally less analytically sensitive than assays  
performed in the central laboratory (Nichols, 2003). For POCT analyses, achieving an  
imprecision of 2% CV is difficult to meet and therefore, and imprecision of 3% CV would be 
acceptable even though not optimal (Shephard, 2006). An evaluation of eight HbA1c POCT  
instruments was conducted according to CLSI protocols EP-10 for imprecision, EP-5 for 
accuracy and EP-9 for bias was conducted to assess compliance to NGSP criteria. The 
exercise showed that only two, the DCA Vantage and other analyzers met the acceptance 
criteria of having a total CV 3% in the clinically relevant range (Holmes et al., 2008). At 
CHBAH and surrounding clinics, Chemical Pathology POCT team of Medical laboratory 
technicians, manages POCT. 
1.2.5. The Prevalence of DM 
As of 2015 there were approximately 392 million people diagnosed with the T2DM 
compared to around 30 million in 1985 (Smyth and Heron, 2006). Urban drift and adoption 
of Western lifestyles, has predisposed African people to risk factors associated with non-
communicable diseases (NCDs). As a result, NCDs like DM are rising rapidly in Africa 
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(Aspray et al., 2000; Murray et al., 1997). DM previously considered rare in Africa is now 
reaching epidemic levels with some epidemiologists predicting that the economic impact of 
DM, as well as the consequent death toll, will soon surpass HIV and AIDS (Chijioke et al., 
2010; Kasiam et al., 2009). The developing world is experiencing the biggest increase of DM, 
and by 2025, more than half of people with DM will be found in developing countries (King 
et al., 1998). In 2000, the prevalence of DM in the World Health Organisation (WHO) 
African Region was estimated at 7.02 million people, including 0.702 million (10%) people 
with T1DM and 6.318 million (90%) with T2DM. CDC National Diabetes Statistics Report 
pointed that 29.1 million or 9.3% of the population in United States have DM. Of these 21 
million had confirmed diagnosis but 8.1 million people 27.8% were undiagnosed (CDC, 
2014).  
 
The rise in DM will eventually lead to a rise in DM related complications like dyslipidaemia 
and stroke will increase compared to non-diabetic subjects. Of serious concern is the link 
between DM and tuberculosis. Individuals with DM have an increased risk the risk of 
developing tuberculosis and individuals with tuberculosis-DM co-morbidity are now more 
than those with tuberculosis-HIV co-infection (Ronacher et al., 2015). Previously, there was 
no concern because there was an apparent separation in the affected communities, the 
developed (western countries) affected by DM and developing countries (Africa, India and 
South America) affected by tuberculosis. The epidemic rise of DM in the developing counties 
is now of serious concern because it will negatively impact on the control and treatment of 
TB.  
 
According to statistics, published on 30 October 2012, there are about 52 million people in 
South Africa and 51% were females. The diversity of the population is shown by the fact that 
79.6% of the population is black, 9% coloured, 9% white and 2.5% Indian/Asian. With a 
population of nearly 13.2 million people, Gauteng province is home to nearly a quarter of the 
population (Statistics South Africa, 2012). According to a South African burden of disease 
study the overall prevalence of DM is estimated to be about 5.5% in people older than 30 
years of age, (Pi-Sunyer et al., 2007).   
 
1.2.6 Pharmacological Management of Diabetes 
In South Africa, the pharmacological management of DM is outlined in the 2012 Society for  
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Endocrinology, Metabolism and Diabetes of South Africa (SEMDSA) Guidelines for the  
Management of T2DM (Amod et al., 2012). The protocol is very closely aligned to the 2016 
ADA revised protocol (ADA, 2016). The generic baseline management under both the 
SEMDSA and ADA are changes in lifestyle that include health eating, physical activity with 
an aim to control weight and DM education. 
 
The first step, metformin a biguanide marketed under the tradename Glucophage is the  
recommended drug. Metformin exerts its effect by activating adenosine monophosphate 
(AMP) kinase, resulting in the reduction of hepatic glucose production (Amira et al., 1990). 
Additional effects include improved peripheral glucose utilisation, reductions in 
gastrointestinal glucose absorption and enhanced incretin responses. Step two is dual therapy, 
if HbA1c is greater than 7 % after three months or more on metformin a second drug like a 
sulphonylurea, thiazolidinediones, dipeptidyl peptidase 4 [DPP-4] inhibitors, glucagon-like 
peptide-1 (GLP-1) receptor agonists) or Sodium glucose cotransporter 2 (SGLT2) inhibitors 
is added.  In our clinic and the public-sector health institutions in general, sulphonylureas 
drugs are available with very few if any offering thiazolidinediones as the second drug. The 
other drugs GLP-1 receptor agonists and DPP4 inhibitors are not available as the second 
drug. 
 
The other option available under this category is that the patient is maintained on oral 
medication but basal insulin, either intermediate or long-acting is given at night between 
21h00-22h00. The sulphonylurea mechanisms of action involve inducing insulin release by 
binding to specific receptors on the pancreatic -cell-KATP channel. The -cell-KATP 
channel is a hetero-octamer, comprising a potassium channel (Kir6.2) and a sulphonylurea 
receptor (SUR1). The binding of sulphonylureas to SUR1 leads to glucose-independent 
closure of the potassium channel, membrane depolarisation, the opening of calcium channels, 
and the release of stored insulin (Proks et al., 2002). Thiazolidinediones (TZDs) also known 
as glitazones (peroxisome proliferator-activated receptors (PPARs)) are a new class of drugs 
for the treatment of T2DM. They are nuclear receptors, which avidly bind to peroxisome 
proliferator-activated receptors gamma (PPARγ) in the adipose tissue stimulating 
adipogenesis and fatty acid uptake. When activated, they bind to DNA in complex including 
retinoid X receptor (RXR), another nuclear receptor resulting in the increase of transcription 
of a number of specific genes and decreasing transcription of others. They enhance storage of 
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fatty acids in adipocytes, thus decreasing dependence on fatty acids for energy and increasing 
utilisation of carbohydrates, mainly glucose for energy (Jerry and Donald, 2004). Dipeptidyl 
peptidase-4 (DPP4) inhibitors, prevent the degradation of endogenous GLP-1 by DPP4. GLP-
1 exerts its main effect by stimulating glucose-dependent insulin release from the pancreatic 
islets. It increases incretin levels which in turn inhibit glucagon release resulting in increased 
insulin secretion. Endogenous GLP-1 has a short half-life of one to two minutes, as a result of 
rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4) and therefore GLP-1 levels 
can be raised therapeutically using intravenous GLP-1 agonists that are resistant to enzymatic 
degradation, or by oral DPP-4 inhibitors. GLP-1 levels are abnormally low in patients with 
T2DM (Doyle and Egan, 2007; Thornberry et al., 2009). Sodium glucose cotransporter 2 
(SGLT2) inhibitors are the newest class of oral agents for the treatment of T2DM. SGLT 
inhibitors block the SGLT2 protein involved in 90% of glucose reabsorption in the proximal 
renal tubule leading to increased renal glucose excretion and thus reducing blood glucose 
levels (Nair et al., 2010). 
 
Step three is triple therapy, if HbA1c is greater than 7 % after three months or more on dual  
therapy, the patient is commenced on a combination of any of the three drugs in step two. 
Step four is a combination of the injectable (insulin) in the form of basal insulin at night and 
meal time insulin if HbA1c is greater than 7 % after three months or more on triple therapy. 
 
1.3 General lipid and lipoprotein metabolism 
In order to appreciate how dyslipidaemia occurs in DM, and how DM affects 
proteins/enzymes involved in lipoprotein metabolism, general lipoprotein metabolism will be 
discussed. The lipid content in lipoproteins is dynamic, with the protein content being 
exchanged during circulation. The exchange of protein components results in one 
transformation from type of lipoprotein to another type of lipoprotein (Grow and Melvin, 
1978). The composition and ratio of constituents of the lipoproteins determines their 
chemical, physical and electrical properties. High triglyceride content results in larger but less 
dense lipoproteins while high TC content results in smaller but denser lipoproteins (Kostner 
and Alaupovic, 1972). Lipid and lipoprotein metabolism involve processes of exchange of 
protein components between lipoproteins resulting in formation of new lipoproteins. The 
process includes i) transfer of apolipoproteins between lipoproteins, ii) transfer of lipids 
between lipoproteins, iii) metabolism of lipid content by enzymes, iv) hydrolysis of TG by 
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lipoprotein lipase (LpL), and esterification of UCl by lecithin cholesterol acyl-transferase 
(LCAT) and v) final clearance of lipoproteins from the circulation by the liver through their 
receptors. All these processes can be categorised into three pathways exogenous, endogenous 
and reverse pathways; and dyslipidaemia develops when any of the components in these 
pathways are compromised. The pathways are intricate with some overlapping aspects. 
Therefore, some enzymes/proteins and lipoproteins that feature prominently in one of the 
three pathways will be briefly discussed in one of the pathways including roles played in 
diabetic dyslipidaemia. 
1.3.1 Exogenous Pathway 
In view of the importance of postprandial lipaemia, this pathway will be discussed in detail. 
The pathway is important in handling the dietary acquired lipids, becoming active in post 
absorptive until one to five hours after a meal. Dietary fat is mainly composed of TG. Lipases 
hydrolyse lipids; lipase secreted by the tongue and soft palate and gastric mucosa can 
hydrolyse up to 30% of fats in the stomach (Hill, 2012). These may have a significant role 
when there is pancreatic dysfunction as they do not require bile salts (BS) and are active at 
gastric pH (Hill, 2012). Dietary lipids in the small intestines stimulates the release of CCK 
(Cholecystokinin), an enzyme which stimulates gall bladder contraction, resulting in the 
release of bile salts and the simultaneous release of pancreatic digestive enzymes. Secretin in 
the upper duodenum but found throughout the ileum, stimulates the release of a bicarbonate 
rich fluid that neutralises the acidic contents from the stomach (Hill, 2012). CE is hydrolysed 
by cholesterol esterase while phospholipids are hydrolysed by phospholipase A2. 
 
With the aid of bile salts the digestive products form micelles that convey the non-polar lipid 
molecules from the lumen of the gut to the epithelial cell surface where absorption is 
facilitated by fatty acid binding protein. In the enterocyte, fatty acids are incorporated into 
TG, which, together with phospholipids, TC and CE and specific apolipoproteins (ApoB-48 
and ApoA-1) are assembled into spherical chylomicrons which are released by exocytosis 
into the intestinal lacteals (Holmes and Lobley, 1989). Apo B48 a specific marker of 
intestinal chylomicron particles has amino acid sequence which represents 48% of the initial  
sequence of ApoB-100. It is synthesised by the intestinal mucosal cells and is the permanent 
structural protein of a chylomicron (Adiels et al., 2012). The lacteals drain into the cisterna 
chyli and thence to the thoracic duct. Chylomicrons finally enter the subclavian vein for 
systemic circulation. Absorption of dietary fatty acids is usually complete whereas absorption 
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of total gut cholesterol (biliary and dietary) is variable. Once in the systemic circulation, 
chylomicrons donate A-I to HDL in exchange of ApoCII and ApoE. When ApoCII is present 
on the surface of chylomicrons, activates lipoprotein lipase situated on the capillary 
endothelial surfaces. LpL hydrolyses TG to yield monoacylglycerol and free fatty acids 
(Carey et al., 1992).  
 
The fatty acids released into circulation associate with albumin to return to the liver if not 
taken up, can be taken up by organs such as muscle (energy source) or adipocytes (storage). 
During chylomicron circulation which can last from 5 to 30 minutes, they rapidly deliver TG 
to peripheral tissues. No chylomicrons should be present in the plasma of a fasting subject six 
to eight hours after a meal. The metabolism of TG rapidly depletes the core of the 
chylomicron particle, reducing its size and increasing its density. In the circulation, 
cholesteryl ester transfer protein (CETP) shuttles between HDL and apoB-containing 
lipoproteins and facilitates the bi-directional transfer of CEs and TG between them and these 
changes result in loss of affinity for ApoC lipoprotein which partitions to HDL (Kontush et 
al., 2015). The chylomicron remnant contains less TG and much more CE than the original 
chylomicrons, making it highly atherogenic. Only ApoB 48 and ApoE remain on the 
chylomicron remnants and the latter serves as ligand for the hepatic receptors (Cooper et al., 
1997). The chylomicron remnants are internalised through the LDL and LRP receptors by 
endocytosis. The components of the chylomicrons are hydrolysed in the lysosomes and the 
cholesterol released from the hepatic lysosomes can enter pathways for the formation of bile 
acids, be secreted into the bile as such, be incorporated in nascent lipoproteins or esterified 
with long fatty acids and can down-regulate HMG CoA-reductase, the rate limiting enzyme 
of cholesterol biosynthesis. Postprandial hypertriglyceridemia is a pro-atherogenic marker for 
predisposition to atherosclerosis and macrovascular disease in T2DM subjects (Kumar et al., 
2010). Measurement of ApoB48 as a marker of chylomicron metabolism can be used to 
assess the integrity of this pathway (Nakajima et al., 2014). Overcoming the TG components 
in this pathway and attaining the baseline metabolic status was the rationale for the patients to 
fast when assessing lipids and lipoproteins profiles. Assessment of cholesterol does not 
require fasting because there is a stringent enterocyte cholesterol homeostasis involving rates 
of sterol synthesis, efflux, and uptake from gut lumen. On the apical surface of enterocytes 
there is active influx of unsterilized cholesterol (UC) as well as unesterified phytosterols into 
the enterocyte through the Niemann-Pick C1-Like 1 (NPC1L1) transporters (Jia et al., 2011). 
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NPC1L1 is also found in the canaliculi membrane of hepatocytes. It functions as a sterol 
transporter to mediate intestinal cholesterol absorption and counter balances hepatobiliary 
cholesterol excretion. Also, on the apical surface adenosine triphosphate (ATP)-binding 
cassette (ABC) transporters ABCG5 and ABCG8 complex promotes active efflux of 
unsterilized sterols from enterocytes back into the intestinal lumen for excretion (Jakulj et al., 
2010). The enterocyte has sterol-excess sensor, the liver X receptors (LXR) that monitor 
sterol levels and activate the genes that regulate NPC1L1, ABCG5 and ABCG G8 (Lehmann 
et al., 1997). Only free or unesterified cholesterol (UC) can be absorbed through gut 
enterocytes. CE which constitutes more than 50% of the dietary cholesterol cannot be 
absorbed due to the bulky acyl side chains. To overcome this limitation, CE can be de-
esterified by pancreatic lipases and esterolases, enzymes that cleave off the side branches to 
CE back to UC so that some dietary CE can be converted to UC for absorption. Similarly, the 
liver is only able to efflux UC via bile but not CE, from hepatocytes to the biliary system. 
The liver CE is de-esterified to UC by cholesterol esterolases to efflux into bile and 
ultimately the gut for excretion. Another important way for the reduction of cholesterol is its 
conversion to bile acid and efflux the bile through ABCB11 transports (Meier, 1995). This 
mechanism, in the form of bile acid sequestrants have been in use for a long time in the 
treatment of hypercholesterolemia. It interrupts enterohepatic recirculation of bile acids, 
thereby stimulating feedback mechanisms on the conversion of cholesterol into bile acids in 
the liver leading to lower cholesterol concentrations in the circulation. The bile acid 
sequestrants are known to improve glycaemic control in patients with T2DM (Sonne et al., 
2014). Further understanding of the exogenous pathway provided another opportunity for the 
development of a second lipid lowering agent ezetimibe at the gut level that inhibit intestinal 
absorption of dietary and biliary cholesterol (Ahmed and Byrne, 2010). 
 
1.3.1.1 Exogenous pathway and ApoE and or PCSK9 
The ApoE that remains on the chylomicron remnants has been well established as the ligand 
for the hepatic receptors for their uptake by the liver (Cooper et al., 1997). PCSK9 is 
abundantly expressed in the intestine.  In addition to the known effects on LDL, PCSK9 has 
been demonstrated to modulate cholesterol transport, metabolism and production of apo B-






1.3.2 Endogenous Pathway 
The endogenous pathway involves metabolism of i) intestinally derived lipoproteins as well 
as ii) de novo derived lipoproteins. Plasma clearance of intestinally derived remnant 
lipoprotein by the liver involves sequestration and internalisation (Mahley and Hussein, 
1991). Chylomicron and VLDL remnants pass through the fenestrae of hepatic sinusoidal 
endothelial cells into the space of Disse. The fenestration acts as a dynamic bio-filter that 
restricts the entry of large chylomicrons while allowing the smaller remnants to enter 
(Cooper, 1997). The initial clearance by the liver begins with sequestration of the remnants 
within the space of Disse, where ApoE secreted by hepatocytes enhances remnant binding 
and uptake. Heparan sulfate proteoglycans (HSPG) abundant in the space of Disse mediate 
the enhanced binding to facilitate the action of LpL on the remnants also present in the space 
of Disse (Hamilton et al., 1990; Stow et al., 1985).  Molecules taken up by the liver bind to 
proteoglycans as well as lipoprotein receptors such as LRP for internalisation or uptake. For 
the intestinally derived remnant lipoprotein, the uptake by hepatocytes includes, i) LDL 
receptors mediated direct uptake (Ishibashi et al., 1996), ii) the HSPG-LRP pathway mediates 
uptake either by transfer of the remnant from the HSPG to the LRP for internalisation or by 
binding of the remnant lipoproteins to HSPG forming a tertiary complex with the LRP that is 
then internalised. The HSPG are critical in the HSPG-LRP pathway because if absent, the 
remnants do not bind and iii) the HSPG alone can mediate remnant lipoprotein uptake 
(Mahley and Ji, 1999). The LDL receptor remnant uptake is independent from both the HSPG 
and the LRP.  After internalisation, remnants are catabolised in the lysosomes with the 
various remnant catabolic products entering various metabolic pathways. 
 
In its early stages, the endogenous pathway resembles the exogenous pathway but instead of  
chylomicrons, the liver produces VLDL in a process that involves a combination of TG and  
cholesteryl esters and apolipoprotein B-100, resulting in their transportation to the peripheral  
tissues (Shelness and Sellers, 2001). During circulation, the nascent VLDL particles interact 
with HDL particles resulting in HDL particles donating apolipoprotein C-II and 
apolipoprotein E to the nascent VLDL. Similar to chylomicrons the addition of 
apolipoproteins C-II and E to nascent VLDL results in its maturity. The Apo C-II on the 
VLDL surface activates endothelial LpL (Goldberg, 1990), which hydrolyses TGs into FFAs 
and glycerol that are taken up by cells. Just as with chylomicrons, the VLDL-C is transferred 
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to HDL, after esterification. Gradually all of the apo C-II and some of the apo E are returned 
to HDL. After the last of the apo C-II has returned to HDL, the remaining particles are known 
as IDL. Intermediate-density lipoproteins (IDL) are the product of LpL processing of VLDL 
and chylomicrons. IDL are smaller than VLDL. They contain equal amounts of TG and TC 
(30% TG, 30% TC) and a moderate amount of protein (15%). The permanent structural 
protein is apo B-100, and IDL also still contain apo E. More than half of the IDL is taken up 
by the LDL receptor, which recognises apo B-100 and apo E.  The rest is converted to LDL 
by the action of hepatic TG lipase (HTGL), located in the vascular endothelium of the liver, 
which removes some of the TG. After the last of the Apo E has returned to HDL, the 
remaining particles are known as LDL that is even smaller than IDL. LDL contains 
predominantly cholesterol (50%) and protein (25%) and a very small amount of TG (5%). In 
healthy individuals six LDL subfractions with mean density ranging from 1.0268 to 1.0597 
g/ml can be identified. The major differences in chemical composition of the subfractions are 
in the cholesteryl ester to triglyceride ratio which gives them different metabolic and 
atherogenic roles (Shen et al., 1981).  The permanent structural protein is apo B-100, which is 
the only protein in LDL that has a long half-life of 3 days. LDL delivers cholesterol to 
peripheral tissues and are eventually taken up by the LDL receptor (at low LDL levels) or by 
the macrophage scavenger receptor (at high LDL levels). 
 
In de novo endogenous pathway, cholesterol is synthesized from acetyl Co-A in the liver 
regulated by HMG-CoA reductase (3-hydroxy-3-methyl-glutaryl-CoA reductase. In negative 
feedback response the enzyme is inhibited by increased intracellular cholesterol derived from 
the degradation of internalised LDL. LDL is internalised via the LDL receptor and therefore, 
competitive inhibition of the enzyme will result in abrogation of the negative feedback 
response and induce the expression of LDL receptors in the liver. The increased LDLR will 
in turn increase the catabolism of plasma LDL and lowers the plasma concentration of 
cholesterol. This mechanism is the rationale behind the actions of statins. The reductase gene 
transcription is regulated by the sterol regulatory element binding protein (SREBP). When 
activated, SREBP binds to the sterol regulatory element (SRE) found on the 5' end of the 
reductase gene, but when SREBP is inactive, it binds to the ER or nuclear membrane with 
another protein called SREBP cleavage-activating protein (SCAP). When cholesterol levels 
are low, SREBP is released and migrates to the nucleus, where it binds to the SRE and 
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transcription is enhanced. When intracellular cholesterol increases, proteolytic cleavage of 
SREBP from the membrane ceases and any proteins in the nucleus are quickly degraded.  
 
1.3.2.1 Endogenous pathway and ApoE and or PCSK9 
ApoE has been associated with increased cholesterol during normal pregnancy (Tanyanyiwa 
et al., 2016) and in the general population it was associated with increased cholesterol and 
LDL (Masemola et al., 2007). The endogenous pathway is affected by PCSK9 through the 
LDL clearance process. Both gain and loss of function PCSK9 mutation have an impact on 
the type of dyslipidaemia that develops. Gain of function mutations reduces the number 
LDLR through inhibition of endocytic recycling of LDLR back to the plasma membrane 
(Zhang et al., 2007). In addition to its role as receptor ligand molecule for chylomicrons in 
the pathway (Cooper, 1997), ApoE modulates the LpL-mediated processing of triglyceride-
rich lipoproteins in the endogenous pathway. LpL-mediated hydrolysis is attributed to the 
positive arginine residues present on ApoE (Rensen and van-Berkel, 1996). 
 
1.3.3 Reverse Pathway  
This deals with the transport of cholesterol in the cells from the peripheral tissues to the liver. 
Nanscent/Newly formed HDL is synthesised in both enterocytes in the liver and from the  
chylomicron surface membrane liberated during chylomicron metabolism (Brunham et al., 
2006). Nascent HDL is a phospholipid disc with no lipid core but during its circulation, 
accept UC from peripheral tissues and circulating VLDL and LDL resulting in a small 
spherical HDL3-C particle. Movement of UC from cells is mediated by ATP-binding cassette 
transporter A1 (ABCA1) which then combines with apoprotein A-I (apo A-I), the structural 
protein for HDL to produce nascent HDL (Oram, 2002). LCAT, which esterifies the surface 
UC provides neutral lipid that forms the core. When the surface cholesterol is esterified, it 
enters the nonpolar core of HDL thus, leaving the surface of HDL free to acquire more 
cholesterol from lipoproteins and cell membranes. The size of HDL particles increases as 
cholesterol esters accumulate (HDL2). The liver, through a putative HDL receptor delivering 
cholesterol, clears some of the HDL2. HDL then transports cholesterol to where it is needed, 
mostly via CETP, and the liver (for clearance).  Some of the HDL2 is cleared by the liver via 
an HDL receptor and most of HDL2 is cycled back to HDL3, by transferring the CE back to 
the TG-rich chylomicron remnants in exchange for TG via CETP. Therefore, the overall 
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effect of HDL is anti-atherogenic because excess cholesterol in living and dead cells is 
returned to the liver by this reverse cholesterol transport pathway.   
1.3.3.1 Reverse pathway and ApoE and or PCSK9 
HDL is involved in both ApoE and PCSK9 through the presence of ApoE on HDL 
molecules.  ApoE in lipoproteins acts as a ligand of LDLR family proteins and promotes 
lipoprotein particle clearance. ApoE is an efficient cholesterol acceptor in HDL, and the 
binding of ApoE in newly secreted HDL increases the particle size (Gordon et al., 1983). 
PCSK9 mediates regulation of ApoE levels in HDL concentration (Choi et al., 2013). The 
high PCSK9 and CETP activity in patients with metabolic syndrome is directly proportional 
to the increasing number of components that constitute metabolic syndrome. The positive 
correlation between PCSK9 levels and the CETP activity could be that higher PCSK9 
concentrations inhibit LDLR recycling resulting in higher LDL plasma. As a substrate, the 
higher LDL levels triggers increased CETP activity. Conversely, higher CETP activity would 
elicit higher LDL and PCSK9 concentrations (Girona et al., 2016). CETP activity is 
significantly increased in familial hypercholesterolemia patients with PCSK9 Leu181Arg 
gain-of-function mutation (Abifadel et al., 2012). 
1.4 Apolipoprotein E 
 Apolipoprotein E (ApoE) is a 299-amino acid peptide with a molecular weight of 34kilo 
Daltons. The 3.7-kilo bases in length ApoE gene is found on chromosome 19 and contains 4 
exons. ApoE is normally present in serum at approximately 5-8 mg per deciliter (Lusis et al., 
1987). Approximately three quarters of the plasma ApoE is synthesized in the liver, in the 
hepatic parenchymal cells where it is incorporated into VLDL. Other organs, including the 
brain, lungs, spleen, adrenals, ovaries, kidneys, muscle cells and macrophages also produce 
small amounts of ApoE (Fazio et al., 1992). The structure of ApoE is divided into three, an 
amino terminal end made up of 165 residues is highly ordered, and the next 35 residues make 
up a random structure and the carboxyl terminal, which is also highly ordered again. The 
Carboxyl terminal forms the strongest lipid binding area. The structure is made up of 
approximately 62% alpha helices, which are amphipathic and important in lipid binding. 
While also providing a more hydrophilic aspect to the water environment, the rest of the 
secondary structure is made up of beta sheets (9%), beta turns (11%) and random structure 
(18%) (Mahley, 1988). The five arginine and three lysine residues between 140 and 160 are 
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essential for binding to the LDL receptor. ApoE is the primary ligand for several lipoprotein 
receptors, and therefore, plays a crucial role in the clearance of lipoproteins from the 
circulation. Chylomicron and VLDL remnants, which are rich in CE than the original 
chylomicrons contain ApoE that serves as ligand for the hepatic receptors. The chylomicron 
remnants are internalised through the LDL and LRP receptors by endocytosis (Havel et al., 
1998). Its lipid clearance role makes it an important determinant of plasma cholesterol and 
potential biomarker for cardiovascular disease risk (Bennet et al., 2007). Studies have shown 
that mice lacking ApoE (ApoE-/-) accumulate cholesterol-rich remnant particles with plasma 
cholesterol reaching very high levels and accelerated development of atherosclerosis (Pendse 
et al., 2009).   
 
1.4.1 Apolipoprotein E isoforms 
ApoE was first isolated from plasma in 1973 and was originally known as arginine-rich  
apolipoprotein. There are three common isoforms of ApoE designated E2, E3 and E4 
according to their charges in isoelectric focusing. The main differences between the isoforms 
shown in Table 1.2 below are at the amino acid residues 112 and 158. ApoE2 has cysteine at 
both residues and it has the lowest affinity for the LDLR, with less than 2% of normal 
receptor binding activity. Apo E3 has a cysteine at residue 112 and arginine at 158 and has a 
much better receptor binding activity. ApoE4 has arginine at both these residues and shows 
100% normal receptor binding activity and hence, it has a very rapid clearance from HDL, 
VLDL and Chylomicrons (Mahley, 1988). ApoE3 and ApoE4 both have normal LDLR 
building activity as the R at 158 forms a salt bridge with aspartate at 154 leaving the series of 
positively charged R and K between 130 and 148 often to interact with the negatively 








1.4.1.1 Minor ApoE isoforms 
Table 1.2 ApoE: Amino acid residue positions and their charge 
Isoform E2/2 E3/3 E4/4 
Relative Charge 0 +1 +2 
Amino Acid on 112 Cysteine Cysteine Arginine 
Amino Acid on 158 Cysteine Arginine Arginine 
+ = Positive 
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Minor ApoE isoforms have been identified: ApoE1 was found to have similar lipid profile to 
ApoE2 and ApoE5 was located as a band in the basic region relative to apoE-4 on an 
isoelectric focusing gel (Ordovas et al., 1987). ApoE7 also known as ApoE-Suita found 
predominantly in the Japanese population is associated with hyperlipidemia and 
atherosclerosis (Yamamura et al., 1999). 
 
1.4.2 ApoE Nomenclature 
Electrophoretic analysis of ApoE showed that it is composed of numerous isoprotein 
components (Utermann et al., 1982). The complex structure of ApoE stems from both genetic 
polymorphism and post-translational sialylation modifications. Genetic studies have shown 
the existence of alleles at two loci that specify six different ApoE phenotypes, three 
homozygous and three heterozygous (Zannis and Breslow, 1981). Early isoelectric focusing 
technique resulted in a nomenclature system (Utermann et al., 1977), which was different 
from later analysis on two-dimensional polyacrylamide gel electrophoresis (Zannis and 
Breslow, 1981). The difference between the isoelectric and polyacrylamide findings gave rise 
to the creation of a uniform system that describes the ApoE isoproteins, alleles, genotypes 
and phenotypes. The ApoE alleles are 4, 3 and 2 while the major asialo ApoE isoproteins 
seen in plasma by two-dimensional gel electrophoresis is designated ApoE4, ApoE3 and 
ApoE2 respectively. ApoE4 is the most basic while ApoE2 is the most acidic ipoprotein. The 
minor plasma ApoE isoproteins that can be eliminated by treatment with neuraminidase are 
collectively designated ApoEs. Thus, the sialo ApoE isoproteins of ApoE4, ApoE3 and 
AapoE2 are designated ApoE4s, ApoE3s and ApoE2s respectively. Distinction between sialo 
apoE isoproteins can be achieved by adding a number after the subscript as ApoE3s1, 
ApoE3s2 and ApoE3s3 (Zannis and Breslow, 1981). 
 
There are six well characterised ApoE genotypes comprising three homozygous states (E-4/4; 
E-3/3 and E-2/2) and three heterozygous (E-4/3; E-3/2 and E-4/2) states. ApoE and  allelic 
frequency shows a variation among populations around the world as shown in Table 1.3. 
Apo-3/3 phenotype is the most common (ranging 50-70%) and the 3 allele makes up a large 
majority of the ApoE gene pool (typically 70-80%) of the population. The high frequency of 
3-allele lead to the belief that it was the wild type, but the presence of 4 allele in nearly all 









Several studies on the ApoE gene reported varying allele frequencies across the world 
between 1995 and 2007. As reflected in Table 1.3 above ApoE3 is the most frequent allele 
(Hallman et al., 2007). Interestingly, in studies from Europe there is a north to south decline 
in the e4 allele, with a higher frequency in the northern region and a lower frequency in the 
southern region (Gerdes at al., 1996). The frequency of the e3 allele is lower in African 
population than the Caucasians, but e4 allele is higher than in Caucasian populations. The 
high frequency of ApoE3 allele seems to imply that it is a product of mutational changes of 
e4 allele, which is found in high frequencies the African ancestral tribes (Corbo and Sacchi, 
1999). The high frequency of e4 allele among the population groups where the food supply 
was scarce could be an evolutional protective adaption in scarce food situation as it increases 
absorption of cholesterol and plasma cholesterol levels. Therefore, it is not surprising to find 
the e4 allele in high frequencies in the oldest populations known as hunter-gatherers like the 
Khoi San and African Pygmies. Several studies looked at ApoE in relation to variable 
pathologies, but no record of studies looked at its behaviour or effects in DM.  
 
1.4.3 Binding Properties 
The binding properties and mechanism show how ApoE is associated with dyslipidaemic 
states. The heparin-binding domain between 131 and 150 amino acids of ApoE is responsible 
for the high affinity binding to the LDL and LRP receptors (Ji et al., 1997). Receptor binding 
Table 1.3 Ethnic distribution of ApoE 
Population and Location ApoE2 ApoE3 ApoE4 N Study 
Caucasian (Western Europe) 10 75 15 2020 Lucotte et al., 1997 
Zimbabweans (Southern Africa) 16 62 23 690 Tanyanyiwa, 2005 
Pygmies (Central African 
Republic) 
6 54 41 70 Zekraoui et al., 1997 
Khoi San (Bushmen) South Africa 8 55 37 247 Sandholzer et al., 1995  
West, Central and East Africans. 12 71 18 470 Zekraoui et al., 1997 
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is due to the ionic interaction between basic amino acid residues in this region and acidic 
amino acid residues of the LDL receptor. The LDL receptor possesses seven repeated 
segments that include critical acidic amino acids aspartate and glutamate near the N-terminus 
representing the ligand-binding site. The LRP contains 31 domains, homologous to the ligand 
binding sites of LDL receptor (Brown and Goldstein, 1983).  Both residues 112 and 158 are 
outside the binding region of ApoE. The binding affinity cannot be directly linked to residue 
112, but residue 158 can have an influence on the binding affinity depending on the salt 
bridge it forms with other amino acids. The basic amino acids in the 131 – 150 regions are 
largely solvent exposed extending away from the backbone of the helix, forming a basic field 
of charge that may be available to interact with the receptor (Beisiegel et al., 1989). The 
backbone structures of ApoE2 and ApoE3 are essentially identical. However, there are local 
changes in the region of the residue 158. In ApoE3, there is a salt bridge between arginine 
158 and aspartate 154.  ApoE2 has a neutral amino acid cysteine rather than the arginine 
residue at 158 thus, prevents the salt bridge formation resulting in aspartate interacting with 
arginine 150, forming a new salt bridge (Weisgraber et al., 1982).  
 
This interaction swings the side chain of arginine 150 into a new plane outside the  
receptor-binding region and disrupts receptor binding because arginine is part of the  
receptor-binding region. Therefore, the substitution at residue 158 of Apo E2 appears to have 
a secondary effect on the receptor-binding domain of ApoE, affecting binding indirectly 
(Lalazar et al., 1988). All autosomal dominant ApoE mutations cause defective LDL receptor 
binding, but their LDL receptor binding activities are higher than those of autosomal 
recessive ApoE2 mutations. ApoE2 Arg145Cys mutation was reported to produce dys in the 
predominantly black African subjects of Xhosa descent (de Villiers et al., 1997). If present, 
these subjects would fall in the mixed dyslipidaemia phenotype category. Another interesting 
aspect in the African population is the ApoE-2/2 genetic status associated with dys, which 
reduces the rate of remnants clearance. Under normal physiological conditions, subjects with 
E2/2 have lower plasma cholesterol; and dyslipidaemia related to reduction in remnant 
clearance is not apparent. The mechanism involved is that the production rate of remnants 
and their clearance rates are balanced because the normal levels of VLDL results in low 
levels of VLDL remnants. The E2/2 low receptor affinity leads to low influx of cholesterol 
rich VLDL remnants resulting in LDLR up regulation in response to lower influx of remnants 
into the liver. The upregulated LDLR results in increased cholesterol internalisation leading 
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to lower plasma cholesterol compared to other ApoE isoforms. Conditions like DM that result 
in increased production of VLDL remnants and hypothyroidism that result in generalised 
reduced clearance producing the dysβ phenotype, hence the conclusion that an additional 
‘hit/stressor’ is still required for dyslipidaemia to become evident.  
 
1.4.3.1 ApoE and dys-lipoproteinaemia 
Dys also known as broad  disease or type III hyperlipidaemia and remnant removal disease 
is a highly atherogenic dyslipidaemia associated with certain ApoE variants (Smelt and Beer, 
2004). Premature or accelerated atherosclerosis occurs in one third to more than one half of  
individuals with Dys. Peripheral vascular disease involving the lower extremities is almost 
as common as coronary artery disease in Dys. This is different from the distribution of 
vascular disease seen in familial hypercholesterolemia in which there is less involvement of 
the lower extremities. Although the mechanism underlying the predisposition for 
atherosclerosis of peripheral vessels in type III is unknown, it is worth noting that certain 
cholesterol-fed animals with high levels of -VLDL have a higher incidence of peripheral 
vascular disease than of coronary atherosclerosis (Mahley et al., 1985). The association of 
homozygous ApoE-2/2 with dys resulted in numerous investigations for the underlying 
mutations or variants in patients presenting the dyslipidaemic picture. Known common 
variants causing dys are shown in Table 1.4 below.  
 
Table 1.4: Some apo E allele variants associated with dyslipoproteinaemia 
Allele Variant Inheritance LDL-R Binding Researchers 
158ArgCys Recessive 2% Emi et al., 1988.  
136ArgSer Unknown 40% Emi et al., 1988 & Wardell et al., 1987 
142ArgCys Dominant 20% Smit et al., 1990 
145ArgCys Dominant 45% de Villiers et al., 1997 
146LysGln Dominant 40% Smit et al., 1990 
E3(Leiden). dominant  defective binding Havekes et al., 1986 
Key: Arg – Arginine; Cys – Cysteiene; E3 – ApoE3; LDL-R – Low density lipoprotein receptor  
 
These variants are rare, and a lot of work is still being done especially in the eastern world 
(Corbo and Sacchi, 1999). ApoE1 has been associated with severe type III 
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hypolipoproteinaemia (Mann et al., 1995). ApoE5 has two common variants both associated 
with high cholesterol but with different effects on the cardiovascular disease (Wardell et al., 
1991). ApoE7 is interesting because it is associated with increased plasma lipid levels and 
accelerated atherosclerosis due to the defective binding to LDL receptors but has preferential 
association with very low-density lipoproteins (VLDL), (Dong et al., 2000). ApoE an 
essential mediator of lipid metabolism in normolipidemic patients plays a major role in 
diabetic dyslipidaemia. The common dyslipidaemic phenotypes associated with both T1DM 
and T2DM includes increases in VLDL triglycerides, decreases in HDL, increased 
smaller/denser LDL, reduced clearance of postprandial chylomicrons, reduction in 
lipoprotein lipase (LpL) activity, and decrease in LDLR (Goldberg, 2001). It has been and 
still remains a problem trying to separate the lipid-independent effects of DM on 
cardiovascular disease from the DM induced hyperlipidemia cardiovascular complications 
(Wu and Huan, 2007; Johnson et al., 2010). The ApoE modulation of diabetic dyslipidaemia 
is through its central link between the processes of glucose and lipoprotein metabolism 
(Isezuo et al., 2003). ApoE4 has been shown to be less inhibitory to glycation and oxidation 
compared to the ApoE3 but more inhibitory than ApoE2 isoform. Modifications like 
glycation and oxidation to the cells of the vessel wall and LDL particles that are atherogenic 
occur more frequently in the diabetic setting (Shuvaev et al., 1999; Miyata and Smith, 1996; 
Mabile et al., 2003,). Animal experiments demonstrated that mice expressing ApoE3 were 
less susceptible to atherogenesis than those expressing E4 (Altenburg et al., 2007).  
1.5 Proprotein Convertase Subtilisin Kexin 9 (PCSK9)  
PCSK9 also known as neural apoptosis regulated convertase, NARC-1 and was initially  
identified as a proprotein convertase family with a role in the regeneration of the liver and  
differentiation of cortical neurons (Seidah et al., 2003). PCSK9 gene is located on the small 
arm of chromosome 1p32 and contains 12 exons and 11 introns (Seidah and Prat, 2007). 
PCSK9 regulates LDL receptors which are plasma membrane glycoproteins responsible for 
the removal of LDL particles in circulation (Brown and Goldstein, 1985). Its involvement in 
lipid metabolism became apparent when those with autosomal dominant mutations developed  
hypercholesterolemia (Abifadel et al., 2003). The development of hypercholesterolemia is 
due to the inability of LDLR recycling leading to high levels and prolonged circulation of 
LDL-C. The prolonged circulation results in increased exposure to free radicals, hence 
susceptibility to oxidation and risk to coronary heart disease (Abifadel et al., 2003). The 
normal feedback mechanism of increasing synthesis of the LDLR is effective only when 
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intracellular cholesterol is low (Brown and Goldstein, 1997), because cholesterol is delivered 
into the cell and PCSK9 acts as chaperone directing LDLR to its degradation (McNutt et al., 
2007). Studies have identified separate routes involved in PCSK9 induced LDLR degradation 
(Poirier et al., 2007). The extensively studied mechanism of action associated with 
hypercholesterolemia involves PCSK9 binding to the first epidermal growth factor-like repeat 
(EGF-A) of LDLR. When LDL binds to the LDLR on which PCSK9 is attached, the PCSK9-
LDL receptor complex is internalised. After internalisation, the PCSK9 component inhibits 
endocytic recycling of LDLR back to the plasma membrane resulting in lysosomal 
degradation of the complex (Zhang et al., 2007). The acidic environment in the endosome 
increases the PCSK9 affinity for the LDL receptor. The epidermal growth factor (EGF)-like 
repeat A of the LDL receptor region has been shown to be essential for recycling of the LDL 
receptor from endosomes to the cell surface when there are no molecules binding at its site 
(Sun et al., 2012). Its role in cholesterol metabolism made its inhibition a prime target for 
treating hypercholesterolemia (Park et al., 2004; Maxwell and Breslow, 2004; Benjannet et 
al., 2004).  One of early methods used was blocking the activity of PCSK9 with an antibody. 
The inhibition prevents the degradation of LDLR thus, enhancing their recycling to the 
surface of the cell (Chan et al., 2009). This increases the clearance of LDL from the 
circulation. Inhibition of PCSK9 was reported in improving the dyslipidaemia seen in T2DM 
patients as well as non-diabetics (Sattar et al., 2016). The other PCSK9 variant is associated 
with increased number of LDL receptors. This enhances removal of circulating LDL leading 
to lower levels in plasma, a feature associated with reduced risk of coronary heart disease 
(Cohen et al., 2006; Zhao et al., 2006). The phenotype of hypercholesterolemia associated 
with reduced number of receptors and hypocholesterolaemia associated with increased 
number of receptors resulted in reports and investigations into PCSK9 mutations.   
1.5.1 PCSK9 Mutations 
PCSK9 gene mutations associated with dyslipidaemia can be classified into two major groups 





























These mutations increase LDLR levels on the surface of the hepatocyte, resulting in increased 
LDL clearance and therefore low plasma LDL levels. The loss-of-function mutations were 
identified in African-Americans with nearly 1 in 50 having one of two Y142X and C679X 
nonsense mutations in PCSK9, which lowers LDL levels by nearly 30% (Cohen et al., 2006; 
Hallman et al., 2007). A separate missense mutation that results in lowering of LDL by nearly 
15% was identified in Caucasians. Besides lowering cholesterol levels there was a significant 
reduction in coronary heart disease (Cameron et al., 2006; Yascara et al., 2014).  Even though 
the loss of function mutation appears to have no adverse consequences, it would be 
interesting to assess the effects of statin induced upregulation of PCSK9 (Dubuc et al., 2004; 
Rashid et al., 2005; Careskey et al., 2008) in diabetic patients especially in the Southern 
African population where loss of function mutation has been reported (Hooper et al., 2007). 
Four loss-of-function mutations have been identified and well described, showing some 
ethnic differences, with one of two nonsense mutations Y142X and C679X being 
 
 
Figure 1.1 Common PCSK9 Mutations 
Schematic representation of common PCSK9 mutations. Gain of function displayed at the top of the frame and 
loss of function mutations at the bottom of the frame. 
 31 
 
predominant in the African population; while the Q152H, R46L, L10A53V and I474V 
PCSK9 variants are found in Caucasians (Cohen et al., 2005). Both L10A53V and I474V 
produce dyslipidaemia in the form of low LDL levels, but they have different serum PCSK9   
concentrations. Such variations point towards the presence exonic variant with different 
effects on LDL levels (Abifadel et al., 2009). It is also possible that there are different 
mechanisms of action in these two variants and therefore PCSK9 measurement might not be a 
marker as a measure of its function (Mayne et al., 2013). A study in Africa reported increased 
plasma TC and LDL levels in E670G carriers than in non-carriers and E670G increased their 
risk for coronary artery disease (Slimani A et al., 2014). 
 
The second group is those causing hypercholesterolemia secondary to the enhanced function 
of the protein (gain-of-function). These mutations decrease LDLR levels on the surface of the 
hepatocyte, resulting in a reduction of LDL clearance, thus increasing their plasma levels. 
The identification of two gain-of-functions increased interest in PCSK9 research, and the 
revelation that FH was not only confined to LDLR mutations (Abifadel et al., 2003).  
1.5.2 PCSK9 and DM 
Until the recent Mendelian randomisation study (Schmidt et al., 2017) and PCSK9 SNP  
association with T2DM (Lotta et al., 2016), this project was the first to look at the possible  
association between T2DM and PCSK9 variants. In the Mendelian randomisation study, it 
was observed that four PCSK9 variants rs11583680, rs11591147, rs2479409, and rs11206510 
demonstrated some associations with increased fasting glucose and WHR. The variants  
associated with lower LDL demonstrated an increased risk of T2DM (Schmidt et al., 2017). 
Emerging reports of an association between alleles influencing lipid metabolism and the risk 
of DM shows that those carrying alleles causing familial hypercholesterolemia have a lower  
incidence of DM compared to unaffected family members (Besseling et al., 2015). 
A positive correlation between PCSK9 levels and HbA1c in patients with T2DM has been  
reported but such correlation was absent in non-diabetic patients (Yang et al., 2016). These  
findings are significant because non-diabetics are expected to have normal HbA1c. Another  
correlation study reported elevated PCSK9 levels in untreated FH patients, especially the  
homozygous patients. In these patients high-dose statin therapy further increased PCSK9 
levels (Raal et al., 2013). PCSK9 inhibitors are effective in lowering LDL and many studies 
suggest a positive association of plasma PCSK9 levels with glycaemic parameters and risk of 
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T2DM. However, the comprehensive the impact of PCSK9 inhibitors on glycemic control 
T2DM remains unclear (Momtazi et al., 2017).  
 
1.6 Assessment of possible gene-gene (ApoE-PCSK9) interactions 
Studying two genes (ApoE and PCSK9) whose variants are independently associated with  
pathology provides an opportunity to interrogate the phenomenon of gene interactions. In 
gene interactions, specific alleles of one gene mask or modify (enhance, suppress or in some 
way alter) the expression of alleles of a second gene. If the interaction is synergistic, the 
contribution of two mutations to the phenotype of a double mutant exceeds the expectations 
from the additive effects of the individual mutations (Perez et al., 2009). Sometimes two 
genes produce a phenotype that might not be the expected product after taking into 
consideration the individual gene effects. For instance, if an ApoE gene variant associated 
with dyslipidaemia is found in a subject carrying a PCSK9 gene also associated with 
dyslipidaemia, the phenotype would be expected to have dyslipidaemia similar to a subject 
with a homozygous gene for dyslipidaemia. In genetic interaction, the results of two different 
genes can reveal the functional relationships between genes and pathways (Mani et al., 2008). 
In qualitative genetics the term epistatic was first used to describe a masking effect where a 
variant or allele at one locus prevents the variant at another locus from manifesting its effect. 
However, in quantitative genetics, epistasis refers to a deviation from additivity in the effect 
of alleles at different loci with respect to their contribution to a quantitative phenotype, for 
example, dyslipidaemia (Fisher, 1918). Considering that ApoE and PCSK9 are 
predominantly associated with the exogenous and endogenous pathways respectively, it 
would be interesting to see the results of different mutations in one subject. Mathematical 
instruments and definitions of the genetic interaction predict four possible outcomes termed 
Product, Additive, Log, and Min. Under certain conditions, the outcomes follow one of the 
predictions but can also deviate dramatically (Boone et al., 2007). 
 
The selection of discriminant and synergic genes has been useful for medical diagnosis and 
prognosis. The mathematical definitions and instruments can be very complex with the pair-
wise interactions I (X 1; X 2; Y) defined as I (X1; X2; Y) =I (X1, X2; Y) −I (X1; Y) −I (X2; 
where I is the symbol for mutual information, I (X 1; Y) is the individual effect of gene X 1 
relative to phenotype Y, I (X 2; Y) is the individual effect of gene X 2 relative to Y, and I (X 
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1, X 2; Y) is the joint effect of X 1 and X 2 relative to Y. A positive value of I (X 1; X 2; Y) 
indicates synergy, while a negative value of I (X 1; X 2; Y) indicates redundancy (Xing et al., 
2017). These mathematical instruments are applied in genome wide association studies 
(GWAS). These studies look at methods to identify associations between genetic regions 
(loci) and traits (including diseases). Looking at the above formula, X1 would possibly be 
ApoE and X2 would be PCSK and the phenotype would be dyslipidaemia. 
 
1.7 Dyslipidaemia 
1.7.1. Classification of Dyslipidaemia 
Dyslipidaemia is the presence of lipid and/or lipoprotein abnormalities characterised by high  
serum TG and TC increased small-LDL and subnormal HDL. For clinical and therapeutic 
management purposes a simpler practical system of classification categorises dyslipidaemias 
based on increases in cholesterol only (pure or isolated hypercholesterolemia), increases in 
TGs only (pure or isolated hypertriglyceridemia), or increases in both TC and TGs (mixed or 
combined hyperlipidaemias). However, this system fails to account for specific lipoprotein 
abnormalities e.g. low HDL or high LDL that contribute to disease despite normal TC and 
TG levels. The World Health Organisation (WHO)/Fredrickson classification is more 
comprehensive, it considers the pattern and relationship of lipoproteins (Fredrickson,1971). 
Even though it is old, its adoption by WHO signifies that it is well known and widely 
accepted and useful in identifying a proportion of both primary and secondary 
hyperlipidaemias. Dyslipidaemia is considered primary if the aetiology is a genetic defect-
giving rise to a product (enzyme) that cannot optimally participate in lipoprotein metabolism. 
This often requires pharmacological intervention with or without life style adjustments. 
Modern and advanced methods have resulted in the discovery of more primary genetic causes 
that may result in hypolipidaemia and were therefore not classified under the 
WHO/Fredrickson system, which looked at hyperlipidaemia. Secondary dyslipidaemia is 
often arising due to failure in another system that is directly linked to lipid metabolism as 
seen in renal pathology, hypothyroidism, DM and obesity. Some secondary dyslipidaemias 
may have an underlying genetic defect with reduced penetrance or may need a hit (factors) 
for them to present a dyslipidaemic phenotype. In cases where it may not be possible to 
identify the possible genetic cause, it is cost effective to exclude secondary causes before  
exploring possible primary causes. In some cases, it is possible to speculate on the possible  
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primary cause based on the time and factors associated with the appearance of the phenotype.  
 
1.7.2 Mechanisms of Secondary Dyslipidaemia 
Secondary dyslipidaemia accounts for ±40% of all hyperlipidaemias, therefore it is important 
and cost effective to exclude them before venturing into the genetic route. Secondary causes 
can precipitate or worsen a coexistent inherited hyperlipidaemia (Carr and Brunzell, 2004). 
Long term complications of DM include renal pathology (nephrotic syndrome and renal 
failure) which can, independent of DM cause dyslipidaemia (Toyama et al., 2014), with a 
picture similar to the one seen in DM. As a common complication of DM and as another 
cause of secondary dyslipidaemia, renal pathology and the mechanism of dyslipidaemia will 
be briefly discussed. 
 
1.7.2.1 Nephrotic syndrome 
Nephrotic syndrome (NS) is characterised by increased permeability of the glomerulus to  
proteins, resulting in proteinuria greater than 2.5 g/day, presence of oedema caused by loss of 
oncotic pressure secondary to urinary loss of proteins. The loss triggers reflex compensatory  


















Figure: 1.2 Schematic representation of the mechanism of dyslipidaemia in nephrotic 
syndrome. FC – Free Cholesterol; HDL – High Density Lipoprotein; LCAT – Lecithin Cholesterol Acyl 
Transferase; LDL – Low Density  







Non-excretion of the larger lipoproteins and loss of smaller metabolising proteins results in  
increased serum lipoproteins producing the dyslipidaemic picture associated with nephrotic  
syndrome (Attman and Alaupovic, 1990). Free cholesterol derived from cells combines with 
apoprotein A-I (apo A-I), a structural protein for HDL to form nascent HDL. The free 
cholesterol on the surface is then esterified by the actions of LCAT and internalised in HDL 
to form HDL3. Therefore, LCAT deficiency resulting from urinary loss in nephrotic 
syndrome causes accumulation of unesterified cholesterol in certain body tissues and HDL 
maturation (conversion of HDL3 to HDL2) is impaired and therefore, reduce/limit the 
cardiovascular protective, functions of HDL (Gavish et al., 1987). Hypoalbuminemia 
secondary to proteinuria stimulates a compensatory increased synthetic function of the liver 
which includes upregulation of 3-hydroxy-3-methylglutaryl CoA reductase with a consequent 
hypercholesterolemia. Therefore, both increased synthesis and decreased clearance of 
lipoproteins may contribute to the dyslipidaemia in nephrotic syndrome (Attman and 
Alaupovic, 1990). The urinary loss of other liporegulatory factors leads to decreased activity 
of lipolytic enzymes and resulting in impaired clearance of cholesterol- and triglyceride-rich  
lipoproteins. Increased Apo (a) biosynthesis elevates the plasma Lp (a) concentration 
increasing the risk for development of cardiovascular disease and thromboembolism 
encountered in in NS (Mahmoodi et al., 2008).  
 
1.7.2.2 Chronic Renal Failure 
There are many causes of chronic renal failure with the most common being 
glomerulonephritis, DM mellitus, and hypertension. However, the net effect is a progressive 
loss in the number of functioning nephrons. Figure 1.3 below shows the mechanism of 





























Central to dyslipidaemia in chronic renal failure is the disruption and alteration of 
components required for the metabolism of HDL (Vaziri, 2006). The downregulation of 
LCAT and upregulation of CETP result in reduction of HDL. The downregulation could be  
secondary to the uremic state, which is not conducive for optimal metabolic functions. The  
reduction in metabolic (catabolic) rate is attributed to the reduced LpL enzyme activity due to 
the increased presence of LpL inhibitors. Apolipoprotein C-III is a potent inhibitor of 
lipoprotein lipase levels increase possibly due to reduced clearance. A decreased 
apolipoprotein C-II, an activator LpL ratio to Apolipoprotein C-III (apolipoprotein C-II/C-III 
ratio) reflects the disproportionate increase of Apolipoprotein C-III (Cheung et al., 1996; 
Hirano et al., 2003). Therefore, the common factor in both NS and CKD is LCAT, which is 
deficient due to renal loss in the former and downregulated due to uraemia in the later. It has 
also been noted that hyperlipidemia can accelerate progression of renal disease by several 
mechanisms (Trevisan et al., 2006). Mesangial cells express LDL receptors and when bound 
LDL is oxidised, it induces mesangial cell proliferation, which in turn enhances the 
production of chemokines like macrophage chemo-attractant protein-1), cytokines such as 
 
Figure 1.3 Schematic representation on the mechanism of dyslipidaemia in chronic renal 
failure. FC – Free Cholesterol; HDL – High Density Lipoprotein; LCAT – Lecithin Cholesterol Acyl Transferase; 










Figure: 1.12: Mechanism of lipid abnormalities in nephrotic syndrome 
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interleukin 6 and growth factors. Macrophage chemo-attractant protein-1 induces recruitment 
of macrophages, which can infiltrate the glomerulus and become foam cells that release 
cytokines. Oxidised LDL increases the adhesion of monocytes to glomerular endothelial 
cells, favouring monocyte infiltration, and affects tubular epithelial cells (Abrass, 2004). 
Hypercholesterolemia and hypertriglyceridemia are also associated with podocyte injury, 
which secondarily leads to mesangial sclerosis (Joles et al., 2000). Oxidised LDL induces 
apoptosis of podocytes and loss of a nephrin an important part of the glomerular filtration 
barrier. This results in increased albumin diffusion in the podocyte monolayers resulting in 
apoptosis (Bussolati et al., 2005). Several studies, Atherosclerosis Risk in Communities study 
(Munter et al., 2000), Physicians’ Health Study (Schaeffner et al., 2003), the Framingham 
Offspring study (Fox et al., 2004) and Helsinki Heart Study (Manittari et al., 1995) show that 
different aspects of dyslipidaemia are associated with development of chronic kidney disease. 
On the other hand, some studies reported that dyslipidaemia worsened renal failure (Massy et 
al., 1994; Hunsicker et al., 1997). Treatment of dyslipidaemia with lipid lowering agent has 
been shown to improve renal function biochemistry (Athyros et al., 2003; Tonelli et al., 
2003). 
 
1.7.3 Lipids and Lipoproteins in diagnosis of dyslipidaemia 
The three most commonly referred or referenced diagnostic criteria for dyslipidaemia 
include: i) National Cholesterol Education Program (NCEP) Adult Treatment Panel III 
(ATPIII); ii) World Health Organisation; and iii) European Atherosclerosis Society. In South 
Africa we adopted the European Guidelines for the Prevention of Cardiovascular Disease to 
replace the previously published South African Lipid Guidelines (Klug et al., 2012). The 
three systems all consider the presence of any one of the following as dyslipidaemic: TC 
>5.2mmol/L; LDL >3.5mmol/L; Triglyceride >1.7mmol/L; HDL <0.9mmol/L in males; and 
<1.0mmol/L in females. The Atherogenic index (TCl ÷ HDL) >5.0 reflects low HDL in 
relation to TC. Hyperlipidaemia is statistically; any lipid value above the 97.5th percentile 
(mean + 2 SD) and these can more specifically be classified as  
i) TC: Ideal <5.2mmol/L, moderate hypercholesterolaemia 5.2 – 7.5mmol/L and severe  
ii) being >7.5mmol/L and this is often seen in patients with genetic defects. 
iii) TG: Ideal <1.7mmol/L, moderate hypertriglyceridaemia 2.5 – 5.0mmol/L and 
moderate to severe being >5mmol/L.      
iv) LDL Ideal level < 3.5 mmol/L. 
 38 
 
v) HDL Ideal level > 1.2 mmol/L. 
vi) Apolipoprotein B, Ideal <100mg/dl. 
vii) Apolipoprotein A, Ideal >120mg/dl 
viii)  Lipoprotein (a), Ideal < 30 mg/dl.  
 
The South African National Health Laboratory Services (NHLS), the laboratory providing  
diagnostic services in all government health institutions incorporates an estimate of the  
Framingham 10-year risk of CHD in the lipid profiles reports. The Framingham risk 
assessment tool provides a prediction on the chances of developing cardiovascular disease in 
the next 10 years. The assessment tool considers the patients, age, gender, TC, HDL, tobacco 
smoking, presence of DM and the patient’s systolic blood pressure and if the blood pressure 
is being pharmacologically managed (D’Agostino et al., 2008). Following the 52nd SEMDSA 
and 15th LASSA meeting in May 2017, treatment targets and goals for cardiovascular disease 
prevention for diabetic dyslipidaemia were recommended. These include TC <4.5mmoml/L, 
LDL <1.8mmol/L, HDL >1.0mmol/L for males and >1.2mmol/L for females, triglyceride 
<1.7mmol/L, systolic blood pressure <140mmHg. diastolic blood pressure <90mmHg and 
BMI <25kg/m2.  
 
Cardiovascular risk assessment science is rapidly evolving with new biomarkers, genetic 
tests, ratios and permutations being evaluated and being promoted for routine use. Even 
though these new considerations correlate significantly with cardiovascular risk, there has 
been no evidence to show that their inclusion to existing risk estimates, improves the 
predictive ability. Parallel to this study, we did a research that was accepted for publication 
by Central African Journal of Medicine in August 2016 reference 06/16. Analytical methods 
available in most public health service sector laboratories can measure TC, TGs, and HDL 
directly and calculate LDL from the Friedewald Equation (Friedewald et al., 1972). In this 
method, VLDL is estimated by TG ÷ 5 mg/dL or TG÷ 2.2 mmol/L because the cholesterol 
concentration in VLDL particles is usually one fifth of the total lipid in the particle. 
Therefore, this calculation is valid only when TGs are <4.5 mmol/l and patients are fasting, 
because postprandial lipids have chylomicrons which have lower VLDL. Therefore, such 
samples overestimate LDL. The calculated LDL value incorporates measures of all non-
HDL, non-chylomicron cholesterol, including that in IDL and lipoprotein (a) Lp (a). LDL can 
also be measured directly using plasma ultracentrifugation (gold standard), which separates 
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chylomicrons and VLDL fractions from HDL and LDL Immunoassay methods are also 
available for the direct measurement of LDL, but these are found mainly in research, private 
and well-resourced laboratories. New formulas for the calculation of LDL have emerged (de 
Cordova et al., 2013; Hattori et al., 1998), but the Friedewald equation is still the method of 
choice in the region (Onyenekwu et al., 2014). Cholesterol is a negative acute phase reactant 
that decreases while lipoprotein (a) levels and TG increases in inflammatory states. As a 
negative acute phase reactant, it was previously recommended that measurement of 
cholesterol should be postponed until after resolution of acute illness. Lipid profiles can vary 
for about 30 days after an acute MI and therefore results obtained within 24 hours after MI 
are usually reliable enough to guide initial lipid-lowering therapy (Jackson et al., 1987). 
 
LDL the current primary target in the management for dyslipidaemia does not seem to have  
reduced the progression to development of (CAD) even if the LDL levels are optimally  
maintained. It appears that besides the LDL constituents there are other atherogenic 
components. Therefore, non-HDL used in the Helsinki Heart Study3 became topical because 
non-HDL represents the cholesterol content present in all the atherogenic lipoproteins 
including LDL (Frick et al., 1987). Thus, non-HDL provides a more holistic picture of the 
atherogenic components.   
 
Advantages of using non-HDL are that non-HDL incorporates all atherogenic lipoproteins,  
including LD, it is easily calculated from a lipid profile by a simple subtraction of HDL from  
TC (non-HDL = TC minus HDL) and therefore, there is no additional costs, there is no need 
for fasting samples as opposed to LDL, which can be affected by triglyceride in non-fasting 
samples (Ballantyne et al., 2001). Current management principles can be applied 
proportionally as high non-HDL would require increased levels of lipid-lowering agents, as 
well as lifestyle modification. Non-HDL management takes into account the patient’s level of 
risk as well as the levels of LDL. Non-HDL levels are cut off and classified according to 
level of risk: i) ≥5.7 mmol/L is considered very high for all individuals, ii) 4.9 – 5.6 mmol/L 
is considered high, iii) 4.1 – 4.8 mmol/L is considered moderately high, iv) 3.4 – 4.0 mmol/L 
is considered near ideal, v) below 3.4 mmol/L is considered ideal for people with risk factors 
for coronary heart disease, and vi) ≤ 2.6 mmol/L is considered ideal for people at very high 
risk of heart disease and this is where the dyslipidaemic participants would be classified 
under. Lipid and Lipoprotein ratios seem to perform better as biological markers of 
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cardiovascular related dyslipidaemia than the use of the individual traditional markers 
(Kannel, 2005; Packard et al., 2005).  
 
1.8 Pharmacological management of dyslipidaemia 
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and 
Treatment of High Blood Cholesterol in Adults [Adult Treatment Panel (ATP)-III], approach 
to managing dyslipidaemia includes lifestyle changes, dietary modifications and increased 
physical activity. Dietary treatment of hyperlipidemia forms the baseline for the dose and 
frequency on which pharmacological intervention can be initiated (NCEP, 1993). DM on its 
own is a major cardiovascular risk factor conferring about three-fold absolute adjusted risk of 
CVD death (Stamler et al., 1993; Sever et al., 2005). In South Africa, the South African Heart 
and the Lipid and Atherosclerosis Society of Southern Africa adopted the European Society 
of Cardiology together with the European Atherosclerosis Society management of 
dyslipidaemia guidelines (Reiner et al., 2011). Based on the updated Framingham risk charts, 
management is based on the cardiovascular risk score and LDL levels. Patients in the very 
high-risk strata are not risk scored. Type 2 DM on its own and patients with chronic kidney 
disease with (glomeruli filtration rate (GFR) <60ml/minute/1.73m2 fall in the very high-risk 
group (Klug et al., 2012). The decision to treat dyslipidaemia in diabetic patients is based on 
the assumption that reducing the LDL from any baseline level will reduce the occurrence of 
cardiovascular disease (CVD). It has been clearly shown that diabetic patients should be 
treated with a statin with a view of maintaining LDL of 2.6mmol/L (<100 mg/dl) (ADA, 
2008). In South Africa the 52nd SEMDSA and 15th LASSA meeting in May 2017 
recommended treatment targets for diabetic dyslipidaemia to achieve TC <4.5mmoml/L, 
LDL <1.8mmol/L, HDL >1.0mmol/L for males and >1.2mmol/L for females and triglyceride 
<1.7mmol/L systolic blood pressure <140mmHg, diastolic blood pressure <90mmHg and 
BMI <25kg/m2 (Amod et al., 2017). 
 
1.8.1 Statins  
Statins have been shown to reduce cardiovascular events and all-cause mortality. Differences 
in structure, potency, lipophilicity and pharmacokinetics exist among the statins, but 
essentially, they all have the same mode of action through inhibition of the activity of  
3-hydroxy-3-methylglutaryl (HMG)-CoA reductase, the enzyme that catalyses conversion of 
HMG-CoA to mevalonate, an early rate-limiting steps in cholesterol synthesis, resulting in  
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decreased cholesterol synthesis (Mabuchi et al., 1981). The common types of statins (brand 
names in brackets) with equivalent doses that can produce a 30–40% reduction in LDL  
respectively include: i) atorvastatin (Lipitor) 10mg, ii) Fluvastatin 80mg (Lescol, Lescol XL 
80mg), iii) lovastatin (Mevacor, Altoprev 40mg), iv) pravastatin (Pravachol  40mg),  
v) rosuvastatin (Crestor 5mg), vi) simvastatin (Zocor 40mg), and vii) pitavastatin (Livalo 
2mg) (Stender et al., 2005).   
 
At CHBAH diabetic clinic and most public-sector health institutions simvastatin (Zocor) is 
the main statin used. The presence of several statins means there is variability in clinical 
response to treatment. The variability could be in part due to pharmacogenetics in the 
metabolism of statin in the pathway that is catalysed by Cytochromes P450 (CYPs) and 
Uridine diphosphate glucuronosyltransferases (UGT) gene family enzymes. The 
pharmacokinetics of individual statins depends on their hydrophobicity with the more 
hydrophilic statin like pravastatin require active transport into the liver and therefore not 
dependent on cytochrome P450 (CYP) enzymes for metabolism. Like other hydrophilic 
compounds the excretions is mainly renal. Less hydrophilic compounds are transported by 
passive diffusion and are metabolised by CYP enzymes and transported into the biliary tract 
for excretion (Whirl-Carrillo et al., 2012).  
 
Besides their lipid lowering functions, statins have other beneficial properties that include  
improvement of endothelial function. The mechanisms in enhancing endothelial function 
include prevention of the downregulation of endothelial nitric oxide synthase (eNOS), an 
enzyme that catalyses the formation of nitric oxide (NO) from L-arginine. eNOS are inhibited 
by caveolin-1, which is increased by LDL and therefore the reduction of LD removes the 
inhibition (Feron et al., 2001). Statins have been reported to possess anti-inflammatory 
properties thereby reducing the risk of coronary artery disease (Ridker et al., 1998). These 
properties were demonstrated in the justification for the use of statins in Primary Prevention: 
An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. 
 
1.8.2 Other lipid lowering drugs  
Ezetimibe, an inhibitor of cholesterol intestinal absorption, is a lipid lowering agent 
commonly used in combination with a statin. It reduces low density lipoprotein (LDL) and 
triglyceride but increases high density lipoprotein cholesterol levels. As seem in other 
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combination therapies ezetimibe and statin achieves LDL targets in a greater proportion of 
patients than statin monotherapy. Besides the significant decrease in lipoproteins it improves 
glycaemic control in T2DM (Sarigianni et al., 2010). Bile-Acid Acid Binding Resins were 
once the major lipid-lowering drugs but are now used as adjuncts to statin therapy for patients 
who require further reduction of cholesterol levels beyond available statin. The commonly 
used drugs are cholestyramine and colestipol, whose mechanism of action is binding bile 
acids (not cholesterol) in the intestine. The enterohepatic circulation of bile acids is 
interrupted resulting in the reduction of serum LDL concentrations in patients who are 
already receiving a statin (Mabuchi et al., 1983).  
 
Nicotinic acid works by inhibiting the mobilisation of free fatty acids from peripheral tissues, 
thereby reducing hepatic synthesis of triglycerides and secretion of VLDL. The reduction in 
VLDL translates to a reduction in LDL (Knopp et al., 1985). Nicotinic acid has also been 
given in combination with other drugs, such as a bile-acid–binding resin, fibrates and statins 
resulting in additional lowering of lipoproteins with a potential to reduce cardiovascular 
events beyond that of monotherapy (Stein et al., 1996). Fibrates, typically clofibrate  
(ethyl p-chlorophenoxyisobutyrate) resemble short-chain fatty acids. They increase fatty-acid 
oxidation in the liver resulting in increased formation of ketone bodies and decreased 
secretion of triglyceride-rich lipoproteins. In muscles, the increase in fatty-acid oxidation is 
associated with an increase in both lipoprotein lipase activity and the uptake of fatty acids. 
Fibrates are the most effective triglyceride lowering drugs. Fibrates also increase the 
buoyancy of LDL particles thus reducing levels of small dense LDL (Auwerx et al., 1996; 
Staels et al., 1998). 
1.9 Diabetic dyslipidaemia  
More cardiovascular disease occurs in patients with DM and one of the common metabolic  
abnormalities in these patients is dyslipidaemia with a characteristic pattern, termed diabetic 
dyslipidemia (Elinasri and Ahmed, 2008). Type II DM coupled with variants of proteins  
associated with lipid metabolism, more than one form of dyslipidaemia can be expected 
(Flores et al., 2003; Hansen, 2003; Gloyn, 2003; Barroso et al., 2003). A combination of the 
two as seen in diabetic dyslipidaemia is myriad of genetic, environmental and geographical 
factors involvement. With such a complex genetic picture, a complete investigation into 
genetics involved dyslipidaemia seen in diabetic patients would be very interesting. This was 
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done in this study by focusing on ApoE and PCSK9 variants. Diabetic dyslipidaemia features 
include reduced high-density lipoprotein (HDL), elevated triglycerides, elevated LDL and 
postprandial lipemia. It is interesting to note that both DM or insulin resistance and 
dyslipidaemia are components in the two definitions of the National Cholesterol Education 
Program Adult Treatment Panel III (NCEP: ATP III) and International Diabetes Federation 
(IDF) for metabolic syndrome (NCEP, 2001). Paralleling the unabated rise in DM is the 
worldwide increase in the prevalence of the metabolic syndrome. Of concern is that in Africa, 
there is an even higher prevalence with a rate of 43% reported for black Zimbabweans 
(Makuyana et al., 2004); and a rate of 60% in a clinical study of 40 urbanised South African 
blacks with established coronary artery disease (CAD) (Ntyintyane et al., 2006). 
 
1.9.1 Subsets of diabetes and dyslipidaemia 
The diagnosis and classification of the different subsets of DM occur in a manner that  
appears to be incidental and therefore, details on the specific type of dyslipidaemia that might 
be present has not been fully characterised. To this end, description of dyslipidaemia in DM 
has been confined to T1DM and T2DM.  Poorly controlled T1DM is commonly associated 
with hypertriglyceridemia and reduced HDL (Ginsberg, 1996). The same picture is seen in 
T2DM except that there is reduction in size of LDL to smaller and more atherogenic species 
known as small dense LDL. Small dense LDL can also be seen in in prediabetes with insulin 
resistance but normal plasma glucose. This feature of abnormal of insulin action and not 
hyperglycaemia is attributed for the lipid abnormality (Haffner et al., 2000).   
1.9.1.1 Lipoprotein abnormalities in DM 
Defects in insulin action and hyperglycaemia can lead to disruptions in lipid metabolism 
resulting in a lipid phenotype associated with hyperglycaemia. T1DM provides a much 
clearer understanding of the relationship among DM, insulin deficiency, and lipid/lipoprotein  
metabolism (Hirano et al., 1991). Diabetic dyslipidaemia is a result of deficiency or absence 
of several factors such as insulin actions on liver apoprotein production, peripheral actions of  
insulin on adipose and muscle, lipoprotein lipase (LpL), actions of CETP. The production of 
apolipoprotein B (apoB), the major protein component of very low-density lipoprotein 
(VLDL) and LDL is increased in DM (Albers et al., 2008). LpL is the major enzyme 
responsible for conversion of lipoprotein triglyceride into free fatty acids, and hence, it is the 
major determinant of both serum triglyceride and HDL concentrations. In both adipose tissue 
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and skeletal muscle, it is insulin dependent. In insulin deficiency its activity is low but 
increases upon insulin therapy. In insulin deficiency, the low LpL results in elevation of total 
and VLDL triglyceride levels with reduction in HDL concentration (Taskinen, 1987). The 
release of stored fatty acids from adipocytes is a stepwise process involving conversion of 
stored triglyceride into fatty acids and monoglycerides that can be transferred across the 
plasma membrane of the cell. The rate limiting enzyme is HSL, which is inhibited by insulin. 
The deficiency of insulin lifts the inhibition, resulting in the characteristic features of diabetic 
dyslipidaemia, a high plasma triglyceride concentration, low HDL concentration and 
increased concentration of small dense LDL particles. These changes associated with DM 
mellitus are secondary to increased free fatty acid flux secondary to insulin resistance 
(Mooradian, 2009). 
 
1.9.2. Mechanism of Diabetic Dyslipidaemias  
1.9.2.1. Postprandial lipemia 
The postprandial theory of atherosclerosis hypothesis proposed that atherosclerosis is a  
postprandial phenomenon that is depended on the metabolic response to the ingestion of food  
(Zilversmit et al., 1979). This essentially reveals the integrity of the lipid exogenous 
metabolic pathway, which if compromised results in increased highly atherogenic remnants. 
The reduced clearance of remnants results in long duration of postprandial lipaemia. The 
dyslipidaemia in postprandial lipaemia is characterised by increase in plasma TG due to the 
reduced LpL activity secondary to decreased insulin function (Kolovou et al., 2005). Subjects 
with type 2 DM have a slower clearance rate of chylomicrons resulting in postprandial 
lipemia. The interaction of the molecules involved in Figure 1.4 below, shows the main 
features, chylomicron remnant with ApoB48 and reduced levels of LpL. Chylomicron 
clearance process involves acquisition of apoCII by chylomicrons upon entry into the blood 
systemic circulation from the thoracic duct (Goldberg, 1990). ApoCII, a cofactor for LpL, is 
acquired primarily from HDL and is attached to the luminal surface of endothelium in 
capillaries by the protein glycosylphosphatidylinositol HDL-binding protein 1 (GPIHBP1) 
and by heparan sulphated proteoglycans. LpL hydrolyses the triglycerides within the 
chylomicron particles. Its activity is enhanced by insulin and therefore in DM the activity is 
reduced. Some of these patients have been found to have underlying lipid disorder, such as 
heterozygous LpL deficiency, that is then exacerbated by DM (Julien et al., 1997). The 
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formation of chylomicrons remnants is reduced by the deficiency in insulin. Therefore, there 
is prolonged circulation of chylomicrons resulting in prolonged post prandial lipemia. 
Chylomicrons contain a truncated form of apoB termed apoB48 that is 48% of full-length 
apoB and lacks the LDL receptor-binding site (Ebara et al., 2000).  
 
 
Figure 1.4: Schematic representation on the mechanism of postprandial lipaemia  
FA – Fatty Acids; LDLR – Low Density Lipoprotein Receptor; ApoB – Apolipoprotein B; Apo C – 
Apolipoprotein C; LRP – Low Density Lipoprotein Related Peptide. 
 
Patients with poor glycaemic control develop hypertriglyceridemia and some may develop 
severe hyperchylomicronaemia. At higher levels the patients can develop eruptive xanthomas 
and pancreatitis. Such patients require exclusion of possible underlying genetic lipid disorder, 









1.9.2.2 VLDL and DM 




Figure 1.5: Schematic representation on the mechanism of VLDL production in 
diabetes.  FA – Fatty Acids; HSL – Hormone Sensitive Lipase; LDL – Low Density lipoprotein;  
LpL – Lipoprotein Lipase; VLDL – Very Loew Density Lipoprotein. 
 
Patients with poor glycaemic control have increased plasma levels of VLDL because the  
deficiency of insulin reduces its suppression of HSL resulting in increased release of fatty 
acids from adipose tissue into the circulation (Meijssen et al., 2001). The fatty acids returning 
to the liver are reassembled into TG and incorporated into VLDL. Like chylomicrons, VLDL 
requires LpL for its plasma catabolism, leading to the production of LDL. The reduced level 
of insulin decreases the actions of LpL and therefore, less fatty acid is removed from VLDL. 
This causes large lighter VLDL to stay in circulation, returning to the liver without complete  
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conversion to LDL. This effect can also be seen in the LpL loss of function mutation 
(Hoffmann et al., 2000). Figure 1.6 below shows how the lipoproteins develop in DM giving 




Figure 1.6: Schematic representation on the mechanism on the formation of HDL, LDL 
and VLDL in DM  
CE – Cholesterol ester; CETP – Cholesterol Ester Transferase Protein; TG – Triglycerides; LDL – Low Density 
lipoprotein; VLDL – Very Low Density Lipoprotein 
 
 
With increased concentrations of VLDL in the circulation, CETP will exchange VLDL  
triglyceride for cholesteryl ester in the core of LDL and HDL. The TG is hydrolysed and  
converted to free fatty acids by the actions of plasma lipases, especially hepatic lipase. This  
results in a decrease in size and an increase in density of both LDL and HDL (Krauss, 2004).  
Increased concentrations of plasma VLDL drives the exchange of TG from VLDL for the  
cholesteryl esters found in HDL mediated by CETP (Hayek et al., 1993). Thus, HDL loses its 
cholesterol ester in exchange for TG. It is the TG in HDL and not cholesteryl ester, which is a 
substrate for hydrolysis by plasma lipases, especially hepatic lipase resulting in a smaller 
HDL that is more rapidly cleared from the plasma resulting in low HDL measurement 
(Horowitz et al., 1993). Secondly in clinical laboratory measurements, it is the cholesterol 
component that is measured and therefore, substitution of TG for CE in the core of the 
particle leads to a decrease in this measurement. 
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1.10 Problem Statement 
The third world/developing world paid more attention to infectious diseases until it started to  
become evident that non-communicable diseases were emerging as the leading cause of 
morbidity and mortality. Like in other developing countries non-communicable diseases 
appeared to manifest in the African people after migration to urban areas, a feature that is 
affecting the whole continent (Kinra et al., 2011). DM is by far the most common non-
communicable disease with cardiovascular disease, a macrovascular complication of DM as a 
leading cause of death. A person with DM is at greater risk of developing heart attack than a 
person without. Dyslipidaemia has been identified as one of the factors associated with 
progression and development of cardiovascular disease in DM. It has also been seen that not 
all people with DM develop dyslipidaemia. The dyslipidaemia that develops has largely been 
labelled as secondary dyslipidaemia. Thus, we seek to contribute knowledge on the possible 
role of ApoE and PCSK9 genetics in the development of diabetic dyslipidaemia in the 
African population. The absence of dyslipidaemia in some diabetic patients as well as 
differences in the pattern of dyslipidaemia in the diabetic patients suggests the possible 
presence of an additional factor.  
 
1.10.1. Research Question 
What are the roles of ApoE and PCSK9 genetic variations in the development of 
dyslipidaemia in diabetic patients of African descent? 
1.10.2. Hypothesis 
1.10.2.1 Null hypothesis 
Apolipoprotein E polymorphism and PCSK9 variants do not have a role in the type or form 
of dyslipidaemia that develops in diabetic patients of African descent. 
1.10.2.1 Alternative Hypothesis 
Different ApoE and PCSK9 variants influence the type or form of dyslipidaemia that 





1.10.3. Broad Aim and Objectives 
The broad aim of this study was to investigate the effects of genetic variation in 
apolipoprotein E and Proprotein convertase subtilisin/kexin type 9 in the development of 
dyslipidaemia in diabetic patients of African descent. 
The aim was met through the following objectives:    
1. Recruitment of diabetic dyslipidaemic and non-dyslipidaemic participants. 
2. Determine the ApoE and PCSK9 distribution between dyslipidaemic and non-
dyslipidaemic participants. 
3. Establishing the presence and phenotype characterisation of dyslipidaemia. 
4. Correlation of ApoE genotypes with different lipoprotein profile phenotypes. 
5.  Correlation of PCSK9 with different lipoprotein profile phenotypes. 






















CHAPTER 2: MATERIALS AND METHODS 
2.1 Ethical clearance 
The study was granted ethical clearance by both University of Cape Town, Human Research 
Ethics Committee (Ref: 089/2013) and University of Witwatersrand Ethics Review 
Committees (Ref: M130130) (Appendix Ai and Aii).  
2.2 Study site  
The study was conducted in the Diabetic Clinic and Chemical Pathology Department of Chris 
Hani Baragwanath Academic Hospital (CHBAH) located south of Johannesburg in South 
Western Townships (SOWETO).  CHIBAH is the third largest hospital in the world 
occupying 70 ha (170 acres), with 3 200 beds and 6 760 staff members. It is a referral centre 
for 34 polyclinics and clinics, and one district hospital in SOWETO. 
2.3 Study population  
The study population consisted mainly of diabetic patients referred from clinics in Soweto 
and other medical centres. They were all of Bantu origin, comprising several ethnic groups 
from around southern, central and east Africa.  
2.3.1 Study Design 
The study was a mixed design which used a respective cohort, whose clinical data informed 
on invitation to participate. Participants were then purposively recruited into either  
dyslipidaemic or non-dyslipidaemic groups. Patients with specific dyslipidaemic patterns 
were included in the dyslipidaemic group and were further grouped into three: 
hypercholesterolemia (TC); hypertriglyceridemia (TG) and mixed profile (TC+TG).  
 
2.3.2 Sample size determination  
The required sample size was determined by the following equation: n = [Z2 (100-p) pd] ÷Ɛ2  
where n = required size number 
Z = Critical value  
P = proportion, according to a recent paper (Daya et al., 2017), the proportion of 
dyslipidaemia among T2DM patients is approximately 94%. 
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Ɛ = Margin of error (we decided on a margin of error of 5%)  
d = design effect, in our case will be 2 phenotypes (dyslipidaemia and non- 
                  dyslipidaemia). 
Z-score corresponds to a confidence level which is a constant value needed for this 
equation.  
Therefore,  
n = [Z2 (100-p) pd] ÷Ɛ2 
n = [1.962 (100-94) 94x2] ÷5%2 
n= [3.8416 x 6 x 184] ÷ 25 
n = 173. 
The minimum sample size required was 173 participants. Two hundred and forty-four 
(n=244) participants were recruited from CHBAH. A larger sample size ensured that power 
of the study was not lost in the event of some samples yielding poor DNA quality and 
quantity. 
2.3.3 Sampling Technique 
The study recruited patients from a retrospective cohort of diabetic patients. A simple 
purposive sampling technique was used to select patients with any of the dyslipidemia 
defined by TC>5.2mmol/L, TG>1.7mmol/L, both TC and TG high) and non-dyslipidemia 
defined by TC<5.2mmol/L and TG<1.7mmol/L. Participants were recruited in the ratio of 2 
dyslipidaemic participants to 1 non-dyslipidaemic participants respectively.   
2.3.4 Recruitment of dyslipidaemic participants 
Self- confirmed black African patients of Bantu origin with ancestral information to three  
generations were recruited in the diabetic clinic at CHBAH. Participants were selected from 
those with full result profiles of laboratory confirmed dyslipidaemia. Patients of African 
Bantu Ancestry greater than 18 years of age with dyslipidaemia after diagnosis of T2DM who 
were willing to consent got included in the study.  In addition, availability of medical records 
and DNA after extraction was also part of the inclusion criteria. Exclusion criteria included: 
patients with known primary causes of dyslipidaemia; patients with non-diabetic related 
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secondary cause of dyslipidaemia such as thyroid disorders; patients with liver failure; 
diabetic patients with prior renal pathology; pregnant patients; patients with DNA samples of 
low integrity and patients with missing medical records.   
2.3.5 Recruitment of non-dyslipidaemic participants  
Initially we looked for ‘healthy’ hospital workers to be the non-dyslipidaemic participants, 
but abandoned the idea after noticing that 4 out of the first 10 volunteers fell in either 
impaired fasting glycaemia (IFG), or impaired glucose tolerance (IGT) or were unaware that 
they had DM. Using the exclusion rule for the study, we recruited participants with good 
control of DM without any form of apparent dyslipidaemia. Recruitment within the same 
environment was due to the assumption that the distribution of exposure among the non-
dyslipidaemic participants was the same as in the dyslipidaemic participants. All the non-
dyslipidaemic had normal HbA1c and normal lipid profiles and was not on any lipid lowering 
medications. 
 
2.4 Analytical methods  
2.4.1 Glycated Haemoglobin (HbA1c) 
2.4.1.1 Point of Care (Diabetic Clinic) Measurement of HbA1c) 
In the diabetic clinic, DCA Vantage is used as Point of care testing (POCT) analyser utilising 
capillary blood samples (Appendix Bi). The analyser employs inhibition of latex 
agglutination for the measurement of specific HbA1c. An agglutinator (synthetic polymer 
containing multiple copies of the immunoreactive portion of HbA1c) causes agglutination of 
latex coated with HbA1c specific mouse monoclonal antibody. This agglutination reaction 
causes increased scattering of light, which is measured as an increase in absorbance at 531nm 
wavelength. HbA1c in whole blood specimens competes for the limited number of antibody-
latex binding sites causing an inhibition of agglutination and a decreased scattering of light. 
The decreased scattering is measured as a decrease in absorbance at 531nm. The HbA1c 
concentration is then quantified using a calibration curve of absorbance versus HbA1c 
concentration. The percentage of HbA1c in the sample is then calculated as follows: % 
HbA1c = ([HbA1c] / [Total Haemoglobin]) x 100. Details for this method are in Appendix Bi 
and assay key performance data is included in Table 2.2. DCA Vantage was supplied by 
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Siemens in Rosebank, Johannesburg, South Africa. In the event of any discrepancy or during 
stock out, diabetic clinic patients’ venous samples were tested in the central laboratory.    
2.4.1.2 Central Laboratory Measurement of Glycated haemoglobin (HbA1c) 
In the Central Laboratory, samples for HbA1c measurement are collected as whole blood in  
Ethylenediamine tetra acetic acid (EDTA) tubes. The sample is haemolysed by a 
haemolysing reagent that incorporates tetradecyl trimethyl ammonium bromide (TTAB) as 
the detergent to eliminate interference from leukocytes. All haemoglobin variants which are 
glycated at the β-chain N-terminus and, which have antibody-recognisable regions identical 
to that of HbA1c are determined by this assay. Therefore, the metabolic state of diabetic 
patients having uraemia or the most frequent hemoglobinopathies (HbAS, HbAC, and HbAE) 
can be determined by this assay.  
 
HbA1c measurement was done on two different platforms. For diabetic in-patients and those 
admitted through the medical admission ward, the measurement was done in the Central 
Laboratory on a Roche analyser Cobas Integra 400. On the Cobas integra 400, haemoglobin 
A1c determination is based on the turbidimetric inhibition immunoassay (TINIA) for 
haemolysed whole blood. Haemoglobin A1c (HbA1c) in the sample reacts with anti-HbA1c 
antibody in the first reagent to form a soluble antigen-antibody complex. The polyhaptens in 
the second reagent react with excess anti-HbA1c antibodies to form an insoluble antibody-
polyhapten complex (Excess anti-HbA1c antibodies + Polyhaptens → Antibody-polyhapten 
complex) that is determined turbidimetrically. The percentage of HbA1c calculation utilises a 
dual but sequential method in which both Hb and HbA1c are measured in the same cuvette. 
The liberated haemoglobin in the haemolysed sample is converted to a stable derivative that 
is measured photometrically during the initial phase of the immunological reaction. In the 
subsequent reaction, glycohemoglobin (HbA1c) in the sample reacts with the anti-HbA1c 
antibody to form soluble antigen-antibody complexes. The two separate measurements are 
expressed as mmol/mol HbA1c according to International Federation of Clinical Chemists 
(IFCC), which is a ratio or % HbA1c according to Diabetes Complications and Control Trial 
(DCCT)/National Glycohemoglobin Standardisation Program (NGSP). They are calculated 
from the (HbA1c/Hb) x 1,000 formula under the IFCC and the units are mmol/mol and 
(HbA1c/Hb) x 91.5 + 2.15 formula for NGSP/DCCT with units expressed as a percentage 




In preparation for this project, correlation studies between the two analysers using two 
possible sample types: capillary samples for patients in the diabetic clinic run on the DCA 
Vantage and venous samples for in-patients and those admitted through the medical 
admission ward were conducted. The rationale for sample type correlation was that most 
POCT tests on blood use capillary blood but discrepancies or confirmation for POCT results 
are resolved in the central laboratory that uses venous blood (Tanyanyiwa et al., 2015). 
2.4.2 Lipid Profile Measurements 
Tests that comprise a lipid profile in most laboratories include TC, TG, and HDL and LDL. 
Measurements of lipid profiles were done using a Roche Modular diagnostic platform 
supplied by Roche Diagnostics (Randburg, South Africa).  
 
2.4.2.1 Total cholesterol  
TC was measured using the fully automated enzymatic method (Appendix C) and the key 
assay performance data is included in Table 2.2 below. The principle employed is based on 
the enzymatic cleavage of CE by cholesterol esterase.  The conversion of TC to cholest-4-en-
3-one and hydrogen peroxide is catalysed by cholesterol oxidase. The hydrogen peroxide 
forms the quinonemine dye in the Trinder reaction. Other assays like those utilised on some 
Beckman Instruments do not incorporate the Trinder reaction step; they determine TC 
concentration by amperometric measurement of the rate of oxygen consumption. CE are 
cleaved by the action of cholesterol esterase to yield UC and free fatty acids. Total 
cholesterol is converted by oxygen with the aid of cholesterol oxidase to cholest-4-en-3-one 
and hydrogen peroxide. Hydrogen peroxide forms a red colour after reacting with 4-
aminophenazone and phenol (Trinder reaction).  
The colour intensity is directly proportional to the concentration of TC. The testing principles 
for TC are encapsulated by the three equations below:  
1)  Cholesterol Esters (CE) +   H2O        Cholesterol + Fatty Acids 
2) Cholesterol + Oxygen        Cholest-4-en-3-one + H2O2 
3) 2H2O2 +4-aminophenozone + phenol   4-p-benzoquinone-monoimino)- phenazone + 4 H2     
 
2.4.2.2 High Density Lipoprotein (HDL)   
High Density Lipoprotein (HDL) is measured using the homogeneous enzymatic colorimetric 
test (Appendix II). In the presence of magnesium ions, dextran sulphate selectively forms 
water‑soluble complexes with low density lipoprotein (LDL), very low-density lipoproteins 
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(VLDL) and chylomicrons, which are resistant to polyethylene glycol (PEG) -modified 
enzymes. The cholesterol concentration in HDL is determined enzymatically by cholesterol 
esterase and cholesterol oxidase coupled with PEG to the amino groups (approx. 40 %). 
Cholesterol esters are broken down quantitatively into free cholesterol and fatty acids by 
cholesterol esterase and in the presence of oxygen, cholesterol is oxidised by cholesterol 
oxidase to Δ4‑cholestenone and hydrogen peroxide as shown below; 
(a) HDL‑cholesterol esters +             PEG‑cholesterol esterase             HDL‑cholesterol + H2O + RCOOH 
(b) HDL‑cholesterol +   PEG‑cholesterol oxidase               Δ4‑cholestenone + O2 + H2O2 
(c) 2 H2O2 + 4‑amino‑antipyrine + peroxidase        purple‑blue pigment + HSDA* + H+ + H2O + 5 H2O 
(where *HSDA = Sodium N‑(2‑hydroxy‑3‑sulfopropyl) -3,5‑dimethoxyaniline). 
 
In the presence of peroxidase, the hydrogen peroxide generated reacts with 
4‑amino‑antipyrine and HSDA to form a purple‑blue dye. The colour intensity of this dye is 
directly proportional to the cholesterol concentration and is measured photometrically. 
 
2.4.2.3 Triglycerides (TG) 
The determination of TG is comprehensively described in Appendix III but key assay 
performance data is included in Table 2.1 below. The principle employed is based on the  
lipase-catalysed hydrolysis of TG to gylcerol and fatty acids. The glycerol portion of the TG 
molecules is used to determine TG concentration after hydrolysis. The TG measurement 
method is based on the principles below. In this method, TG is hydrolysed by lipase to 
release glycerol and fatty acids. The glycerol is reacted with adenosine triphosphate (ATP) in 
a reaction catalysed by glycerol kinase with magnesium as a co-factor to produce glycerol-3-
phosphate and adenosine diphosphate (ADP). The ADP is reacted with phosphoenolpyruvate 
in a reaction catalysed by pyruvate kinase to produce ATP and pyruvate. The pyruvate then 
reduces NADH to NAD + lactate in a reaction catalysed by lactate dehydrogenase. 
  1) TG + 3 H2O  → glycerol + 3 Fatty acids (RCOOH) 
  2) Glycerol + ATP     →  glycerol-3-phosphate + ADP 
  3) Glycerol-3-phosphate + O2 → dihydroxyacetone phosphate + H2O2   
  4) H2O2 + 4-aminophenazone + 4-chlorophenol 4-(p-benzoquinone-monoimino)-phenazone + 2 H2O2 + HCl. 
2.4.2.4 Low Density Lipoprotein (LDL) 
Low Density Lipoprotein (LDL) can be measured using both direct and indirect methods. The 
indirect method based on the Friedewald Equation to calculate LDL using an empirical 
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equation, LDL = (TC – HDL– (TG/2.22) for units in mmol/L was used for this project. The 
factor, TG/2.22 is an estimate of VLDL concentration and is based on the average ratio of TG 
to TC in VLDL (Friedwald et al., 1972). The indirect or calculated method assumes that TC 
is composed of VLDL, LDL and HDL (i.e. TC = VLDL + LDL +HDL). The disadvantage of 
this method is that at high TG levels >4.5mmol/L samples contain chylomicrons, which have 
higher TG/cholesterol ratios than normal. Therefore, the use of the Friedewald equation 
would overestimate VLDL resulting in underestimating LDL. The opposite error occurs if the 
equation is used for patients with Type III hypercholesterolaemia because VLDL has a 
TG/cholesterol ratio in the order of 3:1 and therefore, application of the factor would 
underestimate VLDL resulting in the overestimation of LDL. To overcome this problem, the 
direct LDL method is normally done for diagnostic purposes. Quality Control of lipid 
measurements was carried out using internal and external quality-control schemes that are 
used to ensure high accuracy and precision in these determinations. For internal quality 
control, Precinorm and Precipath control sera were used and results of the tests were only 
accepted when the results for control sera were within the manufacture’s given range. For 
external quality control, unknown concentration control sera from the BIORAD cycle quality 
control program were assayed, and the results were within two standard deviations (+2 SD) 
during the period our samples were run.  
 
The central laboratory (site of analysis) participates in Royal College of Pathologists of 
Australasia (RCPA) external quality control programmes and is South African National 
Accreditation System (SANAS) accredited. A summary of the basic mandatory assay 
performance information is shown in Table 2.1 below. 
Table 2.1 Summary of key assay performance information  
Assay Analytical measuring range Wavelength  CV 
TC 0.1 – 20.7 mmol/L  (sub/main) 700/505 nm 1.6% 
TG 0.1– 10.0 mmol/L (has 1:5 auto dilution)  (sub/main) 700/505 nm 1.9% 
HDL-C 0.08– 3.12 mmol/L (sub/main) 700/600 nm 1.5% 
HbA1c 4.3– 9.5 %   A/B 378/659 nm 1.3% 
HbA1c (POCT) 2.5% – 14% 531 nm. 3% 





2.5.1 DNA Extraction and Quality Control  
DNA was extracted from whole blood samples using the salting out method according to 
Gustafson et al., (1987) with minor modifications (Appendix F).  Extracted genomic DNA 
was quantified using the Nanodrop® ND-1000 Spectrophotometer (Thermo Fisher Scientific, 
Wilmington, DE, USA). Genomic DNA intactness and integrity were verified on a 1% 
agarose gel stained 5μL/mL of the nucleic acid stain GR Green (Excellgen, Rockville, 
Maryland, USA). The molecular weight marker used to guide the size of the DNA was Gene 
Ruler TM 100bp plus ladder (Thermo Fisher Scientific, Wilmington, DE, USA). 
Electrophoresis proceeded at 80V for an hour. After electrophoresis the DNA bands were 
visualised using the Fire Reader V4 Vu Gel documentation system (UVitec Limited, 
Cambridge, UK).  
 
2.5.2 Genetic characterization of ApoE 
ApoE gene variation has been shown to play a role in the differences in lipid levels observed 
among patients. We investigated the role of variants E2, E3 and E4 among South African  
patients. 
 
2.5.2.1 PCR for ApoE 
ApoE gene was amplified using forward and reverse primers 5’-TCC AAG GAG CTG CAG 
GCG GCG CA-3’ and 5’-GCC CCG GCC TGG TAC ACT GCC A-3’ respectively. Primers 
were adapted from a method designed by Marrzoq et al., 2011. A 25μL reaction consisting of 
50ng/μL DNA template, 1U Dream Taq Polymerase (ThermoScientific, Waltham, USA), 
0.2mM dNTPs (Kapa Biosystems, Cape Town, South Africa), 0.4 μM of each primer 
(Integrated DNA Technologies, Illinois, USA), 5x Go Taq flexi buffer (ThermoScientific, 
Waltham, USA) and 1.5 mM magnesium chloride (ThermoScientific, Waltham, USA) made 
up to 25μL using nuclease free distilled water (ThermoScientific, Waltham, USA). 
Amplification was done on the Bio-Rad T100 Thermal Cycler (Bio-Rad Laboratories, 
California, USA), the reaction conditions were an initial denaturation of 95 °C for 3 minutes, 
followed by 40 cycles of denaturation of 95°C for 60 seconds, annealing at 64°C for 30 
seconds and an extension at 72°C for 2 minutes. Final extension was 72°C for 10 minutes. 
PCR products were analysed on 2 % agarose gels to check specificity and size of the 




Determination of the different ApoE alleles was done according to previously established. 
Restriction enzymes AflIII and HaeII purchased from Thermo Fisher Scientific, USA were 
used to digest the amplified ApoE gene fragment.  
 
2.5.2.2 Digestion with AflIII and HaeII for ApoE genotyping 
Two ApoE single-nucleotide polymorphisms (SNPs), rs429358C>T at position 112 and 
rs7412C>T at 158 were examined in this project. They are found in exon 4 of ApoE gene 
where they produce missense mutations. Digestion with AflIII to genotype rs429358 was 
achieved due to the enzyme property of cutting whenever a T allele appears producing 168bp 
and 50bp fragments. If a C allele is present, the cut site is abolished and 218bp intact 
fragment results. Digest with HaeII to genotype rs7412 was achieved due to the enzyme 
property of cutting whenever a C allele appears producing 195bp and 23bp fragments. If a T 
allele appears, the cut site is abolished resulting in a 218bp intact fragment.  
 
To genotype rs7412 and rs429358 single nucleotide polymorphisms, 10 uL of  PCR products  
were  digested overnight at 37°C with HaeII and AflIII, respectively. The digested product 
was then electrophoresed on 3.5% agarose at 60V for 6 hours. The PCR-RFLP results were 
validated Sanger sequencing on ABI 3130xl Genetic analyser (Applied Biosystems, 
California, USA). The expected enzyme digestion products of ApoE are shown in table 2.2 
below. 
 
Table 2.2 AflIII and HaeIII enzyme fragmenting patterns  
 
2.5.3 Characterisation of variation in PCSK9 gene.  
PCSK9 variant PCSK 946L (rs11591147) on exon 1, I474V (rs562556) in exon 9 and E670G 
(rs505151) in exon 12 were characterized to compare lipoprotein levels between male and  
Haplotype rs429358 rs7412 AflIII digest Fragment bp HaeIII Digest Fragment bp 
ApoE3 T C 168 195 
ApoE2 T T 168 218 
ApoE4 C C 218 195 
 59 
 
female carriers of the E670G variant (rs505151). PCSK9 rs28362286 has been reported in 
3.7% black African women attending two antenatal clinics in Zimbabwe and was associated 
with a 27% reduction in LDL (Hooper et al., 2007). It would therefore, mean that the low 
cholesterol translates to reduced cardiovascular risk. 
 
2.5.3.1 Amplification of region of interest  
The regions of interest were on exon 12 of PCSK9 gene and harbour the rs28362286 and 
rs505151 polymorphisms. The region containing PCSK9 rs505151was amplified using 
forward and reverse primers 5’-TCT CCT CGC CAG GAC AGC AAC CT-3’and 5’-TGA 
GGC CCG AGA GGA AAC AGC A-3’ respectively. A 25μL reaction consisting of 50ng/μL 
DNA template, 1U Dream Taq Polymerase (ThermoScientific, Waltham, USA), 0.2mM 
dNTPs (Kapa Biosystems, Cape Town, South Africa), 0.4 μM of each primer (Integrated 
DNA Technologies, Illinois, USA), 5x Go Taq flexi buffer (ThermoScientific, Waltham, 
USA) and 1.5 mM magnesium chloride (ThermoScientific, Waltham, USA) made up to 25μL 
using nuclease free distilled water (ThermoScientific, Waltham, USA). Amplification was 
done on the BioRad T100 Thermal Cycler (Bio-Rad Laboratories, California, USA), the 
reaction conditions were an initial denaturation of 95 °C for 3 minutes, followed by 34 cycles 
of denaturation of 95°C for 30 seconds, annealing at 57°C for 30 seconds and an extension at 
72°C for 30 seconds. Final extension was 72°C for 5 minutes. PCR products were analysed 
on 2 % agarose gels to check specificity and size of the products.  
 
The amplification steps for region containing PCSK9 rs28362286 were the same as described 
above for PCSK9 rs505151 except that denaturation was followed by annealing at 54ºC for 
30 seconds. The following forward and reverse primers 5’-TGT CGG AGG GAG AAA TGA 
AGT GT-3’3’and reverse primer 5’-TGG AGG GCT GAG AGA GGG AGA-3’ were used 
for amplification of the region containing PCSK9 rs28362286 respectively.  
 
2.5.3.2 Post PCR Clean up  
PCR products were purified to remove excess dNTPs and unincorporated primers using a 
standard method which includes the combined use of Exo1 and FastAp (Appendix A17). 1U 
of FastAp™ Thermosensitive alkaline phosphatase (Thermo Scientific, Waltham, USA) and 
4U of Exonuclease 1 (Exo1, ThermoScientific, Waltham, USA) was added to 5μL of the 
PCR product and the reaction made up to 20μL using nuclease free distilled water. The clean-
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up reaction proceeded at 37°C for an hour followed by inactivation of both enzymes at 75 °C 
for 15 minutes. The entire clean up reaction was done in the BioRad MyCycler Thermal 
cycler. 
 2.5.3.3 Sanger sequencing reaction 
Sequencing of the PCR products was done using the BigDye® Terminator v3.1 cycle 
Sequencing Kit (Life Technologies, California, USA). The sequencing reaction involves 
cycles of denaturation of the template PCR product followed by annealing of the sequencing 
primer and extension of the primer by DNA polymerase with the random incorporation of 
ddNTPs. Two sequencing reactions were set up per each PCR product: one with a forward 
sequencing primer and the other with a reverse sequencing primer.  The sequencing primers 
were the same as the PCR primers. Post sequencing precipitation of DNA was done using a 
standard ethanol precipitation coupled with salting out of proteins using sodium acetate. 
Capillary electrophoresis of sequencing products was done on the ABI 3130xl Genetic 
Analyser (Applied Biosystems, California, USA).  
 
2.6 Data Analysis 
2.6.1 Sanger Sequencing data analysis  
Sequencing data visualisation, assembly and analysis was done using SeqMan Pro (DNASTAR 
Inc., Madison, USA) software. Alignment of sequences was done against reference sequences 
accessed from the NCBI Gene website (https://www.ncbi.nlm.nih.gov/gene). 
 
2.6.2 Allele and Genotype Frequency Distribution 
Frequency distribution of alleles was determined and adherence to Hardy Weinberg theorem 
checked. The Hardy-Weinberg Equation theorem states that allele frequencies in a population 
will not change from generation to generation if the breeding population is large; mating is 
random; there are no mutations; no emigration and immigration and no natural selection.  
 
 2.6.3 Statistical Analysis 
Statistical analyses were performed using GraphPad Prism (Version 5, GraphPad Software 
Inc. San Diego, CA) and STATA (Version 11, Stat Soft, USA) statistical programs. 
Normality was tested using Shapiro-Wilk Test. Generally, nonparametric tests were used to 
analyse the data. Mann Whitney or Kruskal-Wallis (with Dunn’s Multiple Comparison) tests 
were used to assess association between clinical parameters, or genotypes for each SNP and 
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lipoprotein levels/concentrations. Statistical significance for the univariate analysis was 
defined as p < 0.05. Two sample t-test was used to compare distribution percentage values 
between dyslipidaemic and non-dyslipidaemic participants. A one-sample t-test was used to 
compare the difference in percentages within the same group. In both cases statistical 
significance was also defined as p < 0.05. To assess dyslipidemia produced by the two 
PCSK9 genotypes in relation to each of the ApoE genotypes, medians of the different 
measured parameters for the two PCSK9 variants were compared using t-test nonparametric 





























CHAPTER 3: RESULTS 
 
3.1 Demographic characteristics of the cohort 
The study subjects were divided into two groups dyslipidaemic (n =165) and non 
dyslipidaemic (n =79) based on their lipid profiles. The non-dyslipidaemic participants were 
patients with good glycaemic control and without dyslipidaemia. The 165 dyslipidaemic 
participants were further divided into three groups; those with high TC (33.3%, n=55), those 
with high TG (29.1%, n=48) and those with both high TC and TG (37.6%, n= 62). The cohort 
comprised of 128 (52%) females and 116 (48%) males.  The characteristics of the 
participants are shown in Table 3.1 below.  
Table 3.1: Demographic Characteristics of the cohort  
Parameter  Non Dyslipidaemic Dyslipidaemic  p-value 
  (n=79)  (n=165)  
Age Median (IQR) 51.00 (42.0 –60.0) 59.00 (52.0 – 64.0)  <0.0001 
     
Systolic blood pressure Median (IQR) 133.0 (125 – 147) 142.0 (127.5 –152.5)  0.0507 
     
Diastolic blood pressure Median (IQR) 79.0 (74.0 – 87.0) 81.0 (74.0 – 89.0)  0.9684 
     
Weight (kg) Median (IQR) 75.0 (67.0 – 90.0)  82.00 (73.0 – 91.0)  0.0018 
     
Height (metres) Median (IQR) 1.61 (1.57 – 1.65) 1.61 (1.56 – 1.68) 0.9415 
     
Body Mass Index Median (IQR) 27.8 (26.2 – 29.2) 30.8 (27.05 – 35.35) 0.0001 
     
HbA1c (%) Median (IQR) 5.4 (4.78 – 5.90)   6.9 (5.85 – 10.85) 0.0001 
     
Total Cholesterol (mmol/L) Median (IQR) 3.7 (3.01 – 4.29) 5.8 (4.95 – 6.46)  0.0001 
     
Triglyceride (mmol/L) Median (IQR) 1.0 (0.75 – 1.3) 2.2 (1.44 – 2.88) 0.0001 
     
LDL-Cholesterol (mmol/L) Median (IQR) 2.0 (1.53 – 2.53)  3.4 (2.64 – 4.21)  0.0001 
     
HDL-Cholesterol (mmol/L) Median (IQR) 1.2(0.91 – 1.45) 1.3(1.03 – 1.57)  0.0104 
     
Non-HDL (mmol/L) Median (IQR) 2.5 (2.03 – 2.98) 4.2 (3.71 – 5.19) 0.0001 
 
Compared with non-dyslipidaemic participants, dyslipidaemic participants had significantly 
higher, body mass index, HbA1c (%), TC, TG, LDL, HDL and non-HDL (p<0.05). There 
was a slight tendency to significance (p-value= 0.051) in systolic blood pressure with 
dyslipidaemic participants being higher, but there was no difference in the diastolic blood 
pressure p- value = 0.9684. Age and height were significantly higher and in the dyslipidaemic 
(p < 0.0001) compared to non-dyslipidaemic participants (p = 0.0018) respectively.  Height 
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between the two groups was not different (p =0.9415). The difference in the measured 
parameters between the dyslipidaemic and non-dyslipidaemic was expected because 
purposive sampling technique was employed. The characteristic features of the three 
dyslipidaemic groups, i) those with high TC only, ii) those with high TG only and iii) those 
with both high TC and TG were compared, and results are shown in Table 3.2 below. 
 
Table 3.2 Demographic characteristics of the dyslipidaemic group 
 
Similar to comparisons made between dyslipidaemic and non-dyslipidaemic participants, the 
differences in the measured parameters between the three groups (those with high cholesterol 
only, those with high triglycerides only and those with both high cholesterol and triglyceride 
/mixed) were also analysed. One-way analysis of variance (ANOVA) did not show any 
significant difference in HbA1c (p-value = 0.166) between the three groups. This means 
glycaemia/glycaemic control does not seem to influence the dyslipidaemic phenotype seen in 
DM. Unlike the significant difference (p <0.0001) in age between the dyslipidaemic and non-
dyslipidaemic, there was no significant difference in age (p = 0.9947) between the three 
dyslipidaemic groups. The data shows significant difference (p = 0.0002) in weight. The 
mixed group had the highest weight with a median of 83.50kg (IQR 76.00 - 91.00) and the 
high cholesterol group had the lowest weight with a median of 75.00kg (IQR 64.0-91.00). 
Parameter  High Cholesterol, 
N=55 
High Triglyceride, N=48 Mixed, N=62 p-value 
Age Median (IQR) 59.00 (53.00-66.00) 57.00 (51.00-63.00) 60.0 (51.75 - 64.00) 0.9946 
      
Systolic blood pressure Median (IQR) 137.00 (126.0-
152.0) 
145.0 (133.3-156.3) 139.0 (126.3-152.0) 0.1125 
      
Diastolic blood pressure Median (IQR) 79.00 (73.0-88.0) 85.00 (77.0-90.0) 79.00 (73.0-85.5.0) 0.061 
      
Weight (kg) Median (IQR) 75.00 (64.0-91.00) 82.5 (76.25 -92.0) 83.50 (76.00 – 91.00 0.0002 
      
Height (metres) Median (IQR) 1.62 (1.56-1.68) 1.60 (1.56-1.68) 1.63 (1.57-1.68) 0.7943 
      
BMI Median (IQR) 27.70 (24.20-34.30) 31.75 (28.88 - 36.33) 31.20 (28.65-35.18) 0.0023 
      
HbA1c (%) Median (IQR) 6.60 (5.50-8.60) 8.65 (5.73-11.20) 6.95 (6.08-11.45) 0.166 





4.68 (4.13-4.92) 6.25 (5.75-6.80) <0.0001 
      
Triglyceride (mmol/L) Median (IQR) 1.20 (1.03-1.45) 2.57 (2.34-3.13) 2.60 (2.10-3.41) <0.0001 





2.34 (1.55-2.65) 3.70 (3.02-4.30) <0.0001 





0.97 (0.77-1.20) 1.25 (1.06-1.43) <0.0001 
      
Non-HDL(mmol/L) Median (IQR) 4.60 (3.80-5.19) 3.63 (3.24-3.90) 5.11 (4.40-5.67) <0.0001 
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There was no significant difference in height, but BMI was significantly different (p 
=0.0023). These results show that triglyceride is the common factor associated with increased 
weight. Significant difference (p < 0.0001) between the lipoproteins in the three groups was 
expected because of purposive sampling technique used. 
3.2 Associations between measured parameters in dyslipidaemic participants 
In this analysis, each one of the measured analytes: HbA1c, TC, TG, LDL and HDL was 
analysed as a dependent variable against the selected cohort characteristics. A summary of the 
correlation analysis is summarised in tables 3.3 to 3.7 below. The study found significant 
association between HbA1c (table 3.3) and age. TC was strongly associated with its main 
fraction LDL, HDL, TG as well as Body Mass Index and HbA1c. TG was strongly associated 
with HbA1c and moderately associated LDL (Table 3.5). LDL (Table 3.6), the main 
cholesterol fraction was strongly associated with age, systolic blood pressure, diastolic blood 
pressure as well as HDL and HbA1c but moderately associated with gender. HDL was 
strongly associated with age (Table 3.7).   
 
Table 3.3 Effects of patient characteristics on HbA1c  
 
Measured parameter OR (CI) 95% p values 
Gender 0.88  (0.45- 1.74)   0.7704 
Age 1.05 (1.02- 1.08) 0.0075 
Systolic blood pressure 1.02  (0.99- 1.05)    0.1563 
Diastolic blood pressure 0.99  (0.95 - 1.04)     0.9277 
Weight 1.01  (0.99- 1.04)     0.2869 
Height 9.13e-28  (0.00 - ∞) 0.9379 
This analysis showed that HbA1c was strongly associated with age. Therefore, the older participants had poorer glycaemic 

























Table 3.4 Effects of patient characteristics on Total Cholesterol 
 
Measured parameter OR      (CI) 95% p values 
Gender 5.91e-02  (8.28e-01, 1.14) 0.78134 
Age 9.73e-01  (9.96e-01, 1.01) 0.45877 
Systolic blood pressure 1.0  (9.96e-01, 1.01) 0.57454 
Diastolic blood pressure 1.0  (9.90e-01, 1.01) 0.94069 
Weight 9.96e-01  (9.86e-01, 1.01) 0.49342 
Height 4.69e-52  (1.26e-188, 1.75e+85) 0.53539 
Triglyceride 1.12  (1.09, 1.15) 3.5e-10 
Low Density Lipoprotein 2.34  (2.17, 2.52) < 2e-16 
High Density Lipoprotein 2.23  (1.87, 2.67) 1.5e-12 
Body Mass Index 1.03 (1.01-1.06) 0.04931 
HbA1c 1.06 (1.03-1.08) 0.00092 
This analysis showed that Total cholesterol was strongly associated with low-density lipoprotein, high-density lipoprotein.  
This is because both low-density lipoprotein and high-density lipoprotein are fraction of total cholesterol. There was a positive correlation 
between BMI and HbA1c with Total cholesterol respectively. Therefore, participants with a high BMI had poor glycaemic control and high 
cholesterol. This can be due to insulin resistance that develops followed by hyperglycaemia. High cholesterol is a result of the metabolic link 
between TC and TG that takes place in secondary dyslipidaemia.      
 
Table 3.5 Effects of patient characteristics on Triglyceride 
 
Measured parameter OR (CI) 95% p values 
Gender 0.60  (9.84e-01- 1.04e+00)    0.185 
Age 1.01  (9.84e-01 - 1.04e+00)    0.5128 
Systolic blood pressure 1.00  (9.81e-01- 1.03e+00)     0.7599 
Diastolic blood pressure 0.99  (9.56e-01- 1.04e+00)   0.8367 
Weight 0.98  (9.51e-01 - 1.02e+00)    0.5673 
Height 4.18e+37   (0.00e+00 - ∞) 0.9076 
Low Density Lipoprotein 0.72 (5.42e-01- 9.61e-01) 0.0612 
High Density Lipoprotein 0.54  (2.71e-01- 1.08e+00)     0.1415 
Body Mass Index 1.08  (9.67e-01- 1.20e+00)     0.2568 
HbA1c 1.16 (1.05e+00-1.08e+00) 0.0175 
This analysis showed that high triglyceride was strongly associated with high HbA1c. This is expected because insulin  
resistance is a common feature in T2DM. Fatty acids provide an alternative source of energy.  
 
Table 3.6 Effects of patient characteristics on LDL 
Measured parameter OR       (CI]) 95% p values 
Gender 1.31    (1.029-1.67)     0.0654 
Age 1.02 (1.004-1.03) 0.0174 
Systolic blood pressure 1.01 (1.003-1.02) 0.0237 
Diastolic blood pressure 0.98    (0.965- 0.996)     0.0397 
Weight 0.99    (0.985-1.00)     0.1823 
Height 1.66    (0.00, 2.93)     0.1814 
High Density Lipoprotein 1.67 (1.286, 2.16)    0.0013 
HbA1c 1.06 (1.017-1.10) 0.0184 
LDL was strongly associated with most of the measured parameters such as older age, high systolic and diastolic blood  
pressure, HDL and HbA1c. Most of these parameters form part of the components that constitute metabolic  










Table 3.7 Effects of patient characteristics on HDL 
 
Measured parameter OR       (CI) 95% p values 
Gender 0.9.7  (0.88-1.08)     0.6646 
Age 1.01 (1.00-1.01) 0.0072 
Systolic blood pressure 0.99  (0.99-1.00)     0.2991 
Diastolic blood pressure 0.99  (0.99-1.01)     0.7636 
Weight 1.00    (0.99- 1.00) 0.8924 
Height 2.22e+43 4.81e+129]     (1.02e-43,) 0.4079 
HbA1c  0.998  (0.98, 1.01) 0.81 
With a p = 0.0072 the analysis showed that HDL is strongly associated age.  
 
3.3 Genetic characterisation 
3.3.1 DNA Quality Tests  
The concentration and quality of the extracted DNA was analysed on the Nano drop  
spectrophotometer. The integrity of genomic DNA shown in Figure 3.1  
















Agarose gel electrophoresis of genomic DNA extracted from whole blood using solution-  
 
3.3.2 ApoE Amplification 
After confirming the presence of genomic DNA, amplification of ApoE exon 4 encompassing 
the 218-single nucleotide polymorphism was performed as shown in Figure 3.2 below.  
 
 
Figure 3.1 Assessing integrity of the genomic DNA   
Agarose gel run for 1 hour at 5V/cm   
MWM=molecular weight marker 

























Figure 3.2 Amplification of ApoE 218 bp fragment. MWM – Molecular weight marker, SNP – 
Single Nucleotide Polymorphism; Lane 1-5 shows amplification of patient DNA samples 
 
  
3.3.3 Identification of ApoE alleles  
All six possible allele combinations including an unverified labelled in this project as ApoE 
X were identified after digestion with AflIII and HaeII enzymes. The digestion products were 























FA – Fatty Acids; LDLR – Low Density Lipoprotein Receptor; ApoB – 
Apolipoprotein B;  ApoC – ApolipoproteinC; LRP – Low Density Lipoprotein 















Figure 3.3 ApoE AflIII and HaeII Enzyme Digestion. Bp – base pairs;  MWM- 
Molecular weight markers; A1 – A5 are DNA samples digested using AflIII 










Results of AflIII and HaeII digestion of ApoE electrophoresis on 3.5% agarose gel run for 6 
hours at 60V. Sample 1= (A1 and H1): Sample 2= (A2 and H2): Sample 3 = (A3 and H3): 
Sample 4 = (A4 and H4) and sample 5 = (A5 and H5). The gel shows that HaeII identified 
the presence of rs7412C allele  when ever the enzyme cuts the PCR product into twoone with 
195bp and the other with 23bp. If T allele appears, the cut site is abolished leaving the 218bp 
fragment intact. On the other hand AflIII identified the presence of genotype rs429358 
because it cuts whenever a T allele appeared giving rise to 168bp and 50bp fragments. If a C 
allele appears, the cut site is abolished and 218bp fragment was left intact.  
 
3.4 PCSK9 Genetic characterisation 
3.4.1 PCR for PCSK9 
Of the 244 participants, 201 (138 dyslipidaemic and 63 non dyslipidaemic participants) were 
successfully genotyped for PCSK9. Results for the PCSK9 rs505151 PCR are shown in 

















The PCR expected product: 167 bp DNA fragment was clearly well defined in all the samples 
marked 1 to 19. 
 
 
Figure 3.4:  PCR for PCSK9 rs505151 SNP characterisation. PCR products were run on a 











3.4.2 PCSK9 Sequencing Results 
 
















The bases are colour coded A= green; C= purple, G= black and T= red Top. Homozygous 
produced a single peak with a single appropriate colour as seen in AA genotype (green) and 
GG genotype (black) in the top and middle frames respectively) Heterozygous produced two 
peaks which were superimposed at the same position with two different colours, each 
representing its own colour code as seen in heterozygous AG (green and black) in the lower 
frame. 
3.5 ApoE   rs429358 Genotype frequency distribution 
Genotypes for ApoE conformed to Hard Weinberg equilibrium and we were able to detect all 
six common genotypes. In addition, there was a genotype with heterozygous features but 
could not be fully characterised and was labelled as ApoE X to differentiate it from the 
known genotypes. The frequency distribution of ApoE genotypes between the dyslipidaemic 
and non-dyslipidaemic participants were compared and shown in Table 3.4 below.  
 
 




Table 3.8 Frequency of Apo E genotypes  
 
There was a difference in the ApoE rs429358 genotype distribution between dyslipidaemic 
and non-dyslipidaemic participants. ApoE3/3 had the highest frequency in the dyslipidaemic 
participants, while being the third in the non-dyslipidaemic. ApoE2/3 ranked as the fifth in 
the dyslipidaemic but second in the non-dyslipidaemic subjects. ApoE2/4 was absent in the 
non-dyslipidaemic participants. ApoE3/3 carriers had slight tendency towards development 
of dyslipidaemia (p = 0.052). On the other hand, ApoE2/3 carriers showed significant 
resistance towards development of dyslipidaemia compared to other genotypes (p<0.0001).   
 
3.6 PCSK9 variant frequency distribution 
Genotypes for PCSK9 conformed to Hard Weinberg equilibrium and the study was able to 
detect all PCSK9 rs505151 and PCSK9rs28362286 genotypes targeted for the study. Table 
3.5 below shows the distribution of the PCSK9 rs505151 and PCSK9 rs28362286 single 





















E2/2 10 0.059 4 0.05 0.775 
E2/3 
9 0.053 20 0.26 
<0.0001 
E2/4 
3 0.018 0 0.00 
0.231 
E3/3 62 0.376 18 0.25 0.0522 
E3/4 60 0.365 24 0.28 1.190 
E4/4 6 0.035 2 0.03 0.839 
ApoE X 15 0.082 11 0.03 0.839 
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Table 3.9 PCSK9 variant frequency Distribution 
 
PCSK9 rs505151A/A had a high frequency distribution in both dyslipidaemic (55%) and 
non-dyslipidaemic (63%). There was no significant difference between the dyslipidaemic and 
non-dyslipidaemic (p = 0.178). PCSK9 rs505151G/A genotype frequency distribution in the 
dyslipidaemic (41%) had a slight tendency towards significance (p = 0.057) for development 
of dyslipidaemia compared to the non dyslipidaemic (27%). PCSK9 rs505151 G/G genotype 
was two-fold more in non-dyslipidaemic (10%) compared to dyslipidaemic (4%) participants 
but did not have any significance (p=0.095) towards resistance in development of 
dyslipidaemia. 
 
PCSK9 rs28362286 C/C genotype had a notably high frequency distribution in both 
dyslipidaemic (94%) and (100%) in non-dyslipidaemic. PCSK9 rs28362286 C/A genotype 
had frequency distribution of 6% in the dyslipidaemic participants only and absent in non-
dyslipidaemic participants. PCSK9 rs28362286 A/A genotype was absent in both 
dyslipidaemic and non-dyslipidaemic participants. There was a significant association (p 
<0.05) between diabetics carrying PCSK9 rs28362286 C/C and PCSK9 rs28362286 C/A 
respectively towards development of dyslipidaemia.   
 
3.7 Comparisons of measured parameters between ApoE genotypes in dyslipidaemic 
participants.  
In order to establish the influence of each ApoE genotype, comparison between each of the 
ApoE genotypes and the measured analytes: HbA1c, TC, TG, LDL and HDL was assessed, 
and the results are summarised in Figure 3.6 below.   









PCSK9rs505151G/G 6 0.04 6 0.10 0.095 
PCSK9rs505151G/A 
56 0.41 17 0.27 
0.057 
PCSK9rs505151A/A  
76 0.55 40 0.63 
0.178 









PCSK9rs 28362286C/C 130  0.94 63 1.00 <0.05 
PCSK9rs28362286C/A 8 0.06 0 0.0 <0.05 






The results show that carriers of the homozygous ApoE 2/2 genotypes had worst glycaemic 
control with a median HbA1c of 10.95% (IQR 5.88%-14.98%). Carriers of the homozygous  
ApoE 4/4 were shown to have the best glycaemic control with median HbA1c levels of 
6.60% (IQR 5.70 – 12.3). In terms of lipoproteins; the results did not show any significant 
specific relationship between the ApoE genotypes to any pattern nor type of dyslipidaemia. 
Carriers of the homozygous ApoE 3/3 had the highest positive influence on TC with median 
of 6.06 mmol/L (IQR 5.48 – 6.71mmol/L). On the other hand, carriers of the homozygous 
ApoE 4/4 displayed the highest influence on TG a median of 2.94mmol/L (IQR 1.75 – 5.13 
mmol/L) as well as the highest non-HDL with a median of 4.68 mmol/L (IQR3.64 – 5.55 
mmol/L). The carriers of the homozygous ApoE 4/4 with the best glycaemic control had two 
of the highest lipoproteins, TG and non-HDL. These results are interesting in that carrier of 
ApoE genotypes showing poor glycaemic control do not display dyslipidaemia as expected in 
secondary dyslipidaemia.     
 
3.8 Comparisons of measured parameters between PCSK9 genotypes in dyslipidaemic 
participants  
Similar to the ApoE genotype the effects or influence of PCSK9 genotype on each of the  




measured analytes: HbA1c, TC, TG, LDL and HDL was assessed. However, unlike ApoE  
genotype, the comparison was only done for PCSK9 rs505151 genotypes because it has two 
well distributed variants, PCSK9 rs505151 A/A (55%) and PCSK9 rs505151 G/A (41%) and 
a small fraction of PCSK9 rs505151 A/A with only 4%. Similar comparative analysis was not 
possible for PCSK9 rs28362286 genotype because PCSK9 rs28362286 C/C constitutes 94%, 
PCSK9 rs28362286 C/A constituting 6% and PCSK9 rs28362286 A/A genotype being 
completely absent. The results of the PCSK9 genotypes influence on the measured 
parameters for the dyslipidaemic participants irrespective of the ApoE genotype genotypes 
are summarised in Figure 3.7 below.  The correlation of the PCSK9 rs505151 genotypes and 
measured parameters did not show any significant difference across all the parameters.  
However, carriers of PCSK9 rs505151 A/A genotype had higher HbA1c with a median of 
10.10% (IQR 7.48 – 12.9) compared to PCSK9 rs505151G/A genotype with a median of 









The results show that even though carriers of PCSK9rs505151G/A had lower HbA1c, they 
had higher atherogenic associated characteristics; higher TC, LDL, TG and non-HDL as well 
as lower HDL compared to PCSK9rs505151A/A genotype.  
 
3.9 Gene-gene (ApoE-PCSK9) interactions 
The results shown in Table 3.6 below compare measured parameters between PCSK9 
rs505151 G/A and PCSK9 rs505151 A/A in each specific ApoE genotype.  Even though they 
did not reach statistical significance, PCSK9 rs505151 G/A had higher values in most cases 
than PCSK9 rs505151 A/A except for the ApoE X where PCSK9 rs505151A/A had higher 
levels. Noted in these results was that the PCSK9 rs505151 A/A- ApoE2/2 interaction had 
higher HbA1c but lower lipid results than other genetic interactions tested. An opposite 
picture is noted in the PCSK9rs505151G/A-ApoE X had higher HbA1c but lower lipid levels. 
Another observation was the significant difference between PCSK9 G/A-ApoE2/3 HDL 
compared to PCSK9 A/A-ApoE2/3 participants (p= 0.02). Considering that ApoE genotypes 
were similar for each pair that was being compared, the difference can be attributed to the 




















G/A -Proprotein convertase subtilisinlike/kexin type 9 - PCSK9rs505151G/A 
PCSK9 A/A-Proprotein convertase subtilisinlike/kexin type 9-PCSK9rs505151A/A 
HbA1c- Glycated haemoglobin; TC- Total Cholesterol; TG – Triglycerides:  LDL-Low density lipoprotein 
HDL- High density lipoprotein and Non-HDL – Non-High-density lipoprotein 
 
The table primarily shows comparisons of measured parameters between the two PCSK9  
genotypes and the different ApoE genotypes. Assessment of possible genetic interaction with 
the ApoE irrespective of PCSK9 genotype and PCSK9 genotype irrespective of the ApoE 








Table 3.10 Lipid comparison between PCSK9 rs505151 G/A and PCSK9 rs505151 A/A 
in each ApoE Genotype 
 


































p- value  0.54 0.85 0.47 0.94 0.94 0.83 

































p- value  0.18 0.53 0.98 0.88 0.02 0.97 

































p- value  0.37 0.43 0.32 0.07 0.18 0.18 

































p- value  0.83 0.58 0.98 0.25 0.89 0.58 

































p- value  0.36 0.56 0.45 0.27 0.5 0.67 
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CHAPTER 4: DISCUSSION 
 
4.1. New findings  
The aim of this study was to evaluate the role of ApoE and PCSK9 genetic variation on the 
type of dyslipidaemia that develops in South African diabetic patients. We hypothesized that 
different ApoE and PCSK9 variants influence the type or form of dyslipidaemia that develops 
in DM. The study established the presence and characterisation of dyslipidaemia in diabetic 
participants. It demonstrated that dyslipidaemia that develops in diabetes is not only due to 
poor glycaemic control but there are underlying genetic factors involved. The study produced 
the first report on the distribution of ApoE and PCSK9 between dyslipidaemic and non-
dyslipidaemic diabetic participants. The findings, which are reported here for the first time, 
are that;  
i) ApoE2/3 diabetics are less likely to develop dyslipidaemia of any form  
ii) ii) ApoE3/3 tend to develop dyslipidaemia,  
iii) PCSK9 rs505151 GA carriers are more likely to develop dyslipidaemia compared to  
      PCSK9 rs505151 AA carriers.   
iv) An incidental, possibly novel finding until verified was the presence of an  
uncharacterised ApoE which was labelled as X. The process of characterisation involves 
isoelectric focusing, comparison with ApoE3 binding ability to LDL (Apo B, E) receptors on 
cultured fibroblasts, which are beyond the scope of this project. 
 
4.2 Measured analytes 
The data presented shows that HbA1c is higher in older participants. This is similar to reports 
from other studies (Arnetz et al., 1982; Yang et al., 1997). However, the higher HbA1c might 
not be due to poor glycaemic control because others studies have demonstrated that aging is  
associated with increased HbA1c levels, independent of glucose levels and insulin resistance 
(Dubowitz et al., 2014). There are no studies on the effects of aging on HbA1c in Africa. 
Such a study would further interrogate the diagnostic specificity of HbA1c. Some researchers  
recommended HbA1c to be considered as a predictor of dyslipidaemia in T2DM in addition 
to its role as glycaemic control monitor (Singh and Kumar, 2011; Hussain et al.,2017). 
HbA1c was positively correlated with high triglyceride. Hence, the recommendation by other 
researchers for its use as an indicator of triglyceride level and predictor of cardiovascular risk 
factors in T2DM (Zaidi. et al., 2015; Naqvi et al., 2017). Correlation of lipoproteins showed a 
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significant correlation of LDL with several parameters that are implicated in cardiovascular 
pathology. The positive correlation with blood pressure has been reported by many 
researchers (Turner et al., 1998; Moro et al., 1999; Verges, 2005). This is due to the LDL 
increased plasma residence time in T2DM which promote cholesterol deposition in the 
arterial wall (Verges, 2005; Lyons and Jenkins, 1997). LDL correlation was similar in many 
instances to TC because it is the largest fraction of TC. HDL results were higher than those 
reported by other researchers (Persegol et al., 2006; Taskinen et al., 1984). In this study age 
positively correlated with HDL.  
4.3 Apo E genotype frequency 
Except for a few areas outlined below, the ApoE genotype and allele frequency in this study 
closely resembles those in some African countries like the Central African Republic, West, 
Central and East Africa (Zekraoui et al., 1997). Compared to a study by Masemola et al., 
(2007) that looked at ApoE genotypes and their relation to lipid levels in a rural South 
African population, the difference is that homozygous ApoE2/2 was absent (0%) in that study 
compared to 5.9% and 5% in dyslipidaemic and non dyslipidaemic diabetic participants 
respectively. Studies among the central, southern, west and east African population reported 
an ApoE2/2 frequency distribution of 2.3%, (Zekraoui et al., 1997). This constitutes 50% of 
what has been found in this study. Homozygous ApoE3/3 and ApoE4/4 had a similar 
distribution pattern with the above-mentioned studies. Results in this study found a frequency 
distribution of 20.6% among the heterozygous ApoE2/3 non dyslipidaemic participants. This 
was similar to 20.2% reported among the rural South African population (Masemola et al., 
2007). An interesting significant (p <0.0001) finding in this study is that dyslipidaemic 
participants had a distribution of only 5.3%, compared to 20.6% among the non 
dyslipidaemic participants. This finding the first of its kind, can be interpreted to mean that 
heterozygous ApoE2/3 diabetic patients seldomly develop dyslipidaemia. Another interesting 
discovery of this study is the frequency distribution of 1.8% among the heterozygous 
ApoE2/4 dyslipidaemic participants, but (0%) among the non dyslipidaemic participants. 
Zekraoui et al., (1997) reported a 4.3% frequency distribution in the African population 
mentioned above. Masemola et al., (2007) reported 17%, compared to its very low frequency 
among the dyslipidaemic participants; and absence in the non-dyslipidaemic diabetic 
participants, may be interpreted that heterozygous ApoE2/4 carriers seldomly develop DM. 




In summary, the study showed for the first time that heterozygous ApoE2/3 DM seldomly  
develop dyslipidaemia while heterozygous ApoE2/4 seldomly develop DM. The similarities 
in the ApoE genotype frequencies distribution between the non dyslipidaemic participants in 
this study and those reported for the general black population in the North-West Province of 
South Africa (Loktionov et al., 1999) and the rural South African population in Limpopo of 
South Africa (Masemola et al., 2007) as well as Caucasians of western Europe (Lucotte et al., 
1997), justifies the n number used in the study. 
4.4 PCSK9 variant frequency distribution  
This study evaluated the frequency distribution of PCSK9rs505151G>A and 
PCSK9rs28362286C>A in both the dyslipidaemic and non-dyslipidaemic participants. The 
study provides the first report on the distribution of PCSK9 rs505151C>A and 
PCSK9rs28362286C>A genotypes in diabetic patients in South Africa. PCSK9 rs505151AA 
was 55% in dyslipidaemic participants compared to 63% in the non-dyslipidaemic 
participants. PCSK9rs505151GA genotype had a notably higher frequency distribution in the 
dyslipidaemic (41%) compared to the non-dyslipidaemic (27%). This difference had 
tendency to significance (p = 0.06), which with a higher n number might be significant. 
However, this tendency to significance maybe interpreted to mean that PCSK9rs505151GA 
genotype has predisposition to development of dyslipidaemia in diabetic subjects. 
PCSK9rs505151GG genotype was two-fold more in non dyslipidaemic (10%) compared to 
dyslipidaemic (4%), therefore, similar to PCSK9rs505151AA genotype might be interpreted 
to infer protection from development of dyslipidaemia.  
 
In a study undertaken to detect the association of PCSK9rs505151G>A with serum lipid 
levels in the Guangxi Bai Ku Yao and Han Chinese population reported a frequency 
distribution that is different from the results of the present study. The Guangxi Bai Ku Yao 
and Han populations had a frequency of 95.99%, 4.01% and 0% in Guangxi Bai Ku Yao, and 
91.02%, 8.36% and 0.62% for A/A, A/G and G/G genotypes respectively (Aung et al., 2011) 
compared to 55%, 41% and 4% found in this study. The difference might be due to the fact 






In this study, PCSK9 rs 28362286 A/A genotype was absent in both dyslipidaemic and  
non-dyslipidaemic participants. PCSK9 rs28362286 C/A is absent in the non dyslipidaemic  
participants with a very small percentage 5.8% in the dyslipidaemic participants. PCSK9 
rs28362286 C/C genotype is predominant in both the dyslipidaemic (94.2%) and  
non-dyslipidaemic (100%). An investigation looking at predicting LDL levels in the black 
South African population, several PCSK9 variants including PCSK9 rs28362286 was 
examined and their frequency determined (van Zyl et al., 2014). They reported a frequency 
distribution of 1350/1428 (94.5%) for PCSK9 rs28362286 C/C and 78/1428 (5.5%) for 
PCSK9 rs28362286 C/A with 0% (absent) PCSK9 rs28362286 A/A, findings which are 
similar to results in this study. The absence of PCSK9 rs28362286 A/A in both dyslipidaemic 
and non dyslipidaemic as well as in the study by van Zyl et al., 2014, can mean that this 
genotype is absent in the black South African population. Absence of gene variants can be 
selective pressures on alleles that may underlie simple vs. complex disorders (Zwick et al., 
2000).  
 
4.5 ApoE genotypes influence on dyslipidaemia  
The study demonstrated that those with poor glycaemic control did not show the 
dyslipidaemia as expected under the secondary dyslipidaemia classification. Even though 
only a few studies correlated glycaemic control to dyslipidaemia, the effects of ApoE4/4 in 
this study concurs with findings of exaggerated dyslipidaemia and atherosclerosis in diabetic 
mice with knock out LDLR and therefore supports the notion that ApoE4/4 could be central 
to diabetic dyslipidaemia (Johnson et al., 2011). The results are also consistent with studies in 
the Afro-Caribbean people where ApoE4/4 genotypes had higher TC levels compared with 
ApoE2/2 genotypes (Larifla et al., 2017). A study in Egypt that looked at ApoE gene variants 
as a risk factor for CAD in T2D patients found that ApoE4/4 had the highest TC (Halim et 
al., 2012). However, a large meta-analysis reported that carriers of the homozygous ApoE2/2 
genotype had lower mean LDL levels than carriers of the homozygous ApoE4/4 genotype 
(Liu et al., 2014).  
 
4.6 PCSK9 rs505151 genotypes influence on dyslipidaemia. 
The study looked at the effects PCSK9 rs505151 genotypes on the levels of lipids and  
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lipoproteins. PCSK9 rs505151 A/A had lower but not significantly different LDL levels 
median 3.79mmol/L (IQR 3.17 – 4.42mmol/L) compared to PCSK9 rs505151 GA with LDL 
median of 4.08mmol/L (IQR 3.27 – 4.35mmol/L) p = 0.75. Even though there was no 
significant difference, the result an important finding because van Zyl et al., (2014) reported a 
significant difference in LDL levels between carriers of the homozygous PCSK9 rs28362286 
C/C and carriers of heterozygous PCSK9 rs28362286 C/A p <0.0001. The Dallas Heart Study 
also identified three PCSK9 variants in the blacks and whites, which were associated with 
lower plasma levels of LDL. Therefore, these studies show that different PCSK9 variants 
have different effects on the lipoproteins (Kotowski et al., 2006). The absence of a direct 
reciprocal correlation between HbA1c levels as a marker of glycaemic control to lipoprotein 
levels as markers of dyslipidaemia, this small study seems to infer that development of 
cholesterol (LDL) related dyslipidaemia might be independent of the level of glycaemic 
control and therefore, not secondary to DM but that there may be another underlying factor, 
which may be genetic. This is the first report on the association of PCSK9, DM and 
dyslipidaemia.  
 
4.7 Gene-gene interactions (genetic synergy or epistasis) 
This forms a simplified discussion looking at genetic interaction to show if there is any 
possible form of synergy between two genes that are known to be associated with 
dyslipidaemia. There are no records on this type of analysis in the African population. Each 
of the ApoE genotype had a dual comparison between two PCSK9 genotypes. Out of all the 
ApoE genotypes, ApoE2/3 had interesting HDL results. CSK9rs505151G/A-ApoE2/3 had 
significantly higher (p = 0.02) HDL compared to PCSK9rs505151A/A-ApoE2/3. Since the 
ApoE was the same, the difference can be attributed to the different PCSK9 genotypes. 
Considering the association of high HDL and cardio protection, it can be interpreted that the 
combination of CSK9rs505151G/A-ApoE2/3 is more CSK9rs505151A/A-ApoE2/3 in DM. 
However, other combinations showed minor differences. For instance, subjects with the 
combination of PCSK9rs505151A/A and ApoE2/2 genotypes had the highest HbA1c, median 
of 9.5% (IQR 5.80 – 14.30). On the other hand, the combination of PCSK9rs505151G/A and 
ApoE2/3 genotypes had the lowest HbA1c median 5.0% (IQR 4.80 – 6.30). Subjects with the 
combination of PCSK9rs505151G/A and ApoE3/3 genotypes had the highest TC, median 
7.70mmol/L (IQR 5.23 – 9.08 mmol/L) but with nearly 50% of HbA1c in PCSK9 
rs505151A/A and ApoE2/2 subjects. The combination of PCSK9rs505151A/A and ApoE2/3 
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genotypes had the lowest total cholesterol median 3.83 mmol/L (IQR 3.12 – 4.95 mmol/L). 
Other studies that did not consider gene interaction reported that APOE ε4 alleles are 
considered a risk for hypercholesterolemia (Saunders et al., 1993). However, there is 
considerable disagreement regarding the degree of hypercholesterolemia between ApoE3/3 
and ApoE4/4 (Knouff et al., 1999). As can be noted, this study agrees with ApoE3/3 being 
associated with hypercholesterolemia. Participants with the combination of 
PCSK9rs505151G/A and ApoE X had the highest TG median 2.71mmol/L (IQR 1.49 – 3.38 
mmol/L) ApoE and PCSK9 effects on TG as well as ApoE X have not been reported before. 
Carriers with a combination of PCSK9rs505151G/A and ApoE3/3 genotypes had the highest 
Non-HDL median 5.14 mmol/L (IQR 3.69 – 5.40 mmol/L). Carriers of the 
PCSK9rs505151A/A and ApoE2/3 genotypes had the lowest HDL median 1.02 mmol/L 
(0.76-1.33 mmol/L). Several reports give a general relationship between ApoE and HDL 
without the possible ApoE isoform associations (El Harchaoui et al., 2009; Ćwiklińska et al., 
2015).  
 
The study results show that the levels of serum LDL were slightly higher in the subjects with 
PCSK9rs505151G/A genotype than those with PCSK9rs505151AA genotype; the difference 
did not reach statistical significance. Several other studies have reported low LDL in some 
PCSK9 variants. In the PROSPER Study, PCSK9 R46L SNP was reported to lower LDL 
without an effect on the risk CVD in the elderly population with a high prevalence of 
cardiovascular disease (Polisecki et al., 2008). Other studies have reported PCSK9 genetic 
variants that persistently lower serum LDL levels than non-carrier black men. The reduction 
in LDL levels is associated with reduced subclinical atherosclerosis burden (Huang et al., 
2009). However, analysis of the effects of two genes ApoE and PCSK9 genotypes displayed 
different patterns of dyslipidaemia in DM and this might be one of the reasons behind the 










CHAPTER 5: STRENGHTS AND LIMITATIONS, CONCLUSION AND    
                         RECOMMENDATIONS 
5.1 Strengths and limitations 
This is the first study in South Africa that investigated the frequency and association of 
various genotypes in the ApoE and PCSK9 gene variants in DM. The study is the first to 
report on the distribution of ApoE and PCSK9 in the diabetic population. In addition to 
reporting on previously identified variants in the African and other populations, an 
uncharacterized variant referred to in this study as ApoE X was noted to have a strong 
association on development of dyslipidaemia. The absence of PCSK9rs28362286A/A 
genotype in the African population is confirmed. Even though there was no clinical 
significance between the different genotypes (ApoE and PCSK9) and measured parameters, 
the study showed that there was no direct reciprocal association between poor glycaemic 
control developments of dyslipidaemia. The inability to achieve statistical significance with 
some results showing a tendency to significance can be attributed to the small sample 
number. Even though the sample number was small, there are several results that are similar 
to those reported in larger studies. 
 
5.2 Conclusion  
The results revealed that there is no direct reciprocal relationship between glycaemic control 
and level or type of dyslipidaemia. Therefore, the study has clearly demonstrated that 
dyslipidaemia found in DM has an underlying genetic influence predisposition. In line with  
pharmacogenetics, application of standard management to diabetic patients with different 
ApoE genotypes will not yield optimum results. Many diabetologists across the world have at 
one stage or another discussed possible patient non-compliance resulting in poor glycaemic 
control leading to dyslipidaemia. The thought of possible underlying genetic causes has not 
received a lot of attention especially in the African patients. With these findings, 
consideration to explore possible underlying genetic predisposition is recommended 
especially in diabetic patients with dyslipidaemia that responds poorly to standard therapy.   
 
5.3 Recommendations 
With these findings, a recommendation to look at underlying genetic predisposition in 
diabetic patients presenting with dyslipidaemia is made. Other researchers of lipid 
metabolism (Ramasamy, 2016) have also made similar recommendations. Racial differences 
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in the response to statins have been reported in South Africa (Raal et al., 2013). Differences 
between Asians and Westerners have also been reported with recommendations to elucidate 
the gene factors (Naito et al., 2017). Lessons can be drawn from advances in diagnosis and 
management of infectious disease where culture and institution of treatment that used to take 
several weeks can now be done within hours due to advances in nanotechnology. Secondly, 
molecular studies from DNA extraction to genotyping that used to take several days can now 
be done within hours at costs much lower than in the past. Point of care testing for TC and 
TG is now already available. Development of dipstick with anti ApoE lipoproteins as a first 
step is a real possibility with finer details looking at the homozygous and heterozygous. What 
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This document outlines policies and procedures pertaining to Hemoglobin A1C testing by DCA Vantage. In an effort to 
be concise, some information may be excluded from the manufacturer’s procedure. It is recommended that operators 
familiarize themselves with the manufacturer’s product information that accompanies each reagent kit and the operators’ 
manual if one exists. 
 
The DCA Vantage Analyzer is a semi-automated bench top system used for the quantitative determination of 
hemoglobin A1C in blood. The measurement of hemoglobin A1C concentration is recommended for monitoring the long-
term care of persons with diabetes. This assay provides a convenient method for the in vitro measurement of percent 
concentration of hemoglobin A1c in blood. 
Test Principle 
The DCA Vantage Analyzer uses a spectrophotometer to analyze the intensity of the light transmitted through the 
cartridge optical window. Whole blood is added to the reagent cartridge, the cartridge is inserted into the DCA Vantage 
Analyzer, and meaningful results are available in 6 minutes. All measurements and calculations are performed 
automatically by the DCA Analyzer, and the screen displays percent HbA1c at the end of the assay. The following 
chemical reaction occurs within the cartridge: For the measurement of total hemoglobin, potassium ferricyanide is used 
to oxidize hemoglobin in the sample to methemoglobin. The methemoglobin then complexes with thiocyanate to form 
thiocyanmethemoglobin, the colored species that is measured. The extent of color development at 531 nm is proportional 
to the concentration of total hemoglobin in the sample. For the measurement of specific HbA1c, an inhibition of latex 
agglutination assay is used. An agglutinator (synthetic polymer containing multiple copies of the immunoreactive portion 
of HbA1c) causes agglutination of latex coated with HbA1c specific mouse monoclonal antibody. This agglutination 
reaction causes increased scattering of light, which is measured as an increase in absorbance at 531 nm. HbA1c in whole 
blood specimens competes for the limited number of antibody-latex binding sites causing an inhibition of agglutination 
and a  
decreased scattering of light. The decreased scattering is measured as a decrease in absorbance at 531 nm. The HbA1c 
concentration is then quantified using a calibration curve of absorbance versus HbA1c concentration. The percent HbA1c 
in the sample is then calculated as follows: 
 
% HbA1c = ([HbA1c] / [Total Hemoglobin]) x 100  
Both the concentration of hemoglobin A1c specifically and the concentration of total hemoglobin are measured, and the 
ratio reported as percent hemoglobin A1c. 
Regulatory Requirements 
I. Each testing site must have a documented quality control program, which is developed in collaboration with or has 
been approved by the MGH Pathology Service. 
 
II. All test results must be maintained in patient records with all required information for four years 
Required information: 
1. Patient’s name 
2. Medical Record Number 
3. Patient’s gender 
4. Patient’s age or date of birth 
5. Date & time test collected, performed and reported 
6. Ordering Physician 
7. Responsible physician (if not 6) 
8. Reference or Target Range 
9. Test Performed 
10. Test units 


























Ensure that the system is in the Home screen, which displays the status of the system and is the starting point for Patient and 
Control Test Sequences. If the system is in the Not Ready state and you cannot initiate a Patient or Control Test Sequence, 
an alert message displays explaining why the system is not ready.  
The Recall menu and the 
System menu can also be accessed from the Home Screen. 
1. Remove a reagent cartridge from the refrigerator and allow it to warm up to 
room temperature. (10 minutes in the unopened foil pouch, or 5 minutes if removed 
from the foil pouch.) 
a. To open the foil pouch, tear down from the corner notch until the entire long side of the pouch is open. Do not use 
scissors. After opening the foil pouch, the reagent cartridge must be used within one hour. 
b. When handling the reagent cartridge, do not touch or otherwise contaminate the optical window (1) or erroneous test 
results may occur. 
c. Discard the reagent cartridge if any of the following conditions exist: 
 The flexible pull-tab is loose or missing. (2) 
 The desiccant bag is missing or open. (3) 
 The cartridge is damaged. 
 Loose desiccant particles are found inside the foil package. 
 If the foil package is open for more than 60 minutes. 
2. Collect the sample using the capillary holder. 
3. Insert the capillary holder containing the sample into the reagent cartridge until the holder snaps into place. The open side 
of the capillary holder should face the foil pull tab. 
4. Scan the Reagent Cartridge: Hold the reagent cartridge so that the barcode faces to the right. Insert the reagent cartridge 
above the “dot” located on the side of the instrument barcode track. Quickly and smoothly, slide the reagent cartridge down. 
A beep sounds to signal a successful scan. 
5. With the barcode facing to the right, insert the reagent cartridge into the cartridge compartment until a gentle a snap is 
heard or felt. NOTE: The cartridge is designed to fit only one way into the system. 
Do not force the cartridge into system. 
6. Using a slow, continuous motion, pull the flexible pull-tab 
completely out of the reagent cartridge and discard. 
7. Close the door. Five seconds after the door is closed, a beep sounds and the assay 
begins. 
NOTE: If you accidentally close the door before you pull the flexible plastic tab, you have 5 seconds to re-open the door 
and pull the tab.  
8. The Sample Data menu screen displays when the instrument detects the system door closes, and indicates a test is in 
progress after the 5-second delay. 
9. Follow the prompts to enter patient’s CSN (scan CSN from EPIC label on tube) and operator ID #. 
10. The Result screen displays when the system finishes analyzing the sample. Press the “print” button on the screen to print 
results. 
11. Remove the Reagent Cartridge 
12. Open the cartridge compartment door. 
13. Locate the button on the right side of the cartridge compartment. 
14. Push and hold it down with your right hand. 
15. With your left hand, gently push the tab on the cartridge to the right to release the cartridge. 
16. Discard in biohazard container. 
NOTE: You can cancel a test any time. To cancel a test, select Cancel. If a test in progress is cancelled, you must discard 
the sample. 
Symbol Interpretation 
result preceded by a less than (<) sign concentration is below the lower limit of the test (i.e. <2.5%) 
result preceded by a greater than (>) sign Concentration is above the upper limit of the test (i.e. >14.0% for patient samples; 
>16.0% for control samples.) result followed by a minus sign (-) result is below the Reference Range 



























HgbA1C 3.8 – 6.4% None 3.0 – 10.0% 
The tested ranges are those ranges that were tested during functional sensitivity and linearity testing. 
* Clinical policy and Procedure Manual 
Laboratory Results: Guidelines for Retreving and Reporting. 
Maintenance 
Turn the power off and disconnect the power cord before cleaning (You can leave the DCA Vantage system on always, 
except during maintenance and cleaning procedures.) 
Turning the system off 
1. At the Home screen, select Turn Off. A message displays asking if you want to shut down the system. 
2. Select Yes. 
3. Turn the power switch to the off position when the system shut down is complete 
Weekly 
Cleaning: 
Barcode Window: Clean the barcode window with a lint-free cloth dampened with water or 
ethanol 
Exterior: Clean the exterior with a lint-free cloth dampened with water or ethanol. Do not 
allow liquid to drip into system. 
NOTE: To disinfect the exterior of the system, expose the surface to 0.5% sodium hypochlorite for 10 
minutes. Remove any visible blood on the system before disinfection.  
Do not use any other type of solvent, oil, grease, or silicone spray on any part of the system 
Running the Optical Test 
See Operator’s Manual for instructions 
Document all instrument maintenance and cleaning on the appropriate log sheets 
Connectivity and Downtime procedure 
1. The DCA Vantage analyzer is connected to Telcor (POCT management system) through an interface on thenetwork. 
2. In the event of connectivity failure, document the results on the patient’s chart with the units and reference ranges. 
Results can be re-transmitted in the “Recall Results” menu. 
3. Contact the POCT program for assistance. (ext.6-1462, 3-5392 or 6-3858) 
Technical Assistance 
Siemens Medical Solutions Technical Care Center: 1-877-229-3711 
Customer Service: 1-800-255-3232 
Serial Number: 
Customer Account Number: 
References 
1. DCA Vantage ™ Analyzer Operator’s Guide, Ref. 06489264, Rev. C, 2011-07. 
Cross – References 
DCA Vantage HgbA1C Training and Competency Assessment Record 
DCA Vantage Maintenance Log 
DCA Vantage Operator Training Checklist 
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The GUSTAFSON et al 1987 as modified by C Dandara et al was employed in for extraction and 
purification of DNA from 5ml frozen blood sample.  
1) Frozen samples were thawed at room temperature and at times in a water bath at room temperature.  
2) The sample was dispensed into 15ml appropriately labelled sterile screw top polypropylene tubes. 
3) The sample tubes were rinsed with 1 ml PBS (Phosphate Buffered Saline) and the solution added to the 
polypropylene tube. 
4) A 1:2 dilution was acievbed by adding with 2 volumes of PBS to the sample. There are many different 
ways to prepare PBS. Some formulations do not contain potassium, while others contain calcium or 
magnesium. Ours was based on the composition in the table below and ttis is the most common 
composition of PBS (1X). The simplest way to prepare a PBS solution is to use PBS buffer tablets or 
pouches. They are formulated to give a ready-to-use PBS solution upon dissolution in a specified quantity 
of distilled water. They are available in the standard volumes: 100, 200, 500 and 1000 mL. We used the 
1000mL pouches. 
Salt   Molecular Weight Concentration (mmol/L) Concentration (g/L) 
  NaCl    58.443   154    9 
  Na2HPO4   141.959  5.6     0.79 
  KH2PO4   136.086   1    0.13 
pH was adjusted to 7.4 with HCl 
5) Mix by inverting the tubes. The phosphate buffered saline (PBS), a balanced salt solution provides the 
essential balanced salt solution is to maintain pH and osmotic balance as well as provide cells with water 
and essential inorganic ions. It maintains cells in a viable state for short periods during the processing 
periods outside their natural habitat. One of the early formulas of PBS was developed by Renato 
Dulbecco, published in 19541 which are termed DPBS for Dulbecco’s phosphate buffered saline. 
6) The samples were centrifuged at 2200g (2300 rpm) for 15 minutes 
7) The supernatant was carefully poured out leaving a reddish pellet at the bottom. 
8) The pellet was resuspended in 10mL of Sucrose Triton X-100 Lysing Buffer and vortex.  
The addition of sucrose produces a hypertonic solution which results in cell crenation tghus producing an 






























MgCl2 in Triton offers DNA protection during subsequent steps. When membranes are busted by TRIS, there 
is no compartmentalization in the solution anymore. MgCl2 from te Triton is already present to bind to DNA 
and thus protecting it against DNase proteins that will alsoi be released when the membranes are broken. The 
binding of MgCl2 to DNA denies access of DNase to the DNA from being broken down. 
Triton X-100 is a nonionic hydrophilic surfactant/detergent that is commonly used in laboratories to lyse cells 
to extract protein or organelles, or to permeabilize the membranes of living cells. 
9) Place on ice for 5 minutes. This part is optional but it gives one a chance to review (take stock) the next 
steps and and also take a break as the below zero temperature slows down all possible metabolic activities.   
10) Samples were spun for for 15 minutes or longer at 2200g (2300 rpm in TH.4 rotor)   
11) The supernatant was carefully poured off leaving pellets that ranged from pink to white in colour. 
12 Mixing by inversion is required after each of the following three steps. 
12. i) The pellet was resuspended in 3 mL of TRIS20EDTA5 (T20E5) (The 3ml is calculated from the initial 
blood volume of 5ml X 0.6 =3mL. This is the first step in cell lysis TRIS 
(tris(hydroxymethyl)aminomethane): 
When the cells are broken apart, their DNA and contents spill into the buffer. Additionally, RNase A (destroys 
RNA), proteases (destroys proteins), and SDS (sodium dodecyl sulfate, solubilizes the membrane fragments). 
All these components, fragmented RNA and proteins can have a big impact on the pH of the solution. DNA is 
pH sensitive, it is therefore important to ave a buffer can maintain the pH at a steady point. TRIS offers the 
optimum stable pH, usually 8.0 for DNA extraction, and its preference over other buffers is that it interacts 
with the lipopolysaccharides present on the outer membrane which helps to permeabilize the membrane. This 
effect is enhanced with the addition of EDTA (ethylenediaminetetraacetic acid), which binds divalent cations 
such as calcium and magnesium. These ions help maintain the integrity of the cell membrane and therefore, 
eliminating them with EDTA further destabilizes the membrane resulting in cell lysis.  
12. ii) 200µl of 10% SDS was added producing a final concentration of 1%.  
Sodium dodecyl sulfate (SDS), a strong anionic denaturing detergent that can solubilise proteins and lipids 
that form the membrane. It removes the -ve ions from the protein and destroys its confirmation. Loss of 
confirmation results in the protein losing its structure. This results in the cell membranes and nuclear 
envelopes to break down and expose the chromosomes that contain the DNA.In addition to removing the 









































12. iii) 37.5µl Protenase K, 20mg/mL to final concentration of 250µg/mL –  
The lypholised proteinase K is reconstituted wit 12.5ml of deionised water to give a concentration of 
20mg/mL 
The desired enzyme concentration in the final volume of 3ml (from 12i) is 250ug/mL but te available 
concentration is 20mg/mL 
ViCi=V2C2 
X x 20mg/mL =3ml x 250ug/mL 
X x 20000ug/mL = 3ml x 250ug/mL 
X = 3ml x 250/20000 
X = 0.0375ml  0.0375 x 1000 = 37.5ul 
Therefore 37.5ul of the reconstituted enzyme when added to 3ml gives 250ug/ml 
Proteinase K (EC 3.4.21.64, protease K, Tritirachium album serine proteinase is a broad-spectrum serine 
protease. The enzyme was discovered in 1974 in extracts of the fungus Engyodontium album (formerly 
Tritirachium album). Proteinase K is able to digest native keratin (hair), hence, the name "Proteinase K". 
The predominant site of cleavage is the peptide bond adjacent to the carboxyl group of aliphatic and 
aromatic amino acids with blocked alpha amino groups. It is commonly used for its broad specificity. 
This enzyme belongs to Peptidase family S8. The molecular weight of Proteinase K is 28,900 daltons 
(28.9 kDa). 
Enzyme activity 
Activated by calcium (1–5μmoles), the enzyme digests proteins preferentially after hydrophobic amino 
acids (aliphatic, aromatic and other hydrophobic amino acids). Although calcium ions do not affect the 
enzyme activity, they do contribute to its stability. Proteins will be completely digested if the incubation 
time is long and the protease concentration high enough. Upon removal of the calcium ions, the stability 
of the enzyme is reduced, but the proteolytic activity remains. Proteinase K has two binding sites for 
Ca2+, which are located close to the active center, but are not directly involved in the catalytic 
mechanism. The residual activity is sufficient to digest proteins, which usually contaminate nucleic acid 
preparations. Therefore, the digestion with Proteinase K for the purification of nucleic acids is usually 
performed in the presence of EDTA (inhibition of calcium-dependent enzymes such as nucleases). 
Proteinase K is also stable over a wide pH range (4–12), with a pH optimum of pH 8.0. An elevation of 
the reaction temperature from 37 °C to 50–60 °C may increase the activity several times, like the 
addition of 0.5–1% sodium dodecyl sulfate (SDS). 




































14)  After incubation 1mL of saturated NaCl was added and mixed vigorously for 15 seconds 
NaCl provides Na+ ions that will block negative charge from phosphates on DNA.  Negatively charged phosphates 
on DNA cause molecules to repel each other. The Na+ ions will form an ionic bond with the negatively charged 
phosphates on the DNA, neutralizing the negative charges and allowing the DNA molecules to come together. 
Negatively charged phosphates on DNA cause molecules to repel each other neutralizing the negative charges and 
allows the DNA molecules to come together 
15) The prepartation was spin for 30 minutes at 2400g. A white pellet composed of protein precipitated by salt should 
was visible. 
16)  The supernatant containing DNA was transferred to appropriately labellede new 15ml sterile screw top 
polypropylene tubes. 
17) In order to precipitate the DNA, two volumes (approximately 9ml) of absolute alcohol kept at room temperature 
were added. 
18)  Several inversions approximately 50 times results in DNA precipitation. Interactions between two charges within 
a solvent are governed by Coulomb’s law. Ethanol is the most commonly used alcohol component in precipitations of 
DNA and RNA. DNA is polar due to its highly charged phosphate backbone. Its polarity makes it water-soluble.  
Electric force which normally holds salt crystals together by way of ionic bonds is weakened in the presence of water 
allowing ions to separate from the crystal and spread through solution.  
Ethanol has a much lower dielectric constant than water does (24 vs 80, respectively). By lowering the dielectric 
constant of a solution containing nucleic acids and monovalent cations, the Coulomb force of attraction increases 
between the cations and the negatively charged nucleic acid backbone 
If enough ethanol is added, the electrical attraction between phosphate groups and any positive ions present in 
solution becomes strong enough to form stable ionic bonds and DNA precipitation causing it to separate out of 
solution. This usually happens when ethanol composes over 64% of the solution.   
19) The preparation was spun for 10 minutes at at 2400g.  
20) 1 mL of 70% ice-cold alcohol was used to wash the DNA. The 30% water allows partial dissolution of DNA and 
permits adhesion to the plastic wall of the tube. 
21) The tubes were spun for 10 minutes at 2400g and the supernatant was removed carefully ensuring that there was 
no DNA adhering on the sides of the tubes. 






































23) DNA was redissolved in the approximate volume of TE (50-100µL) 
TE buffer is a commonly used buffer solution in molecular biology, especially in procedures involving DNA, 
cDNA or RNA. "TE" is derived from its components: Tris, a common pH buffer, and EDTA, a molecule that 
chelates cations like Mg2+. The purpose of TE buffer is to solubilize DNA or RNA, while protecting it from 
degradation. TE buffer is also called as T10E1 Buffer, and read as "T ten E one buffer". To make a 100-ml solution 
of T10E1 Buffer, 1 ml of 1 M Tris-HCl (pH 8.0) and 0.2 ml EDTA (0.5 M) and made up with double distilled 
water up to 100ml. Based on nuclease studies from the 1980s, the pH is usually adjusted to 7.5 for RNA and 8.0 for 
DNA 
The respective DNA and RNA nucleases are supposed to be less active at these pH values, but pH 8.0 can safely be 
used for storage of both DNA and RNA. EDTA further inactivates DNAse, by binding to metal cations which act 
as cofactors and therefore required by this enzyme.  Genomic and plasmid DNA can be stored in TE Buffer at 4°C 
(39.2°F) for short-term use, or -20°C (-4°F) to -80°C (-112°F) for long-term storage. 
24. The DNA in TE was transferred to sterile DNA cryotubes. See Figure below 
Isolated DNA Storage preparation  
DNA in TE was transferred to sterile DNA cryotubes 
DNA concentration measurement 
DNA concentration and quality was analysed on Nanodrop spectrophotometer (Thermo Scientific ND-1000). For 
each sample, 1.5 μl of dissolved DNA was loaded on the spectrophotometer, which provided the DNA 
concentration in ng/μl (values above 100 ng/μl were considered optimal), the 260/230 ratio determines the organic 
chemicals and solvent contamination. It is important to have this ratio above 1.6 for qPCR. This was very useful 
wen chloroporm was used as to precipitate te DNA. The 260/280 ratio determines protein contamination. Ratios 
above 1.8 reflect minimal proten contamination due to incomplete digestion. This is usually encountered due to 
subopimal temperature, inadequate incubation and unsufficient enzyme concentration. Samples were stored as 
stock DNA and working DNA was prepared for genotyping and stock DNA stored at −20°C prior to genotyping. 
DNA 1% Integrity Assessment   
Gel Preparation 
1) 1g/mL of Seakem LE Agarose (1%W/V) was weighed using a triple beam balance.  






































3) Appropriate volume of 1x TBE (Tris Borate EDTA) buffer was added (e.g. 100mL 1xTBE and 1g Agarose)   
Preparation of Stock 2L of 10xTBE  
• 218 g Tris base  
• 110 g Boric acid  
• 9.3 g EDTA 
Dissolve the ingredients in 1.9 L of distilled water. pH to about 8.3 using NaOH and make up to 2 L 
(TAE –Tris Acetate EDTA is alsdo used by otherc laboratories.)  
4) The solution was placed in a microwave.  The agarose solution can boil over very easily so it was checked 
regularly. Usually we stopped it after 45 seconds to swirl.  Oven gloves were worn during the removal swirling of 
the conical flask.  
5) Once fully dissolved, the solution was clear and transparent and allowed to cool down by placing it in a 
container with water at room temperature and gently swirling the solution.   
6) When the solution was cool enough to touch, Gel Green stain was added based on the 5ul Gel Green to 100mL 
of the gel solution proportion. Gel Green a proprietary dye is less toxic than ethidium bromide.  Proprietary dyes 
bind to DNA and are fluorescent, meaning that they absorb invisible UV light and transmit the energy as visible 
light. 
7) While the agarose was cooling, the gel tanks were prepared. The Gel solution was poured into a small 8x10 cm 
gels (minigels) which give good photographs because we found that larger gels did not good pictures. 
8) The gel was poured gel slowly into the tank with a comb in position avoiding any bubbles.  
9) The conical flask was rinsed immediately.  
10) The gel was left to set for at least 30 minutes, preferably 1 hour, with the lid on if possible. 
11) After setting, 1 x TBE buffer, the running buffer was added to the gel tank to submerge the gel to 2–5 mm 
depth.   
Sample preparation 
12) A para film was laid onto a smooth even bench surface and labelled from left to right with appropriate DNA 
sample numbers.  
13) In front of each number 3µl of 1x loading buffer/dye was dispensed. Loading dye/buffers  
give colour and density to the sample to make it easy to load into the wells and settle at the bottom. The dyes are 
negatively charged in neutral buffers and thus move in the same direction as the DNA during electrophoresis. The 































The most common dyes are bromophenol blue (Sigma B8026) and xylene cyanol (Sigma X4126). Density is 
provided by glycerol or sucrose.  The loading dye was prepared as: i- 25 mg bromophenol blue or xylene cyanol  
ii- 4 g sucrose  
iii- H2O to 10 mL  
14) Equal volume of DNA samples 3µl were dispensed onto the corresponding loading buffer spot and gently 
mixed with the pipette tip and the mixture was dispensed into the corresponding gel well from left to right. 
15) 3µl of the molecular weight marker (size marker) was loaded into the first and last wells) 
Fermentas GeneRuler 100bp DNA Ladder containing 14 discrete fragments in base pairs ranging from 3000, 
2000, 1500, 1200, 1031, 900, 800, 700, 600, 500, 400, 300, 200, 100 was utilised as molecular marker 
Gel Running 
16) An agarose gel was placed in this buffer-filled gel tank and an electrical field is applied via the power 
supply to the rear. DNA migrates from negative –cathode (black wire at the far end) towards positive –anode (red 
wire). 
17) To avoid heating up the gel we utilised the principle of 5V/cm when running the gel (if the electrodes are 10 
cm apart then run the gel at 50 V), we set ours at 100V and ran for 40 minutes. 
Above 5 V/cm the agarose may heat up and begin to melt. Slower rate 2 V/cm for 10 minutes to allow the DNA 
to move into the gel slowly and evenly, and then speed up the gel later gives better resolution 
18) An agarose gel is placed in this buffer-filled box and an electrical field is applied via the power supply to 
the rear. DNA migrates from negative –cathode (black wire at the far end) towards positive –anode (red wire). To 
check that the current was running we looked for evolving gas bubbles at the electrodes. 
Viewing the gel 
19) After switching off and unplugging the gel tank, the gel was carried in it’s holder to the UV Viewing 
apparatus.  
20) Tech Fire   the gel (in its holder if possible) to the dark-room to look at on the UV light-box.  
21) The viewing apparatus UV Tech Fire Reader was utilised.  
2)  Gel holders are not UV transparent the gel was placed onto the glass surface (dock) and preview was 
selected to edit the image with camera dials under white light. 
23) UV Dock door was closed, white light switched off, then preview was also stopped and te UV light was 
switched on. 
Note UV is carcinogenic and must not be allowed to shine on naked skin or eyes.  






























































































































































Area amplified by…: 218bp 




























































Study title:  
GENETICS AND DIABETIC DYSLIPIDAEMIA IN THE BLACK SOUTH AFRICANS 
Greeting: Good day, my name is Donald Tanyanyiwa. I work in Chemical Pathology here 
at Chris Hani Baragwanath Academic Hospital  
Introduction:  
We are doing some work to help us understand causes of increased fat /lipids in some African 
people with diabetes. It is known that some people with DMdevelop abnormal levels of 
fats/lipids.  People are born with fat carrying protein, which may be different because of 
changes (mutations/polymorphism) in the seed (genes) that produce them and that causes them 
to do their job differently; others do it faster than others. The change may occur in one seed or 
many seeds. This causes some people to have increased amounts of different types of fat 
because their fat carrying proteins will not be working properly or may be reduced.  Fats/Lipids 
are required by the body, but when in excess it becomes harmful. The body normally manages 
to keep the fat within the required levels, but during illness or the presence of inherited disease, 
the body may not be able to clear the fat. 
High amounts of these fats have been associated with disruption of the normal heart and blood 
transport system.  A lot of research to identify the different causes of increased amount has 
been done but very little if any has been done to identify the common causes of fat 
accumulation in African people with diabetes. The study will examine to see if 
mutations/polymorphism in the genes of some (four proteins) associated with lipid metabolism 
are responsible for the abnormal fat/lipid (cholesterol and triglyceride) content in people with 
diabetes. The study will require only a small amount of blood (1.5 teaspoons) of the blood 
already sent to the laboratory for diagnostics purposes. There will be no immediate benefits to 
you but depending on the results benefits may be realised later. Patients who do not participate 
or withdraw from the study will continue to receive the same recommended standard 
intervention as the participants. It is hoped that the findings and advice given to the patients 
will go a long way in improving the quality of life. Venesection is a very safe method of 
obtaining blood for the repeat lipogram if required. The only risk that can be encountered is 
prolonged bleeding in those with some coagulopathy, a condition that will be excluded by the 




































Invitation to participate:  We saw from your results that you are one of those diabetic people 
with increased amounts of these fats. Usually a small amount of blood (one and half (1½) 
teaspoons) is sent to test fat content in blood. We are asking your permission to keep that blood 
and find out the reason why the fat is increased 
   
What is involved in the study – We will not need any blood from you and we will not 
examine you. However, we will require your permission to go and look at your hospital/clinic 
file to get your age, and how you are being treated. If you are taking tablets we will record their 
names.  You will not be expected to make any special visit to Chris Hani Baragwanath 
Academic Hospital for this study.   
 
Risks: There is no risk at all in this study because the fat carrying protein is already in the blood 
you sent to the laboratory and that is the one we will be using. 
Benefits - The benefits of this study will only be realized if the cause of increased fat is 
identified and because it is the first such study, I will present it for as a PhD thesis.   
 
Participation is voluntary – It is your right to accept or refuses to take part in this study and 
whatever decision you make nothing will change regarding your treatment. It is also your right 






















































CONSENT FOR STYDY ON DIABETIC DYSLIPIDAEMIA IN BLACK SOUTH AFRI-CANS 
Name----------------------------------------------------------------------------------------------------------- 
Address--------------------------------------------------------------------------------------------------------  
Analysis and storage of Biologic Samples: Plasma and DNA  
 I hereby consent to the removal, storage waiting processing, and analysis of the above material from my 
own body for the purpose of diagnosis and research into disorders of lipid and lipoprotein metabolism 
associated with diabetes. After due explanation I understand that  
1) Conventional procedures and techniques are employed and that the health risk is minimal. 
2) The material and results of the investigations remain strictly confidential according to medical 
practice and such ethical guidelines that govern research at the universities and country at large. To 
preserve anonymity, the samples are coded by numbers and my written consent is required for release of 
identifiable information to another party 
3)  Precise diagnosis may not always be possible because the defect(s) may not yet be known or there is 
inadequate information to derive the defect owing to modulatory roles that other genes or the 
environment may play.   
4) The stored material may be used anonymously in future to derive information or for research 
purposes. Such future use may be of no direct benefit to the subject. 
5) Permission to participate in the study may be withdrawn at any time and any stored biological 
material will also be destroyed. The withdrawal will not affect the subject’s future medical care. 
6) I confirm that the purpose of this study was explained in the language that I preferred and I fully 
understood it. I have not received any financial benefit and I do not expect to receive any in future and 
undertake not to make any future financial claims following the outcome and publica-tion of the finding. 
Singed at -------------------------------------------day -----------------month---------2013 
Print Name ---------------------------------------- Signature---------------------------------- 
Witness (Subject’s Choice) 
Print Name ---------------------------------------- Signature---------------------------------- 
Witness (Health Personnel) 
















    DIABETIC DYSLIPIDAEMIA DATA COLLECTION  
SHEET 
PROJECT NUMBER DDL------/2013 
FOLDER NUMBER  
  
GENDER MALE  FEMALE  
   
DATE OF BIRTH        /         / AGE                       YEARS 
    
 
DATE IN DIABETIC CLINIC    
LIPOGRAM 
 DATE  
Total Cholesterol  HDL-Cholesterol  
 
Triglyceride  LDL-Cholesterol  
 
    
TYPE OF DYSLIPIDAEMIA 
1 HYPERCHOLESTEROLAEMIA   
2 HYPERTRIGLYCERIDAEMIA   
3 MIXED   
 
MUTATION OR POLYMORPHYSM IDENTIFIED 
ApoE  
PCSK9  
 
